wednesday, april 22 at-a-glance

April 18-22, 2015 • Philadelphia, PA 573

WEDNESDAY, APRIL 22 AT-A-GLANCEAll sessions eligible for CME credit unless otherwise noted.

7:00 a.m.-8:00 a.m. Meet-the-Expert Sessions 574-575

8:00 a.m.-10:00 p.m. Plenary Session 576

8:00 a.m.-12:00 p.m. Poster Sessions 577-609

8:00 a.m.-12:00 p.m. Late-Breaking Poster Sessions 610

10:00 a.m.-11:30 p.m. NCI/NIH-Sponsored Session 611

10:00 a.m.-12:00 p.m. Major Symposia 612-615

10:00 a.m.-12:00 p.m. Recent Advances in Epidemiology and 616Prevention Research

10:00 a.m.-12:00 p.m. Recent Advances in Organ Site Research 617-618

12:00 p.m.-1:30 p.m. Plenary Session 619

14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 573

574 AACR ANNUAL MEETING 2015

MEET-THE-EXPERT SESSIONSWednesday, 7:00 a.m.-8:00 a.m.

Room 113, Pennsylvania Convention CenterBeyond Oncogenes: What Are the NextCategories of Anticancer Targets?Tak W. Mak, Campbell Family Institute for Breast CancerResearch, Toronto, ON, Canada

For the last three decades, the “Oncogene Revolution”prompted investigators to concentrate on the developmentof agents against oncogenes, with the goal of blocking cellgrowth and metastasis. It has now become clear that thecancer cell genome is too varied and the number ofoncogenes too numerous for this strategy to workeffectively for most tumors. A relatively new and promisingapproach is to enhance the infiltration into the tumormicroenvironment of leukocytes that can kill cancer cells.Two other classes of target genes relevant in this contextare those involved in cancer cell metabolic adaptation andthe maintenance of aneuploidy. In this review, I discussrecent data from our group and other laboratories aimed atexploiting these strategies.

Room 108, Pennsylvania Convention CenterDNA Damage, Checkpoint Signaling, andTherapeutic OpportunitiesHelen M. Piwnica-Worms, The University of Texas MDAnderson Cancer Center, Houston, TX

Genotoxic stress induces cells to adopt alternate fatesdepending on the cell type and the extent of accumulatedDNA damage. These include cell death (apoptosis),permanent cell cycle arrest (senescence), or recoverable cellcycle arrest (through activation of cell cycle checkpoints andDNA repair). DNA damage activates the ATM and ATRsignaling pathways, which in turn utilize downstreamcheckpoint proteins including CHK1, CHK2, and p53 toregulate the cellular response to DNA damage. Loss ofcheckpoint integrity is a universal feature of cancer cells. Thissession will discuss how an understanding of fundamentalprinciples governing cell cycle and checkpoint control canpotentially be exploited to target cancer cell vulnerabilities.

Room 122, Pennsylvania Convention CenterThe Gut Microbiome and Colorectal Cancer:Who Is There and What Are They Doing?Temitope O. Keku, University of North Carolina at ChapelHill, Chapel Hill, NC

The human gut is home to a complex microbiota thatcontributes to the overall homeostasis of the host.

Abnormalities in the gut microbiota have been implicatedin a variety of diseases including obesity, inflammatorybowel diseases, and cancer. However, most of these studieshave largely focused on “Who is there?” There is a need forfunctional and mechanistic studies to determine how themicrobiota or microbial products initiate and promotecarcinogenesis. One might then take this bench to bedsideand bedside to bench approaches. This session will discussresults from recent studies that provide evidence that shiftsin microbial communities or specific microbes promote orprotect against colorectal adenomas and cancer. Thepresentation will also include a discussion of potentialmechanisms and associations with diet and inflammation,and will address future directions in the field.

Room 121, Pennsylvania Convention CenterMultiple Biochemical Pathways ControllingCell DeathXiaodong Wang, National Institute of Biological Sciences,Beijing, China

Efficacy of different cancer therapies often depends on theefficiency of these therapies, regardless if it is chemo,radiation, or immune-based, to induce cancer cell death.Apoptosis, a form of cell death mediated by the activitiesof a group of intracellular proteases named caspases, hasbeen occupying the center stage of cell death research.Recently, a new form of programmed cell death mediatedby receptor-interacting kinase 3, RIP3, and its substrateMLKL, a pseudokinase, has drawn major attention from theresearch field. This form of cell death is negativelyregulated by caspase activities and is dispensable foranimal development reproduction. However, emergingevidence has indicated that this form of cell death, alsotermed necroptosis, has a significant involvement in thepathological process of many diseases.

Room 119, Pennsylvania Convention CenterReporting Germline Findings from ClinicalGenome Sequencing TrialsSharon E. Plon, Baylor College of Medicine, Houston, TX

In this session, Dr. Plon will review some of the recentlydeveloped projects that involve performing whole exomeor genome sequencing of pediatric and adult cancerpatients and returning germline results to patients/familiesas part of the study design. Several trials are wellunderway through the NHGRI Clinical Sequencing



Exploratory Research Consortium. Issues that investigatorsneed to consider which will be discussed include: 1)consenting patients/parents to clinical genomics, 2) therange of pathogenic mutations related to the patient’sphenotype being returned, 3) how to handle variants ofuncertain significance in cancer genes, 4) how to approachthe return of incidental findings, 5) planning for thepossibility of patient demise prior to return of results and6) what forms of validation are being used prior toreturning results.

Room 115, Pennsylvania Convention CenterTissue Tension Engages DevelopmentalPrograms to Promote Tumor ProgressionValerie M. Weaver, UCSF Medical Center, San Francisco, CA

All cells experience force and possess mechanosensorymechanisms that enable them to detect physical stimuliand to transduce these cues into biochemical signals thatmodulate cell and tissue behavior. Tumors consistentlyexhibit abnormally high cell and tissue level forces andtransformed cells demonstrate perturbed mechanosensing.We have been studying how cells sense and transducemechanical cues to regulate their behavior and thephysiological relevance of altered mechanical force in cellsand tissues to tumor formation and metastasis. Using anarray of in vitro and in vivo models we find that the ECMprogressively stiffens in various solid tumors includingbreast, pancreas, glioblastoma, and skin, and we have beenable to show that ECM tension modulates transition toinvasion and metastasis. ECM stiffness compromises tissuemorphogenesis and destabilizes tissue architecture bypromoting integrin focal adhesions which potentiategrowth factor receptor signaling and induce cytoskeletalremodeling and actomyosin contractility. By enhancingintegrin signaling to ERK and PI3 kinase, ECM stiffnesspotentiates the tumorigenic effects of oncogenes andpromotes tumor progression and aggression. Recently, wecould show that a stiff ECM promotes tumor aggression bycompromising the tissue vasculature to induce hypoxia andactivate HIF1a and by directly activating HIF1a. High tumorHIF1a in turn alters tissue metabolism, stimulatesinflammation and induces an epithelial to mesenchymaltransition. We also find that many oncogenes such as Rasor ErbB2 or the loss of signaling in tumor cells such as theabsence of TGF beta increase tumor cell contractility. Wefind that high tumor cell tension also induces malignancyand contributes to tumor aggression by inducing ECMremodeling and stiffening to drive focal adhesion assembly

and enhance integrin signaling in a vicious feed forwardcircuit. The relevance of these findings to tumor preventionand therapy will be discussed. (Supported by DOD BCRPW81XWH-05-1-0330 and NIH U54CA163155-01,1U01CA151925-01, RO1CA138818-01A1, 2RO1CA085492-11A1,and R01CA140663-01A2 to VMW, NIH 1U01ES019458-01 toZW and U54CA143836-01 to JL, NCI P50CA058207 toVMW, CP, LC and SH and KG110560 to SH and LC.)

Room 120, Pennsylvania Convention CenterUnderstanding Sensitivity and Resistance to Targeted Therapeutics and Immunotherapeutics Using MouseModels of Lung CancerKwok-Kin Wong, Dana-Farber Cancer Institute, Boston, MA

Genetically engineered mouse (GEM) cancer models haveproved invaluable in cancer drug development. In the eraof precision medicine, these models facilitate theunderstanding of primary and acquired resistancemechanisms to novel therapeutics stratified by thegenotypes of the cancers in these GEM models. In addition,GEM models are one of the few model systems in whichcancers are initiated and progressed within an intactimmune system. This session will highlight the recentadvances in the different approaches used with the lungcancer GEM models to understand the mechanisms ofsensitivity and resistance to targeted therapeutics,immunotherapeutics, as well as combination therapies.

Room 103, Pennsylvania Convention CenterUpdate on Targeting PI3Kα in Breast CancerJosé Baselga, Memorial Sloan Kettering Cancer Center,New York, NY

PIK3CA, the gene encoding for p110α, is frequently mutatedin hormone-dependent breast cancer. PI3Kα specificinhibitors have shown remarkable clinical activity in thephase I setting in patients with breast tumors that harborPI3Kα mutations and these agents are also entering nowphase III studies in combination with hormonal therapies.The underlying reason to study these agents in combinationwith hormonal therapies is compelling. The PI3K and ERpathways cooperate in tumor progression. In addition, anti-estrogen therapy induces the activation of the PI3Kpathway in vitro and we have also observed that PI3Kinhibition results in a powerful activation of ER signaling.



PLENARY SESSIONWednesday, 8:00 a.m.-10:00 a.m.

Terrace Ballroom I-IV (400 Level), Pennsylvania Convention CenterOncology Meets Immunology: Not Just Another “Hallmark”Chairperson: Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania,Philadelphia, PA

It is now well-appreciated that a fundamental aspect of cancer biology involves interactions ofneoplastic cells with the immune system, which can either promote or inhibit tumor growth,depending on complex networks in the tumor microenvironment. Mechanistic insights from basicstudies in cancer immunology have resulted in novel, rational therapeutics for patients with advancedcancer that have produced unprecedented clinical results, even in tumors not previously regarded asamenable to such approaches. The consensus in the field – to be illustrated in this Plenary Session – isthat we have only seen the tip of the iceberg for cancer immunotherapy, posing a challenge toinvestigators, advocates, government, industry, and others to capture this opportunity quickly andfully for the benefit of our patients.

8:00 a.m. Engineering improved cancer vaccinesGlenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA

8:30 a.m. Leukocytes as targets for therapy in solid tumorsLisa M. Coussens, OHSU Knight Cancer Institute, Portland, OR

9:00 a.m. Fatal attraction: A new story featuring the immune system and pancreatic cancer [PL04-03]*Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, MD

9:30 a.m. The mechanistic basis of cancer immunotherapyIra Mellman, Genentech, Inc., South San Francisco, CA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).


Poster Molecular and Cellular BiologyAdvances in Genomics and Transcriptomics(not eligible for CME credit)

Poster Abstract Poster AbstractBoard Number Board Number

1. 4735 Single-cell sequencing from formalin-fixed paraffin-embedded breast cancers: a powerful tool to address intratumorgenetic heterogeneity. Luciano G. Martelotto, Rita A. Sakr, TimourBaslan, Linda Rodgers, Hilary Cox, Jude Kendall, Tari A. King, BrittaWeigelt, James Hicks, Jorge S. Reis-Filho.

2. 4736 Absolute quantification of BCR-ABL RNA usingmultiplexed digital RT-PCR. Maria E. Arcila, Ryma Benayed, IwonaKiecka, Coren Milbury, Michael Mauro, Michael L. Samuels.

3. 4737 Comprehensive profiling of immunoglobulin sequencesusing hybrid capture-based next generation sequencing in B-cellhematologic malignancies. Michelle K. Nahas, Lauren E. Young, JeffGardner, Omar Abdel-Wahab, Jie He, Amy L. Donahue, Kristina M.Knapp, Geoff A. Otto, Doron Lipson, Vincent A. Miller, Ross L. Levine,Philip J. Stephens.

4. 4738 Maximize recovery of quality nucleic acid from formalin-fixed paraffin-embedded tissue samples using a novel, flexiblepurification technology. Doug Wieczorek, Brad Hook, Eric Vincent,Trista Schagat.

5. 4739 Genetic predisposition to DNA double strand breakrepair defect defines a new class of familial colon cancer.Sanjeevani Arora, Hong Yan, Iltaeg Cho, Hua-Ying Fan, Biao Luo,Xiaowu Gai, Dale Bodian, Joe Vockley, Yan Zhou, Elizabeth Handorf,Mark Andrake, Emmanuelle Nicolas, Ilya Serebriiskii, Tim Yen, MichaelHall, Greg Enders, Erica Golemis.

6. 4740 Evaluation of highly-multiplexed custom panels fortargeted massively parallel semiconductor sequencing on paraffinDNA. Vassiliki Kotoula, Aggeliki Lyberopoulou, KyriakiPapadopoulou, Elpida Charalambous, Sotiris Lakis, Zoi Alexopoulou,Eleftheria Tsolaki, Konstantinos Lilakos, George Fountzilas.

7. 4741 Improving pancreatic cancer drug discovery byleveraging genomics to select better in vitro models. YoonjeongCha, Andrew Lysaght, Rain Cui, Brian Weiner, Sarah Kolitz, FadiTowfic, Jason Funt, Kevin Fowler, Badri Vardarajan, MaximArtyomov, Benjamin Zeskind, Rebecca Kusko.

8. 4742 Using 1ng of DNA to detect haplotype phasing and genefusions from whole exome sequencing of cancer cell lines. MirnaJarosz, Michael Schnall-Levin, Grace X. Zheng, Patrick Marks, SofiaKyriazopoulou-Panagiotopoulou, Patrice Mudivarti, Kristina Giorda.

9. 4743 A population-based approach to address clinical cancercare: The national genomics platform. Ogan Abaan, Amrita Basu,Noah Brown, Bret Light, David Deal, Michael Hultner.

10. 4744 Solving genomic assay trade-offs with an optimized,extended cancer gene panel for research and clinical applications.Michael J. Clark, Sean M. Boyle, Elena Helman, Shujun Luo, GaborBartha, Massimo Morra, Anil Patwardhan, Christian Haudenschild,Mirian Karbelashvili, Parin Sripakdeevong, Jason Harris, DeannaChurch, Stephen Chervitz, John West, Richard Chen.

11. 4745 Precision cancer medicine program for whole-exomesequencing of metastatic tumors reveals biomarkers of response.Himisha Beltran, Kenneth Eng, Juan Miguel Mosquera, AlexandrosSigaras, Alessandro Romanel, Hanna Rennart, Myriam Kossai, ChantalPauli, Bishoy Faltas, Jacqueline Fontugne, Brian Robinson, David M.Nanus, Scott T. Tagawa, Jenny Z. Xiang, Francesca Demichelis, DavidRickman, Andrea Sboner, Olivier Elemento, Mark A. Rubin.

12. 4746 Mapping the “dark matter” of cancer genome - Longrepeats, complex structural variations with nanochanneltechnology. H. Cao, A Hastie, A. Pang, W. Andrews, T.Anantharaman, T. Chan, M. Saghbini, H. Sadoski, M. Austin, Z.Dzakula, T. Dickinson, E. Holmlin, X. Xun, P. Kwok, M. Rossi.

13. 4747 Genomic alterations in ductal carcinoma in situcompared with Invasive breast cancer: a quantitative real-timePCR study. Trillium E. Chang, Keisha Warren, Ranju Nair, Tian Y. Lu,Adewunmi Adeoye, Vladimir Iakovlev, Susan J. Done.

14. 4748 Revealing the molecular portrait of triple negativebreast tumors from an understudied population through omicsanalysis of formalin-fixed and paraffin-embedded tissues. FelipeVaca-Paniagua, Rosa María Alvarez-Gomez, Carlos Perez-Plasencia,Hector Aquiles Maldonado-Martínez, Veronica Fragoso-Ontiveros,Federico Lasa-Gonsebatt, Luis A. Herrera, David Cantú, EnriqueBargallo-Rocha, Alejandro Mohar, Geoffroy Durand, Nathalie Forey,Catherine Voegele, Maxime Vallee, Florence Le Calvez-Kelm, JamesMcKay, Maude Ardin, Stephanie Villar, Jiri Zavadil, Magali Olivier.

15. 4749 Simultaneous multi-omic measurement of nucleic-acidsand proteins at 800-plex using single-molecule optical barcodes:Application to cancer immunotherapy. Joseph M. Beechem, GaryGeiss, Brian Filanoski, Brian Birditt.

16. 4750 Transcriptome sequencing of the Reed-Sternberg cellsof classical Hodgkin lymphoma. Jonathan Reichel, Joshua Brody,Olivier Elemento, Raul Rabadan, Ethel Cesarman.

17. 4751 Simple modifications in Ion Torrent Variant Caller (TVC)parameters improve somatic variant detection from circulatingtumor cells and cell free DNA to 1% allele frequency. ColinDavidson, Yongming Sun, Christopher Davies, Chaitali Parikh, WarrenTom, Fiona Hyland, Charles Scafe, Dalia Dhingra.

18. 4752 Genomic cytometry: Single cell mutation analysiscombining PCR with flow cytometry. William C. Hyun, AdamSciambi, Maurizio Pellegrino, Dennis Eastburn.

19. 4753 An effective detection method for the EGFR singlemutation T790M using BNA-NC clamping real-time PCR. Sung-KunKim, Xiaoyun Liu, Aaron Castro, Leticia Loredo, Miguel Castro.

20. 4754 Development of fluorescent probes for detection of DNAbase excision repair in human cancer cells. Allison G. Condie, YanYan, Stanton L. Gerson, Yanming Wang.

21. 4755 Maximize genomic analysis through dual recovery ofDNA and RNA from the same clinical sample. Angie Cheng, NatalieHernandez, Mu Li, Charmaine San Jose Hinahon, Susan Magdaleno.

22. 4756 Genomic profile of AML-ETO rearranged acute myeloidleukemia. Youngil Koh, Dae-Yoon Kim, Jong-Kwang Kim, Yeun-JuneChung, Sung-Soo Yoon, Hyung-Lae Kim.

23. 4757 Whole exome sequencing reveals a distinct mutationpattern in metastatic small cell lung cancer compared to non-smallcell lung cancer. Ali Saber, Klaas Kok, Martijn M. Terpstra, WimTimens, Sijmen Aukema, T. Jeroen Hiltermann, Harry J. Groen, Ankevan den Berg.

24. 4758 Genomic profiling of prostate cancer in Koreanpopulation. Ha Young Park, Jong-il Kim, Weon Seo Park, Kang HyunLee.

25. 4759 Whole genome sequencing of sequentially acquired lungand lymph node metastatic sites from a never smoker lungadenocarcinoma patient revealed extensive genomicheterogeneity. Shaojian Gao, Constance Cultraro, Romi BIswas,Corey A. Carter, Tapan K. Maity, Anish Thomas, Arun Rajan, PaulMeltzer, David Schrump, Giuseppe Giaccone, Javed Khan, UdayanGuha.

26. 4760 Stromal contribution to the colorectal cancertranscriptome. Claudio Isella, Andrea Terrasi, Sara E. Bellomo,Consalvo Petti, Andrea Muratore, Alfredo Mellano, Mark De Ridder,Paola Cassoni, Guy Storme, Andrea Bertotti, Enzo Medico.

27. 4761 Characterization of individual foci of multifocal invasivelobular breast cancer using gene expression profiling. PoojaAdvani, Nadine Norton, Daniel J. Serie, Xochiquetzal Geiger, Julia E.Crook, Aubrey E. Thompson, Edith A. Perez, Alvaro Moreno Aspitia.

11

POSTER SESSION Poster Section 1 • Wednesday, 8:00 AM-12:00 PM


Poster Molecular and Cellular BiologyEpigenetic Changes in Cancer 2(not eligible for CME credit)


1. 4762 ITPKA expression in lung and other cancers,regulated via gene body methylation, functions as anoncogene. Yi-Wei Wang, Xiaotu Ma, Yu-An D. Zhang, Mei-Jung Wang, Yasushi Yatabe, Stephen Lam, Luc Girard, Jeou-Yuan Chen, Adi F. Gazdar.

2. 4763 Correlation of CpG island methylation withclinical and pathologic characteristics in metastaticcolorectal cancer patients. Shailesh M. Advani, Michael S.Lee, Michael J. Overman, David Fogelman, Bryan K. Kee,Shanequa D. Manuel, Jennifer Davis, Van Karlyle Morris,Callisia N. Clarke, Carrie R. Daniel, David G. Menter, Stanley R.Hamilton, Dipen M. Maru, Scott Kopetz.

3. 4764 The Bromodomain inhibitors regulate longnoncoding RNAs controlling glioblastoma progression.Chiara Pastori, Philip Kapranov, Clara Penas, Georges St.Laurent, Nagi Ayad, Claes Wahlestedt.

4. 4765 A drill-down approach to identifying an ERnegative-specific gene signature. Maria J. Worsham,Dhananjay Chitale, Kang Mei Chen, Indrani Datta, Josena K.Stephen, George Divine.

5. 4766 DNA methylation changes in Lynch syndromeassociated colorectal adenomas and carcinomas. SatuValo, Sippy Kaur, Ari Ristimäki, Laura Renkonen-Sinisalo,Heikki Järvinen, Jukka-Pekka Mecklin, Minna Nyström, PäiviPeltomäki.

6. 4767 DNA sequences differentially associated withSirt1 and Dnmt3b during melanoma progression. FabianaMarcelino Meliso, Camila T. da Silva, Simon Coetzee, ThaísSarraf Sabedot, Houtan Noushmehr, Regine Schneider-Stock,Miriam Galvonas Jasiulionis.

8. 4769 CHFR methylation is an independent prognosticmarker of poor prognosis in gastric cancer. KiichiSugimoto, Alicia Hulbert, Zhihao Lu, Chen Chen, Tomoaki Ito,Hiromitsu Komiyama, Yutaka Kojima, Michitoshi Goto, YuichiTomiki, Hajime Orita, Kazuhiro Sakamoto, Koichi Sato,Malcolm V. Brock.

9. 4770 Levels of 5-methyl-cytosine and 5-hydroxymethyl-cytosine in hepatocellular carcinomaprognosis. Lissette Delgado-Cruzata, Hui Chen Wu, TiffanyThomas, Abby B. Siegel, Jing Shen, Yu-Jing Zhang, AbhishekGoyal, Christine C. Hsu, Helen Remotti, Regina M. Santella.

10. 4771 Epigenetic modification of LY6K in CGI shore andCGI regulates LY6K gene activation and metastaticfunction in breast cancer. Hyun Kyung Kong, Sae JeongPark, Ye Sol Kim, Jong Hoon Park.

11. 4772 Aberrantly hypermethylated Homeobox A2derepresses metalloproteinase-9 through TBP andpromotes invasion in nasopharyngeal carcinoma. CHEN-CHING PENG.

12. 4773 Aberrant methylation at chromosome 6p as novelbiomarkers for diagnosis and prognosis of nasopharyngealcarcinoma. Wei Dai, Arthur Kwok Leung Cheung, JosephineMun Yee Ko, Hong Zheng, Yue Cheng, Roger Kai CheongNgan, Wai Tong Ng, Anne Wing Mui Lee, Chun Chung Yau,Victor Ho Fu Lee, Maria Li Lung.

13. 4774 Histone H2AX is a novel regulator of epithelial tomesenchymal transition. SOSSOU U. WEYEMI, Christophe E.Redon, Rohini Choudhuri, Daisuke Maeda, Manjula Kasoji,Natalie Abrams, William M. Bonner.

14. 4775 Gene-specific methylation profiles in male breastcancer. Piera Rizzolo, Valentina Silvestri, AnnaSara Navazio,Virginia Valentini, Veronica Zelli, Mario Falchetti, Ines Zanna,Simonetta Bianchi, Domenico Palli, Laura Ottini.

16. 4777 Triptolide inhibits Wnt signaling due to DNAmethylation alteration that is determined by dynamichistone 3 K79 lysine methylation in NSCLC. Youqiang Li,Binghui Shen, Jae Kim, Dan Raz.

17. 4778 HP1-mediated spatiotemporal control ofestrogen-responsive transcription in breast cancer cells.Pei-Yin Hsu, Hang-Kai Hsu, Victor X. Jin, Zelton D. Sharp, TimH.-M. Huang.

18. 4779 RUVBL1 and RUBVL2 are chromatin remodelersthat represent prognostic and novel therapeutic targetsfor a subset of non-small cell lung cancers (NSCLCs). PaulM. Yenerall, Rahul Kollipara, Ryan Carstens, KennethHuffman, Luc Girard, Jaime Rodriguez, Ignacio Wistuba,David Mangelsdorf, John Minna, Ralf Kittler.

19. 4780 Nucleosome organization and accessibility of p53response elements in the chromatin context. Peter R.LoVerso, Victor B. Zhurkin, Feng Cui.

20. 4781 A comprehensive screen for protein kinasesinvolved in histone phosphorylation using a biochemicalin-vitro approach. Daniel Mueller, Frank Totzke, ConstanceKetterer, Christian Beisenherz-Huss, Diane Krämer, ThomasWeber, Carolin Heidemann-Dinger, Michael H. Kubbutat.

21. 4782 Genome-wide chromatin profiling in bladder andprostate cancers. Sohyoung Kim, Lyuba Varticovski, QizongLao, Songjoon Baek, Myong-Hee Sung, Lars Grøntved,Michael L. Nickerson, Bethtrice Thompson, Dan Theodorescu,Michael Dean, Gordon H. Hager.

22. 4783 Novel molecular markers of bladder cancerprogression identified by global chromatin profiling.Lyuba Varticovski, Sohyoung Kim, Michael L. Nickerson,Bethtrice Thompson, Qizong Lao, Lars Grøntved, SongjoonBaek, Myong-Hee Sung, Dan Theodorescu, Michael Dean,Gordon L. Hager.

23. 4784 Effect of epigenetic drugs on chromatinremodeling complexes disrupted in cancer. MontserratPérez-Salvia, Laia Simó-Riudalbas, Manel Esteller.

24. 4785 Deficiency of cystathionine beta synthase genedoes not affect tumor formation and survival of E�-mycmice. Sapna Gupta, Warren D. Kruger.

25. 4786 Cellular localization of PRMT5 correlates withpoor recurrent free survival in triple-negative breastcancer (TNBC). Elaine P. Alexander, Christian T. Earl, XiaokuiMo, Konstantin Shilo, Robert A. Baiocchi, Maryam B.Lustberg.

26. 4787 Cyclin G2, a novel target of the SNF5/BAF47tumor suppressor gene. Darmood Wei, Aubri Charboneau,Ho-yoon Chung, Donastas Sakellariou-Thompson, BrianDavies, Dennis A. Simpson, Yasumichi Kuwahara, William K.Kaufmann, Charles W. Roberts, Bernard E. Weissman.

27. 4788 Enhancer of zeste homolog 2 couples withHOTAIR to inhibit tumor suppressor miR-34a in humanpancreatic ductal adenocarcinoma. Samson Li, YangchaoChen.

28. 4789 Epigenetic targeting of triple negative breastcancer. Sylvia S. Gayle, Jennifer Brancato, Kristen W. Bonk,Ruth Keri.

29. 4790 Noncanonical functions of EZH2 in triple-negativebreast cancers. Talha Anwar, Heather Moore, SarahBergholtz, Celina Kleer.

22



Poster Molecular and Cellular BiologyGenomics 3(not eligible for CME credit)


1. 4791 Prognostic model of lower grade gliomas. Kosuke Aoki,Hiromichi Suzuki, Hideo Nakamura, Masahiro Mizoguchi, Tetsuya Abe,Satoru Miyano, Ichiro Takeuchi, Toshihiko Wakabayashi, Seishi Ogawa,Atsushi Natsume.

2. 4792 Comprehensive molecular pathology analysis of small boweladenocarcinoma reveals novel targets with clinical utility. MuhammadA. Alvi, Darragh G. McArt, Paul Kelly, Marc-Aurel Fuchs, MatthewAlderdice, Clare M. McCabe, Victoria Bingham, Claire McGready, StephenMcQuaid, Perry Maxwell, Peter Hamilton, Jacqueline A. James, RichardWilson, Manuel Salto-Tellez.

3. 4793 Rapid pan-cancer identification of previously unidentifiedfusion genes to enable novel targeted therapeutics. Henrik Edgren,Kalle Ojala, Anja Ruusulehto, Gopi Ganji.

4. 4794 Identification of FOXM1 driven gene network as a prognosticmarker in breast cancer. In-Sun Chu, Seon-Kyu Kim, Yun-Gil Roh, Sun-Hee Leem.

5. 4795 A novel gene fusion in glioblastoma and a radiationresponse methylation signature identified by genomic characterizationof glioma sphere-forming cells. Qianghu Wang, Ravesanker Ezhilarasan,Lindsey D. Goodman, Joy Gumin, Siyuan Zheng, Kosuke Yoshihara, PengSun, Jie Yang, Tim Heffernan, Giulio Draetta, Kenneth D. Aldape, FrederickF. Lang, Roel G. Verhaak, Erik P. Sulman.

6. 4796 A founder mutation in the BAP1 gene among four caucasianfamilies with high incidences of malignant peritoneal mesotheliomaand uveal melanoma: a molecular and genealogical study in a 10-generation BAP1 cancer syndrome kindred. Erin Flores, Mitsuru Emi,Todd Johnson, Tatsuhiko Tsunoda, Dusty Behner, Harriet Hoffman, MaryHesdorffer, Masaki Nasu, Andrea Napolitano, Francine Baumann, HainingYang, Michele Carbone.

7. 4797 Mutation signature and intratumor heterogeneity ofesophageal squamous cell carcinoma in a Chinese cohort. QingxuanSong, Mengfei Liu, Jian Bai, Amir Abliz, Wenqing Yuan, Zhen Liu, JingjingLiu, Changhong Zeng, Hong Cai, Yang Ke, Jun Li.

8. 4798 Genomic alterations in ERBB2 define a subset ofpleomorphic invasive lobular breast cancer. Kim M. Hirshfield, ReneeSanders, Heather K. Feld, Nicola Barnard, Li Liang, Hua Zhong, GyanBhanot, Amrik S. Sahota, Andrew Brooks, Lorna Rodriguez-Rodriguez,Shridar Ganesan.

9. 4799 Variation in mutational landscape among small colonicpolyps with differential growth rates. Chelsie K. Sievers, Perry J.Pickhardt, Kristina Matkowskyj, Dawn Albrecht, Luli Zou, David Kim,Meghan Lubner, Mark Reichelderfer, Richard Halberg.

10. 4800 Identification of candidate predisposition genes for familialuterine leiomyomas. Hanna-Riikka Heinonen, Outi Uimari, JaanaTolvanen, Markku Ryynänen, Lauri A. Aaltonen, Pia Vahteristo.

11. 4801 Integrated genomic analysis of chromosome 11 in squamoustumors. Vonn Walter, Ying Du, Xiaoying Yin, Wei Sun, Matthew D.Wilkerson, Michele C. Hayward, Ashley H. Salazar, Charles M. Perou, DavidN. Hayes.

12. 4802 Transcriptional landscape of lung squamous cell carcinomain Northeast Asian patients. Arang Rhie, Hyesun Cho, Min Hwan Son,Seong-Keun Yoo, Jong-Yeon Shin, Jeong-Sun Seo.

13. 4803 BAP1 mutation is a frequent somatic event in peritonealmalignant mesothelioma. Olivier Harismendy, Hakan Alakus, Shawn Yost,Brian Woo, Randall French, Grace Y. Lin, Kristen Jepsen, Kelly A. Frazer,Andrew M. Lowy.

14. 4804 High throughput whole exome DNA and transcriptome RNAsequencing to identify genetic drivers and alterations in HPV-negativeand HPV-positive HNSCC cell lines. Hui Cheng, Xinping Yang, Han Si,Anthony Saleh, Jamie Coupar, Robert L. Ferris, Wendell G. Yarbrough,Mark E. Prince, Thomas E. Carey, Carter Van Waes, Zhong Chen.

15. 4805 Whole genome sequencing of primary breast cancers andmatched distant metastases. Man-Hung Tang, Malin Dahlgren, ChristianBrueffer, Christof Winter, Yilun Chen, Eleonor Olsson, Martin Sjöström,Pär-Ola Bendahl, Emma Niméus-Malmström, Lao H. Saal, Åke Borg, SofiaK. Gruvberger-Saal.

16. 4806 Characterizing the genomic landscape of premalignantcolorectal polyps using next-generation sequencing. Ester Borras,Anthony San Lucas, Kyle Chang, Gita Bhatia, Hong Wu, Jerry Fowler, Y.Nancy You, Patrick M. Lynch, Melissa W. Taggart, Ernest T. Hawk, GabrielCapella, Paul Scheet, Eduardo Vilar.

17. 4807 Discovery of novel alternative splicing events in humanpapillomavirus-related oropharyngeal squamous cell carcinoma.Theresa Guo, Daria Gaykalova, Michael Considine, Justin A. Bishop, WilliamH. Westra, Zubair Khan, Elana Fertig, Joseph A. Califano.

18. 4808 Identification of genes with variants in HPV-associated headand neck squamous cell carcinoma. Shama Virani, Pelle B. Hall, YanxiaoZhang, Lada A. Koneva, Alisha Virani, Katie M. Rentschler, Thomas E.Carey, Laura S. Rozek, Maureen A. Sartor.

19. 4809 Validation of molecular subtypes of urothelial carcinoma ofbladder in multi-institutional and public cohorts. Vipulkumar Dadhania,Charles G. Guo, Tadeusz Majewski, Li Zhang, Jolanta Bondaruk, ShizhenZhang, Woonyoung Choi, David McConkey, Colin Dinney, Keith Baggerly,Bogdan A. Czerniak.

20. 4810 Exome sequencing of refractory diffuse large B-celllymphomas highlights candidate genes for targeted resequencing.Sylvain Mareschal, Pierre-Julien Viailly, Philippe Bertrand, Elodie Bohers,Jean-Philippe Jais, Martin Figeac, Thierry J. Molina, Fabienne Desmots,Thierry Fest, Gilles Salles, Corinne Haioun, Hervé Tilly, Karen Leroy, FabriceJardin.

21. 4811 Pro-oncogenic role of NOTCH1 in early tongue squamouscell carcinoma. Pawan Upadhyay, Jyotirmoi Aich, VidyalakshmiSethunath, Prachi Dani, Sadhana Kannan, Pratik Chandrani, KavithaSonawane, Beamon Agarwal, Shubhada Kane, Sudhir Nair, Amit Dutt.

22. 4812 Creation of a novel gene delivery system for highthroughput candidate oncogene validation. Charlotte R. Feddersen.

23. 4813 High-depth sequencing of 800 cancer-associated genes in 48matched tumor-normal tissues to identify somatic alterations includinglow-frequency variants in colorectal cancer. Clarinda Chua, Dan LiangHo, Yuka Suzuki, Simeen Malik, John McPherson, Anna Gan, Dennis Koh,Choon Leong Tang, Sarah Boon Hsi Ng, Patrick Tan, Steve Rozen, IainBeehuat Tan.

24. 4814 Inferring liver cancer evolution from spatial and temporalgenomic heterogeneity. Qiang Gao, Zhi-Chao Wang, Rui-Bin Xi, Jia Fan.

25. 4815 Tumor heterogeneity of advanced primary lung cancerevaluated by multiregion sequencing. Sang-Won Um, Je-Gun Joung, SuYeon Lee, Joon Seol Bae, Jinha Park, Woong-Yang Park.

26. 4816 Design, validation, and interpretation of an NGS assay foractionable variants in solid tumors. Susan M. Mockus, GuruprasadAnanda, Micaela Lundquist, Vanessa Spotlow, Al Simons, Talia Mitchell,Grace A. Stafford, Christopher S. Potter, Vivek Philip, Timothy Stearns,Anuj Srivastava, Mary Barter, Lucy Rowe, Joan Malcolm, Carol Bult, RadhaKrishna Murthy Katuturi, Karen Rasmussen, Douglas Hinerfeld.

27. 4817 Microsatellite instability status in endometrioid endometrialcarcinomas is associated with distinct types and patterns of PI3Kpathway mutations. Caterina Marchio, Maria R. De Filippo, Charlotte K.Ng, Robert A. Soslow, Jorge S. Reis-Filho, Britta Weigelt.

28. 4818 Array-CGH and miRNA expression profiling of triple negativebreast cancer in African-American women. Kenny Regis, Michelle Jaldin,Akanksha Mahajan, Anju Duttargi, Laura Sheahan, Yuriy Gusev, SubhaMadhavan, Luciane R. Cavalli.

29. 4819 Differential evolution of tumor heterogeneity inleiomyosarcomas and liposarcomas suggested by genomic profiling.Ali Amin-Mansour.

30. 4820 A comparison of bulk versus single-cell whole-exomesequencing to study cancer genetic heterogeneity. John B. Williamson,Hongyong Zhang, Paul Lott, Ruta Sahasrabudhe, Stephanie Soares, SusieAirhart, Clifford Tepper, Chong-Xian Pan, Ralph DeVere-White, LuisCarvajal-Carmona.

33



Poster Molecular and Cellular BiologyIdentification of Molecular Markers(not eligible for CME credit)


1. 4821 Association of polymorphisms in TP53, CXCL2, MDM2,MDM4 and BCL2 genes and proliferative prostate diseases amongLebanese men. Ruhul H. Kuddus, Asmahan A. El Ezzi, Mohammed A.El-Saidi, Scott Baker, Wissam Zaidan.

2. 4822 Lack of expression of FOXO3 correlates with poorprognosis on uterine sarcomas. Thais G. Almeida, Natalia Garcia,Isabela W. Cunha, Glauco Baiocchi, Fernando A. Soares, Gustavo A.Maciel, Edmund C. Baracat, Katia C. Carvalho.

3. 4823 Serum level of urokinase plasminogen activatorreceptor is suggested as diagnostic and prognostic biomarker inprostate cancer. Sven Wach, Omar Al-Janabi, Katrin Weigelt,Kersten Fischer, Thomas Greither, Marios Marcou, Gerit Theil, ElkeNolte, Hans-Juergen Holzhausen, Robert Stoehr, Verena Huppert,Arndt Hartmann, Paolo Fornara, Bernd Wullich, Helge W. Taubert.

4. 4824 Pancreatic adenocarcinoma: Comparative analysis ofcancer stem cell markers between neoadjuvant and treatmentnaïve specimens. Whitney Horsley, Melissa Stanley, Bert O’Neil, SafiShahda, George Sandusky.

5. 4825 Association between genetic profiles and histologicalclassifications of 18 Japanese pseudomyxoma peritonei. ReiNoguchi.

6. 4826 Cancer/testis antigen expression pattern is a potentialbiomarker for prostate cancer aggressiveness. Luciane T.Kagohara, Prakash Kulkarni, Takumi Shiraishi, Guangjing Zhu, RobertVessella, Robert Veltri.

7. 4827 Gene copy number and protein expression of growthfactor receptors EGFR and HER2 and their prognostic potential inpenile squamous cell carcinoma. Alice M. Silva-Amancio, Jose I.Neves, Isabela W. Cunha, Walter da Costa, Gustavo C. Guimarães,Fernando A. Soares.

8. 4828 Differential gene expression profile of tissue factorpathway inhibitor-2 (TFPI-2) in malignant pleural mesothelioma.Anil Wali, Ying Wang, Adi Tarca, Fulvio Lonardo, Zhandong Liu, Arun K.Rishi, Harvey I. Pass.

9. 4829 The clinical significance of APOBEC3B in esophagealsquamous cell carcinoma. Keisuke Kosumi, Yoshifumi Baba,Takatsugu Ishimoto, Kenichi Nakamura, Kazuto Harada, MayukoOhuchi, Yuki Kiyozumi, Daisuke Izumi, Ryuma Tokunaga, JunjiKurashige, Ryuichi Karashima, Yukiharu Hiyoshi, Shiro Iwagami,Yasuo Sakamoto, Yuji Miyamoto, Naoya Yoshida, MasayukiWatanabe, Hideo Baba.

10. 4830 The correlation between CXCR7 expression and EGFRmutation in non-small cell lung cancer. Yiping Han.

11. 4831 Analysis of genetic variations in neuroblastoma usingdeep targeted sequencing. Niloufar Javanmardi, Susanne Fransson,Malin Ostensson, Rose-marie Sjoberg, Per Kogner, TommyMartinsson.

12. 4832 Independent prognostic role of chromosome 12pdeletion in prostate cancer. Sarah J. Minner, Ramin Ahray, MartinaKluth, Thorsten Schlomm, Ronald Simon, Guido Sauter, MariaChristina Tsourlakis.

13. 4833 Single-cell genetic analysis reveals insights into clonaldevelopment of cervical cancer and confirms TERC as an early anddominant aberration. Leanora S. Hernandez, Amanda Bradley, TimoGaiser, Sonia Andersson, E. Michael Gertz, Salim A. Chowdhury,Russel Schwartz, Alejandro Schäffer, Kerstin Heselmeyer-Haddad,Thomas Ried.

14. 4834 Single cell multiplex gene expression analysis to unravelheterogeneity of PDX samples established from tumors of breastcancer patients with different ethnicity. Ebrahim Azizi, Evelyn M.Jiagge, Shamileh Fouladdel, Shukmei Wong, Michele L. Dziubinski, MarySehl, Anahita Kyani, Jun Li, Hui Jiang, Tahra K. Luther, Shawn G. Clouthier,Sean P. McDermott, John Carpten, Lisa A. Newman, Sofia D. Merajver,Max S. Wicha.

15. 4835 A new biomarker of response to 5-azacitidine therapy inMDS and AML patients: SIRPB1. Viviana Guadagnuolo, CristinaPapayannidis, Ilaria Iacobucci, Giorgia Simonetti, Antonella Padella, StefaniaPaolini, Mariachiara Abbenante, Sarah Parisi, Francesca Volpato, Chiara Sartor,Maria Chiara Fontana, Massimo Delledonne, Michele Malagola, Carla Filì,Domenico Russo, Sandro Grilli, Michele Cavo, Giovanni Martinelli.

16. 4836 Presence of FTO rs9939609 and rs9930506 and severityof prostate cancer in Puerto Ricans. Jeannette Salgado-Montilla,Jorge Rodríguez-Caban, Lorena Gonzalez-Sepulveda, Ricardo Sanchez-Ortiz, Margarita Irizarry-Ramirez.

18. 4838 Inhibitor of differentiation-1 (Id1) expression correlateswith epithelial-mesenchymal transition (EMT)-related proteins inepithelial ovarian cancer (EOC) and constitutes a novel prognosticfactor. Victoria Heredia, Andres Redondo, Jorge Barriuso, AlbertoBerjón, Cristian Perna, Patricia Cruz, Alicia Hernández, Javier deSantiago, Esther Díaz, María Miguel, Beatriz Castelo, Laura Yébenes,Jaime Feliú, David Hardisson, Marta Mendiola.

20. 4840 The role of miR-146a and novel Rhenium compounds onprostate cancer cell lines derived from African Americans andEuropean American patients. Monet Stevenson, Jameel Joyner,Khadija Dildar, Oladipo Adedeji, Krishnan Prabhakaran, Hirendra N.Banerjee, Santosh Mandal, Fazlul Sarkar.

21. 4841 NF-kB - p53 gene associations and prostate cancer risk.Radhika G. Andavolu, Catherine Stafford, Murthy V. Andavolu, Jean-Luc Cardenas, Jacob Rubin, Ross Shore, Svetlana Rubakovic.

22. 4842 Pharmacodynamic stratification of metastatic colorectalcancer patients using genomic datasets. Sharon Austin, Fang YinLo, Kellie Howard, Mollie McWhorter, Heather Collins, Amanda Leonti,Lindsey Maassel, Christopher Subia, Tuuli Saloranta, Nicole Heying,Leila Ritter, Kerry Deutsch, James Cox, Steven Anderson, AnupMadan, Timothy Yeatman.

23. 4843 A next generation sequencing (NGS) genome wide copynumber variation (CNV) assay for comparison of circulating tumorcell (CTC) heterogeneity. Stephanie Green, Mark Landers, JessicaLouw, Adam Jendrisak, Ryan Dittamore, Dena Marrinucci.

24. 4844 High throughput detection of PRKD1 mutations insalivary gland tumors using in situ mutation detection in tissuemicroarrays. Piotr T. Wysocki, William H. Westra, Shahnaz Begum,David Sidransky, Mariana Brait.

25. 4845 Microarray analysis of melanoma autologous tumor celllines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients withmetastatic melanoma. Andrew N. Cornforth, Gary Fogel, DenyshaCarbonell, Robert O. Dillman.

26. 4846 Automated RNA and DNA purification from FFPEsamples. Michelle Mandrekar, Douglas Horejsh, Samantha Lewis,Chris Moreland, Marjeta Urh.

27. 4847 Identifying molecular targets and mechanisms oftreatment resistance in inflammatory breast cancer (IBC) usingnext-generation sequencing (NGS) and reverse-phase proteinmicroarrays (RPMA). Laura K. Austin, Keithe Shensky, Juan Palazzo,Tiffany Avery, Rebecca Jaslow, Corrine Ramos, Nicholas Hoke,Emanuel Petricoin, Massimo Cristofanilli.

28. 4848 SNP array reveals a new deletion of JAK2 in AMLpatients. Viviana Guadagnuolo, Maria Chiara Fontana, AntonellaPadella, Ilaria Iacobucci, Cristina Papayannidis, Giorgia Simonetti,Anna Ferrari, Giovanni Marconi, Stefania Paolini, Maria ChiaraAbbenante, Sarah Parisi, Francesca Volpato, Chiara Sartor, EmanuelaOttaviani, Massimo Delledonne, Michele Cavo, Guido Biasco, GiovanniMartinelli.

44



Poster Molecular and Cellular BiologyMethods and Tools in Computational Cancer Biology(not eligible for CME credit)


1. 4849 GenomeSpace: An environment for frictionlessbioinformatics. Michael M. Reich.

2 . 4850 Identifying copy number alterations fromtargeted sequencing data. Bernard Fendler, Ryan Abo,Samuel Hunter, Matthew Ducar, Elizabeth Garcia, Paul VanHummelen, Neal Lindeman, Laura MacConaill.

3. 4851 BubbleTree: an intuitive visualization to elucidatetumoral aneuploidy and clonality in somatic mosaicismusing copy number ratio and allele frequency. Wei Zhu,Mike Kuziora, Chris Morehouse, Tianwei Zhang, YinongSebastian, Zheng Liu, Dong Shen, Jiaqi Huang, ZhengweiDong, Yi Gu, Feng Xue, Liyan Jiang, Yihong Yao, Brandon W.Higgs.

4. 4852 Performances evaluation of algorithms foridentifying differentially expressed genes in RNA-seqdata. Chin-Ting Wu, Mong-Hsun Tsai, Tzu-Pin Lu, Liang-Chuan Lai, Eric Y. Chuang.

5. 4853 A bioinformatics approach to drug discovery:patient based connectivity mapping. Brooke L. Fridley,Rama Raghavan, Gottfried E. Konecny, Chen Wang, Ellen L.Goode, Harsh B. Pathak, Stephen Hyter.

6. 4854 A computational framework for prioritizingnoncoding regulatory variants in cancer. Yao Fu, Zhu Liu,Shaoke Lou, Vincenza Colonna, Jason Bedford, Xinmeng Mu,Kevin Y. Yip, Hyun M. Kang, Tuuli Lappalainen, AndreaSboner, Haiyuan Yu, 1000 Genomes Project Consortium,Mark Rubin, Chris Tyler-Smith, Ekta Khurana, Mark Gerstein.

7. 4855 DBGC: database of gastric cancer. Yingyan Yu.

8. 4856 ITD Assembler: An algorithm for internal tandemduplication discovery from short-read sequencing data.Oliver A. Hampton, Navin Rustagi, Jie Li, Liu Xi, Richard A.Gibbs, Sharon E. Plon, Marek Kimmel, David A. Wheeler.

9. 4857 The Stanford-Cancer Genome Atlas Portal: Aweb/mobile navigation interface for exploring the clinicalassociations of cancer drivers. HoJoon Lee, Jennifer Palm,Hanlee P. Ji.

10. 4858 Cloud-based variant analysis solution usingcontrol-accessed sequencing data. Chunlin Xiao, EugeneYaschenko, Stephen Sherry.

11. 4859 Development of a cancer transcriptome analysistoolkit: identification of gene fusions in chroniclymphocytic leukemia. Nikolaus D. Obholzer, Brian J. Haas,Dan-Avi Landau, Nathalie Pochet, Aviv Regev, Catherine Wu.

12. 4860 Detection of genetically distinct subclones incancer: a novel NGS algorithm with high spatial andgenetic resolution. Konstantinos Karagiannis, KonstantinChumakov, Vahan Simonyan, Raja Mazumder.

13. 4861 Hybrid clustering methodologies to distinguishCNAs and/or SNVs that drive subclonal differentiation insamples from a breast cancer patient primary tumor andmetastatic lymph nodes. Mia D. Champion, Princy Francis,Barbara A. Pockaj, Michael T. Barrett.

14. 4862 PredICT: a novel solution for capturing,assembling and combining in vivo data. Rhys D. Jones,Marie Cooke, James Hinchliffe, Justin Morley, Simon T. Barry.

15. 4863 Streamlining NGS workflows using cancersamples by the application of the DNA Integrity Number(DIN) from the Genomic DNA ScreenTape assay. EvaSchmidt, Isabell Pechtl, Barry McHoull, Melissa Liu.

16. 4864 VarDict: A novel and versatile variant caller fornext-generation sequencing in cancer research. ZhongwuLai, Aleksandra Markovets, Miika Ahdesmaki, Justin Johnson.

17. 4865 PhyloSpan: using multi[[Unsupported Character -Codename ]]-mutation reads to resolve subclonalarchitectures from heterogeneous tumor samples. Amit G.Deshwar, Levi Boyles, Jeff Wintersinger, Paul C. Boutros, YeeWhye Teh, Quaid Morris.

18. 4866 Modeling synergistic anti-PD-1 immunotherapycombinations with virtual tumor. Frances A. Brightman,David Orrell, Eric Fernandez, Christophe Chassagnole.

19. 4867 Comparative analysis of RNA sequencingmethods for characterization of cancer transcriptomics.Ryan P. Abo, Ling Lin, Samuel S. Hunter, Deniz N. Dolcen,Rachel R. Paquette, Angelica Laing, Luc de Waal, Aaron R.Thorner, Matthew D. Ducar, Liuda Ziaugra, William C. Hahn,Matthew L. Meyerson, Laura E. MacConaill, Paul VanHummelen.

20. 4868 CODEX: a normalization and copy numbervariation detection method for whole-exome sequencing.Yuchao Jiang, Derek A. Oldridge, Sharon J. Diskin, Nancy R.Zhang.

21. 4869 Validation of a procedure for simultaneousvariant calling and differential expression in cancer study.Gang Feng, Jamie Osman, Sean Leighton, Lynn Carmichael,Yuchen Bai, John Begemann, Richard Mazzarella.

22. 4870 GenePool: A cloud-based technology for rapidlydata mining large-scale, patient-derived cancer genomiccohorts including The Cancer Genome Atlas. SandeepSanga, Antoaneta Vladimirova, Richard D. Goold, Tod M.Klingler.

23. 4871 A new multiple feature approach for rapid andhighly accurate somatic structural variation discovery fromwhole cancer genome sequencing. Li C. Xia, John Bell,Jiamin Chen, Nancy R. Zhang, Hanlee P. Ji.

24. 4872 Improving bioinformatic analysis pipelines forcalling somatic mutations in tumors and tumor derived celllines. Bradley Wubbenhorst.

25. 4873 Epicopy: Measuring DNA copy number variationusing high-density methylation microarrays. SoonwengCho, Hyun-seok Kim, Leslie M. Cope, Christopher B. Umbricht.

26. 4874 OASIS: A centralized portal for cancer omics dataanalysis. Julio Fernandez-Banet, Anthony Esposito, ScottCoffin, Sabine Schefzick, Ying Ding, Keith Ching, IstvanHorvath, Peter Roberts, Paul Rejto, Zhengyan Kan.

27. 4875 HIVE Proteomics: Integrated, cloud-based RNA-Seq and proteomics analysis of prostate adenocarcinomasamples. Hayley Dingerdissen, Raja Mazumder.

28. 4876 An integrated pipeline for detecting andcharacterizing structural variation in cancer. Minita Shah,Dayna M. Oschwald, Soren Germer, Michael C. Zody, TobyBloom, Anne-Katrin Emde.

29. 4877 A modular software solution (underdevelopment) to expedite sequencing workflow andmitigate legacy workflow issues in regulatoryenvironments. Lisa Kelly, Jessica Gordon.

55



Poster Molecular and Cellular BiologyNew Developments in Sequencing(not eligible for CME credit)


1. 4878 Analytical and technical validation of a cost-effective diagnostic test for BRCA1, BRCA2 and TP53.Manimala Sen, Pooja Agrawal, Vikram Vittal P., MithuaGhosh, M.L. Sheela, Divya Vishwanath, Kiran Kumari, SwethaN.S.N., Vaibhavi Pathak, Gouri Deshpande, Ashraf Mannan,Rupali Gadkari, Suman Kapoor, Jamuna Yadhav, MohammedYousuff, Satish Sankaran, Ramesh Hariharan, PreveenRamamoorthy, Kalyanasundaram Subramanian, VaijayantiGupta.

2. 4879 Reducing amplification artifacts in highlymultiplex amplicon sequencing by using molecularbarcodes. Quan Peng, Ravi Vijaya Satya, Marcus Lewis,Pranay Randad, John DiCarlo, Yexun Wang.

3. 4880 Characterization of genetic concordance betweenprimary tumor cells, circulating tumor cells, andmetastatic tumor cells from patients with prostate cancer.Lixin Yang, Linling Chen, Yafan Wang, Jeremy Jones, YunYen, Sofia Loera, Raju Pillai, Peiguo Chu, DennisWeisenburger.

4. 4881 Analysis of long-noncoding RNA interaction atchromatin by chromatin isolation by RNA purification(ChIRP). Kan Saito, Konstantin Taganov, John M. Rosenfeld,Nick Asbrock, Vi Chu.

5. 4882 Megabase-scale phased haplotypes of geneticaberrations from whole cancer genome sequencing ofprimary colorectal tumors. Billy Lau, John M. Bell, MichaelSchnall-Levin, Mirna Jarosz, Erik Hopmans, Christina M.Wood, Grace X. Zheng, Kristina Giorda, Hanlee P. Ji.

6. 4883 A novel target capture approach for nextgeneration sequencing and its application to oncogenicmutation detection. Yanxia Bei, Brendan Galvin, CynthiaRichard.

7. 4884 Highly sensitive fusion transcript detection andquantification in cancer. Lisa C. Watson, Stephen M. Gross,Irina Khrevtukova, Smita Pathak, Claire Attwooll, JasonGoode, Anthony Mai, Gary P. Schroth.

8. 4885 TOMA OS-Seq: A clinically oriented targetedresequencing method for detecting all mutation classes inDNA isolated from FFPE, FNAs and plasma. Yosr Bouhlal,Alexander McKenzie, Austin P. So.

9. 4886 Repair of challenging FFPE DNA improves librarysuccess rate and sequencing quality. Pingfang Liu, LixinChen, Laurence Ettwiller, Christine Sumner, Fiona Stewart,Eileen Dimalanta, Theodore Davis, Thomas Evans.

10. 4887 TCR profiling of T lymphocytes in ovarian tumorsand malignant ascites using next-generation sequencing.Miran Jang, Poh-Yin Yew, Kosei Hasegawa, Yuji Ikeda, KeiichiFujiwara, Gini F. Fleming, Yusuke Nakamura, Jae-Hyun Park.

11. 4888 Clinical sequencing in the National Institute ofHealth’s Clinical Sequencing Exploratory Research (CSER)Program. Catherine Crawford, Charlisse Caga-Anan, DaveKaufman, Alexander Lee, Jean Mcewen, Sheri Schully,Carolyn Hutter, Lucia Hindorff.

12. 4889 Clonal structure analysis of cancer genomes atsingle molecule resolution. Billy Lau, Hanlee Ji.

13. 4890 Duplex sequencing of AML reveals extensive subclonal heterogeneity. Lawrence A. Loeb, Michael W. Schmitt,Mark J. Prindle, Pamela S. Becker.

14. 4891 Comprehensive genetic profiling of chromosomaltranslocations in lung cancer tumors: development andvalidation of a next-generation sequencing panel in aninternational multicenter study. Pierre Laurent - Puig, JoseLouis Costa, Orla Sheils, Bastiaan Tops, Andrea Mafficini,Delphine Le Corre, Henriette Kurth, Anna Maria Rachiglio,Helene Blons, Eliana Amato, Christoph Noppen, RenatoFranco, Anne Reiman, Roy Bastien, Noah Welker, Jose CarlosMachado, Ian Cree, Harriet Feilotter, Marjolijn Ligtenberg,Aldo Scarpa, Nicola Normanno, Kazuto Nishio, Cecily Vaughn.

15. 4892 Methods for accurate reporting of confidenceintervals in clinical applications of next generationsequencing (NGS). Erin L. Crawford, Thomas Blomquist,James C. Willey.

16. 4893 High-throughput mutation sequencing of the fullexon regions in BRCA1 and BRCA2 genes usingnanofluidic-PCR prepared libraries. Jun Wang, Guoli Li,Ming Chen, Jianfu Heng, Xinwu Guo, Limin Peng, Fan Zhang,Zibo Li, Shouman Wang, Zhi Xiao, Lizhong Dai, Wenjun Yi, LiliTang.

17. 4894 Targeted sequencing of myeloid cancers usingsingle-molecule enrichment in picodroplets. Michael L.Samuels, Steve K. Kotsopoulos, Frances Long, Holly Gettler,Omo Clement, Jeff Olson.

18. 4895 A one-tube assay for simultaneous detection ofgene mutation, fusion, copy number alteration andexpression. Zongli Zheng, Ranjit Shetty, Matthew Liebers,Jessica L. Cambry, Lindsay A. Bernardo, Darrell Borger, LongP. Le, John A. Iafrate.

20. 4897 Accurate variant detection using molecularbarcodes. Charmian Cher, Henrik Johansson, Javelin Chi,Katie Zobeck, Linus Forsmark, Magnus Isaksson, HollyHogrefe.

21. 4898 Full-length isoform sequencing of the humanMCF-7 cell line using PacBio long reads. Elizabeth Tseng,Tyson Clark, Meredith H. Ashby, Gloria Shenykman.

22. 4899 Tumor T-cell receptor (TCR) diversity elucidatesthe immune response to genetic alterations of muscle-invasive bladder cancer. Noura Choudhury, Kai Lee Yap,Kazuma Kiyotani, Poh Yin Yew, Alexa Campanile, TatjanaAntic, Gary Steinberg, Jae-Hyun Park, Peter H. O’Donnell,Yusuke Nakamura.

23. 4900 A highly multiplexed control material to satisfythe complex needs of targeted next generationsequencing (NGS) oncology assays. Nakul Nataraj, Mona D.Shahbazian, Aron Lau, Mahjabeen Yucekul, Patty Chiang,Suzy V. Le, Kara Norman.

24. 4901 Comparison of gene expression platforms: RNA-Seq, Fluidigm, and Nanostring. Erica B. Schleifman, MaipeloMotlhabi, Craig Cummings, Rin Nakamura, Linda Bosch,Rajesh Patel, An Do, Andrew Watson, Thomas Sandmann,Walter Darbonne, Ian McCaffery, Eric Peters, Rajiv Raja.

25. 4902 Detecting low abundant mutations in circulatingcell free DNA and FFPE samples. Julie Laliberte, CatherineCouture, Vladimir Makarov, Cassie Schumacher, SukhinderSandhu, Laurie Kurihara, Timothy Harkins.

26. 4903 Microarray gene expression analysis of humanprostate cancer PC-3 cells targeted by Salmonellatyphimurium A1-R. Ming Zhao, Wen Wu, Chongyi Lu, YongZhang, Robert M. Hoffman, Hui Qi, Meng Yang, Yanqin Gu,Yiyu Lu, Shibing Su, Hui Zhang, Qianmei Zhou, Qilong Chen.

27. 4904 Developing a universal target retrieval solutionand protocol for RNA in situ hybridization based onRNAscope technology. Li-chong Wang, Liuliu Pan, Kuang-Jung Chang, Daniel Kim, Xingyong Wu, Hongwei Wang,Casey Kernag, Bingqing Zhang, Mingxiao He, Nan Su, Xiao-Jun Ma, Yuling Luo.

66



Poster Molecular and Cellular BiologyNew Technologies to Identify Genetic Alterations(not eligible for CME credit)


1. 4905 Comprehensive genomic analyses of oral squamous cellcarcinoma tissues by semiconductor-based next-generationsequencing. Takafumi Nakagaki, Yasushi Sasaki, Kenta Kobashi, KousukeTakeda, Miyuki Tamura, Tomoko Ohashi, Kazuhiro Ogi, Masashi Idogawa,Hiroyoshi Hiratsuka, Takashi Tokino.

2. 4906 TP53 mutations are mutually exclusive with FLT3 and NPMmutations in AML patients and are strongly associated with complexkaryotype and poor outcome. Anna Ferrari, Cristina Papayannidis, ElisaZuffa, Carmen Baldazzi, Antonella Padella, Eugenia Franchini, IlariaIacobucci, Stefania Paolini, Viviana Guadagnuolo, Margherita Perricone,Valentina Robustelli, Claudia Venturi, Maria Chiara Abbenante, SarahParisi, Chiara Sartor, Francesca Volpato, Federica Cattina, GiorgiaSimonetti, Maria Chiara Fontana, Maria Teresa Bochicchio, FedericaFrabetti, Elisa Lani, Katia Mancuso, Beatrice Zannetti, Simona Luatti,Emanuela Ottaviani, Nicoletta Testoni, Giovanni Martinelli.

3. 4907 The Emerging technology of Yb2Ti2O7 electrolyte-insulator-semiconductor biosensors for rapid screening of targeted mutation.Jhou Cheng Han, Kao Shin Hsun, Pang Sow Neng, Pan Tung Ming, WengWen Hui.

4. 4908 Establishment of multiplexed ultra-sensitive detection ofepidermal growth factor receptor mutations using picodroplet digitalPCR. Hiroaki Akamatsu, Yasuhiro Koh, Masaru Watanabe, Takashi Kikuchi,Masanori Nakanishi, Kazuto Matsunaga, Nobuyuki Yamamoto.

5. 4909 Increased IR-A/IR-B ratio in non-small cell lung cancersassociates with lower epithelial-mesenchymal transition signature andlonger survival in squamous cell lung carcinoma. Jiaqi Huang, Wei Zhu,Liyan Jiang, Katie Streicher, Chris Morehouse, Philip Brohawn, XiaoXiaoGe, Zhengwei Dong, Xiaolu Yin, Guanshan Zhu, Yi Gu, Parthiv Mahadevia,Brandon W. Higgs, Yihong Yao.

6. 4910 Sensitive, specific and highly multiplexed mutationdetection for cancer management. Lit Yeen Tan, Elisa Mokany, SamanthaWalker, Tina Lonergan, Alison Todd.

7. 4911 Mutually exclusive FGFR2, HER2, and KRAS geneamplifications in gastric cancer revealed by multicolor FISH. Kakoli Das,Bavani Gunasegaran, Iain Beehuat Tan, Niantao Deng, Kiat Hon Lim,Patrick Tan.

8. 4912 Screening of multiplex gene mutations using cell-free DNAin lung cancer patients. Nak-Jung Kwon, Jae Sook Sung, Ahreum Seong,Hyunmi Kim, Woo Chung Lee, Yeul Hong Kim, Kap-Seok Yang, Jeong-SunSeo.

9. 4913 Highly complex oligonucleotide libraries for use in high-resolution RNA and RNA/DNA fluorescence in situ hybridization invarious sample types. Robert A. Ach, Mistuni Ghosh, Peter Tsang, AliciaScheffer-Wong, Laurakay Bruhn, Alice Yamada.

10. 4914 Polymorphism analysis of the enzymes MTHF and DPDmutation in patients with colorectal cancer submitted to chemotherapytreatment with 5-Fluorouracil (5-FU). Diego M. de Souza.

11. 4915 Tracking genomic alterations in young patients with headand neck carcinomas using whole-exome sequencing. Priscila M.Miranda, Fabio A. Marchi, Maísa Pinheiro, Luiz P. Kowalski, Silvia R.Rogatto.

12. 4916 Development of a NGS-based method for EGFRvIIIdetection: sequence analysis of the junction. Jianhua Zhao, ShreySukhadia, Alan Fox, David Lieberman, Barnett Li, Robert D. Daber,Matthew C. Hiemenz, David B. Roth, Maria Martinez-Large, Arati Desai,Donald M. O’Rourke, Marcela V. Maus, Jennifer J. Morrissette.

13. 4917 Identification of genetic heterogeneity by whole exomesequencing using cell free DNA from blood samples. Kayo Asada,Katsutoshi Oda, Kengo Gotoh, Reiko Kurikawa, Shogo Yamamoto, KenjiTatsuno, Hiroki Ueda, Yuji Ikeda, Yuriko Uehara, Kenbun Sone, OsamuHiraike-Wada, Kei Kawana, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii,Hiroyuki Aburatani.

14. 4918 Concordance of circulating tumor DNA (ctDNA) and next-generation sequencing (NGS) as molecular monitoring tools inmetastatic breast cancer (MBC). Laura K. Austin, Tiffany Avery, RebeccaJaslow, Paolo Fortina, Dragan Sebisanovic, LaiMun Siew, Aubrey Zapanta,AmirAli Talasaz, Massimo Cristofanilli.

15. 4919 Tumor heterogeneity represented in human cancer cell lines.Lysa-Anne Volpe, John Foulke, Michael Jackson, Luping Chen, David H.Randle, Hannah J. Gitschier, Kelly Gardner, Fang Tian.

16. 4920 The detection of circulating tumor DNA using Quantstudio3D digital PCR. Adam H. Greer, Glenn Mills, Hong Yin.

17. 4921 Next-generation sequencing as a potential tool in thediagnostics of APC mosaicism in FAP patient. Kiyoshi Yamaguchi,Mitsuhiro Komura, Rui Yamaguchi, Seiya Imoto, Eigo Shimizu, ShinichiKasuya, Tetsuo Shibuya, Seira Hatakeyama, Norihiko Takahashi, TsuneoIkenoue, Keisuke Hata, Giichiro Tsurita, Masaru Shinozaki, Yutaka Suzuki,Sumio Sugano, Satoru Miyano, Yoichi Furukawa.

18. 4922 Analysis of copy number changes in HNSCC by MLPA. NejatDalay, Orkun Gurbuz, Elif Baltaci, Emin Karaman, Nur Buyru.

19. 4923 Detecting copy number variation using dNTP limited PCRand high-resolution melting. Luming Zhou, Bobert Palais, Carl Wittwer.

20. 4924 Multiparameter ploidy profiling: a powerful tool toinvestigate the genomics of diploid tumor populations. Thomas Lorber,Sabrina Rau, Valeria Perrina, Michael Barrett, Christian Ruiz, LukasBubendorf.

21. 4925 Liquid biopsy using the ion AmpliSeq v2 cancer panel.WeiHua Liu, Zhenyu Yan, Candice L. Horn, Fabio Nunes, Steven M. Bray,Philip J. Ebert, Peng Fang, Jennifer Biroschak, Cindy Spittle, ChadGalderisi, Jin Li.

22. 4926 EML4-ALK pre-mRNA and mature mRNA fusion detectionusing RNA fluorescence in situ hybridization (RNA FISH). Sally R.Coassin, Byung-Chul Kim, Hans E. Johansson.

23. 4927 Next-generation sequencing enables new approach tomolecular cytogenetics. Jie He, Jeffrey Gardner, James X. Sun, OmarAbdel-Wahab, Andrew M. Intlekofer, Michelle K. Nahas, Jo-Anne Vergilio,Jeffery S. Ross, Roman Yelenskey, Ross Levine, Geoff Otto, Doron Lipson,Vincent Miller, Philip Stephens.

24. 4928 Clinical utility of circulating tumor DNA (ctDNA) in advancedand metastatic breast cancer. Laura K. Austin, Rebecca Jaslow, TiffanyAvery, Paolo Fortina, Dragan Sebisanovic, LaiMun Siew, Aubrey Zapanta,AmirAli Talasaz, Massimo Cristofanilli.

25. 4929 An ARMS PCR assay for detection of PI3KCA mutations inFFPE tumor samples. Dehua D. Yu.

26. 4930 Next generation sequencing performance for the detectionof mutations in plasma cell free DNA. Ana Justino, Gabriela Fernandes,Ana Barroso, Barbara Parente, Venceslau Hespanhol, Jose C. Machado,Jose L. Costa.

27. 4931 A circulating cell free DNA workflow for targeted sequencing- from isolation through validation. Dalia Dhingra, Xingwang Fang, MattCarter, Dumitru Brinza, Charles Scafe, Christopher Davies, Fiona Hyland.

28. 4932 Development of a highly sensitive library prep method foridentifying pathogenic variants from FFPE tumor samples. Amanda G.Young, Charles Lin.

29. 4933 Sanger sequencing of low amount of genomic DNA and FFPEDNA with PCR primers derived from the Ion AmpliSeq cancer hotspotpanel. Edgar H. Schreiber, Adam Broomer, Mark Andersen, Kamini Varma.

30. 4934 Mosaic RNase IIIb domain DICER1 mutations in children withmultiple primary tumors. Leanne de Kock, Barbara Rivera Polo, Mona Wu,Evan Weber, Claudio Sandoval, Saskia M. Hopman, J. Hans M. Merks, Annetvan Hagen, D. A. Plager, Nelly Sabbaghian, Nancy Hamel, DorothéeBouron-Dal Soglio, John R. Priest, William D. Foulkes.

77



Poster Molecular and Cellular BiologyOncogenes and Tumor Suppressors 3(not eligible for CME credit)


2. 4936 The interaction and effects of hypoxia,surrounding fibroblasts and p16 expression on breastcancer cell migration and invasion. Yi Lu, Jun Zhang.

4. 4938 APC in breast cancer: the ABCs of geneexpression. Katia Fernandez Soto, Monica K.VanKlompenberg, Jennifer Cole, Jenifer R. Prosperi.

5. 4939 The baffling effect of bafilomycin on Notchsignaling in triple-negative breast cancer. SahithiPamarthy, Mukesh K. Jaiswal, Arpita Kulshrestha, GajendraKatara, Safaa Ibrahim, Alice Gilman-Sachs, Kenneth D.Beaman.

6. 4940 Role of Smad3 linker phosphorylation in breastcancer progression. Fang Liu, Wen Xie, Zhengxue Liu,Tanima Roy, Eunjin Bae, Lalage M. Wakefield, Seong-Jin Kim,Akira Ooshima, Michael Reiss, Isao Matsuura.

7. 4941 Profilin-1 is a key determinant for tumorigenicpotential of breast cancer cells. Chang Jiang, Zhijie Ding,Marion Joy, Laura Vollmer, Dave Gau, Su Hyeong Kim,Shivendra Singh, Andreas Vogt, Partha Roy.

8. 4942 Activation of Phosphatase toward theRetinoblastoma protein in breast and colorectal cancer cellspheroids. Jacklynn Egger, Lisa Antonucci, Maria Lane,Nancy A. Krucher.

9. 4943 Engulfment gene GULP1 is a functional tumorsuppressor through influencing TGF-� pathway and issilenced by promoter methylation in urothelial carcinoma.Masamichi Hayashi, Leonardo O. Reis, Alexander Baras,Leonel Maldonado, Eliza Guida, Evgeny Izumchenko, MarianaBrait, Trinity Bivalacqua, George J. Netto, Wayne Koch, DavidSidransky, Mohammad O. Hoque.

10. 4944 Identification of B-cell lymphoma 6 as a noveltherapeutic target in glioblastoma. Ye Chen, Liang Xu,Masaharu Hazawa, Anand M. Thippeswamy, Henry Yang,Markus Müschen, De-Chen Lin, Phillip Koeffler.

11. 4945 A novel role for drebrin in regulating progranulinbioactivity in bladder cancer. Shi-Qiong Xu, SimoneBuraschi, Alaide Morcavallo, Marco Genua, Tomoaki Shirao,Stephen C. Peiper, Leonard G. Gomella, Antonino Belfiore,Renato V. Iozzo, Andrea Morrione.

12. 4946 Investigating candidate genomic alteration whichaffects the local recurrence in patients with desmoidfibromatosis. Sehhoon Park, Youngil Koh, Se-Hoon Lee,Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Dong-WanKim, Dae Seog Heo.

13. 4947 HACE1 is a putative tumor suppressor gene inB-cell lymphomagenesis down-regulated by bothdeletion and epigenetic mechanisms. AbdelilahBouzelfen, Marion Alcantara, Hafid Kora, Philippe Bertrand,Sylvain Mareschal, Elodie Bohers, Catherine Maingonnat,Philippe Ruminy, Sahil Adriouch, Gaetan Riou, Martin Figeac,Thierry Fest, Christian Bastard, Hervé Tilly, Jean-BaptisteLatouche, Fabrice Jardin.

14. 4948 The cytosolic domain of a disintergrin andmetalloprotease (ADAM) 15 promotes non-small cell lungcancer (NSCLC) proliferation. Hsin-Han Hou.

15. 4949 HAS2 is a critical effector for AGL mediatedregulation of tumor growth. Sunny Guin, Yuanbin Ru,Carolyn R. Lew, Neeraj Agarwal, Charles Owens, DanTheodorescu.

16. 4950 Defective expression of partition-defective 3(PAR-3) is associated with adverse prognostic factors inesophageal squamous cell carcinoma. Tomoko Kitaichi,Koichiroh Yasui, Akira Tomie, Yasuyuki Gen, Osamu Dohi, YujiNaito, Yoshito Itoh.

17. 4951 Expression analysis of the LOT1 gene in head andneck cancer. SEDA EKIZOGLU ERATAK, Emin Karaman, NURA. BUYRU.

18. 4952 WWOX and LOT1 genes are down-regulated innon-small cell lung cancer (NSCLC). Onur Baykara, SedaEkizoglu Eratak, Kamil Kaynak, Hikmet Koseoglu, Nur Buyru.

19. 4953 Molecular and cellular localization profiles oftristetraprolin in colorectal cancer: Implications for tumorprogression in diverse patient populations. Esther A.Suswam, Balananda-Dhurjati K. Putcha, Amit K. Tiwari,Trafina Jadhav, Kiera D. Walker, Lualhati Harkins, SamirAmer, Isam-Eldin Eltoum, Sejong Bae, Upender Manne.

20. 4954 Serine/arginine splicing factor 1 (SRSF1)mediates DNA repair and chemo-sensitivity and drivesgrowth in small cell lung cancer. Sarah J. Conley, Xin Yao,Jiaqi Huang, Brandon Higgs, Zhibin Hu, Zhan Xiao, HaihongZhong, Zheng Liu, Philip Brohawn, Xiaoxiao Ge, MegganCzapiga, Vaheh Oganesyan, Haihua Fu, David Tice, RonaldHerbst, Xinying Su, Yi Gu, Jianren Gu, Baohui Han, LauraRichman, Bahija Jallal, Liyan Jiang, Hongbing Shen, YihongYao.

21. 4955 Somatic alteration and depleted nuclearexpression of BAP1 in human esophageal squamous cellcarcinomas. Takahiro Mori, Makiko Sumii, FumiyoshiFujishima, Kazuko Ueno, Masao Nagasaki, Chikashi Ishioka,Natsuko Chiba.

22. 4956 Hsp27 negatively affects Hippo tumor suppressorpathway to regulate cell survival in cancer. Sepideh Vahid,Daksh Thaper, Amina Zoubeidi.

23. 4957 Next generation sequencing demonstratesassociation between tumor suppressor gene aberrationsand poor outcome in patients with cancer. MariaSchwaederle, Gregory A. Daniels, David E. Piccioni, Paul T.Fanta, Richard B. Schwab, Kelly A. Shimabukuro, Barbara A.Parker, Razelle Kurzrock.

24. 4958 Melanoma transition is frequently accompaniedby a loss of cytoglobin, a putative tumor suppressor, inmelanocytes. Yoshihiko Fujita, Satoshi Koinuma, Marco DeVelasco, Bolz Jan, Yosuke Togashi, Masato Terashima,Hidetoshi Hayashi, Takuya Matsuo, Kazuto Nishio.

25. 4959 Klotho suppresses colon cancer throughmodulation of the Wnt pathway and unfolded proteinresponse. Tammi Rubinstein, Shiri Shahmoon, Gil Har Zahav,Nir Skalka, Tal Etan, Rina Arbesfeld, Metsada Pasmanik-Chor,Tami Rubinek, Ido Wolf.

26. 4960 ERp46 (thioredoxin domain-containing protein 5,TXND5) promotes prostate cancer growth in vitro and invivo. Jehonathan H. Pinthus, Sarah N. Hopmans, StephanieFederov, Wilhelmina C. Duivenvoorden.

27. 4961 Functional analysis of prostate cancer-specificMED12 mutation. Kati Kämpjärvi, Nam Hee Kim, Min Ju Park,Mikko Turunen, Netta Mäkinen, Tuomas Heikkinen, SallaKeskitalo, Markku Varjosalo, Thomas G. Boyer, Pia Vahteristo.

28. 4962 Inhibition of TGF-�-RUNX3 signaling by activatedShh is correlated with the development of TGF-�resistance in gastric cancer cells. Seong Hye Park, Jung LimKim, Bo Ram Kim, Yoo Jin Na, Sang Cheul Oh.

29. 4963 Prognostic significance of the expression ofnuclear EIF5A2 in human melanoma. Shahram Khosravi,Magdalena Martinka, Christopher J. Ong.

30. 4964 Nonsense MED12 mutation in a patient with T-cellacute lymphoblastic leukemia. Tuomas Heikkinen, KatiKämpjärvi, Salla Keskitalo, Mikko Turunen, HeikkiKuusanmäki, Netta Mäkinen, Satu Mustjoki, CarolineHeckman, Markku Varjosalo, Pia Vahteristo.

88



Poster Molecular and Cellular BiologyProtein and Lipid Modifications in Cancer(not eligible for CME credit)


1. 4965 Multiple ubiquitin-conjugating enzymesmodulate the ubiquitination and downregulation of theEGFR by the Cbl RING finger ubiquitin ligase. Ke Ma, PhilipRyan, Rachel Klevit, Stanley Lipkowitz.

2. 4966 Identification of deubiquitinating enzyme USP19as a regulator of EWS/FLI1 protein turnover in Ewingsarcoma. Maria E. Gierisch, Laura A. Lopez-Garcia, FranziskaPfistner, Felix K. Niggli, Beat W. Schaefer.

3. 4967 The BAP1 deubiquitinase promotes triple-negative breast cancer partially by stabilizing the KLF5transcription factor. Ceshi Chen, Junying Qin, ZhongmeiZhou.

4. 4968 microRNA-mediated silencing of COP1 andaltered ubiquitination of key oncogenic transcriptionfactors promote cancer stem cell (CSC) phenotype andprostate cancer progression. Cecilia Dallavalle, DomenicoAlbino, Gianluca Civenni, Laura Curti, Paola Ostano, MauriziaMello-Grand, Ramon Garcia-Escudero, Giovanna Chiorino,Carlo V. Catapano, Giuseppina M. Carbone.

5. 4969 Metformin causes AR degradation via Skp2-mediated ubiquitination. Joy C. Yang, Allen C. Gao,Christopher P. Evans.

6. 4970 USP15 regulates SMURF2 kinetics through C-lobemediated deubiquitination. Pieter J. Eichhorn, PrasannaIyengar, Patrick Jaynes, Chandra Verma.

7. 4971 Detection of receptor and non receptor tyrosinekinases in the culture filtrates of astrocytes and cancercells. Venkateswara R. Gogineni.

8. 4972 Investigating the role of Syk in TGF-� inducedP-bodies and breast cancer metastasis. Shana D. Hardy,Robert L. Geahlen.

9. 4973 A novel cellular class I phosphoinositide-3-kinase(PI3K) isoform-specific occupancy assay demonstrates adirect correlation between PI3K isoform activity andphospho-AKT levels. Lina Gu, Erin Brophy, Erin Murphy,Bonnie Tillotson, Jonathan DiNitto, Louis Grenier, Janid Ali.

10. 4974 IL-1 receptor-associated kinase-1 and -4expression in Hodgkin lymphoma. Victoria S. Giffi, KenishaM. Younger, Zeba Singh, Qing Chen, Eduardo Davila, Amy S.Kimball.

11. 4975 All-trans retinoic acid induces proliferation,survival and migration in A549 lung cancer cells byactivating the ERK signaling pathway through atranscription independent mechanism. Reyna S. QuinteroBarceinas, Alejandro García-Regalado, Elena Aréchaga-Ocampo, Claudia H. González-De la Rosa.

12. 4976 Inhibition of eIF4B suppresses the growth andinduces the apoptosis of Bcr-Abl positive cells. Ke Chen,Jian-Ling Yang, Guijie Guo, Jilong Chen.

13. 4977 Dramatic differences in the extents and patternsof PKC delta modification among the different members ofthe NCI-60 cancer cell line panel. Noemi Kedei, Jin-QiuChen, Michelle Herrmann, Tiffany Hu, Karina Chang, Peter M.Blumberg.

14. 4978 Identification and therapeutic targeting ofsignaling pathways in Ruxolitinib resistant cells. Peter P.Sayeski, Shireen Vali, Ansu Kumar, Neeraj Singh, SusumuKobayashi, Taher Abbasi.

15. 4979 SIRT1 regulates the function of the KRAB-associated protein 1 (KAP1) in DNA damage responsesignaling. Yi-Hui Lin, Zhenkun Lou.

16. 4980 Rational design of combination therapies andblock of acquired targeted drug resistance. Hadas Reuveni,Lana Kuperschmidt, Shani Carmi, Neta Moskovitz, SalomonStemmer, Izhak Haviv.

17. 4981 Angiotensin-(1-7) targets c-Met signaling byup-regulating the phosphatase PTP1b to reduce triplenegative breast cancer. Guorui Deng, Linda Metheny-Barlow, Patricia E. Gallagher, E. Ann Tallant.

18. 4982 Increased core fucosylation, a glycan alterationassociated with cancer, is the result of hepatocytededifferentiation. Anand S. Mehta, Mary Ann Comunale,Siddhartha Rawat, Jessica Garner, Lucy Betesh, MengjunWang, Laura Steel, Michael Bouchard.

19. 4983 GALNT3 mediated differential MUC4 glycosylationin the progression of pancreatic cancer. Seema Chugh,Vinayaga S. Gnanapragassam, Maneesh Jain, MoorthyPonnusamy, Surinder K. Batra.

20. 4984 EMT and breast cancer metastasis driven byplasma membrane fluidity. Jeffrey T. Chang.

99



Poster Molecular and Cellular BiologyReceptor Signaling and Cancer(not eligible for CME credit)


1. 4985 Notch1 as a key mediator in promoting advancedcastration-resistant prostate cancer. Tanya Stoyanova,Claire Faltermeier, Bryan Smith, Andrew Goldstein, Xi Zhang,Justin Drake, John Lee, Sandra Orellana, Steven Blum,Donghui Cheng, Kenneth Pienta, Jiaoti Huang, Owen Witte.

2. 4986 Distinct temporal regulation of RET isoforminternalization: Roles of clathrin and AP2. Mathieu J. Crupi,Piriya Yoganathan, Leslie N. Bone, Eric Lian, Andrew Fetz,Costin N. Antonescu, Lois M. Mulligan.

3. 4987 IL8, VEGF and IGF-1 rescue ovarian cancer cellsundergoing ARHI-mediated- autophagic cell death. ZhenLu, Aaron F. Orozco, Margie Sutton, Wang Yan, Weiqun Mao,Robert Bast.

4. 4988 A7 nicotinic acetylcholine receptor mediated thechemosensitivity of gastric cancer cells. Chien-Yu Huang,Yu-Jia Chang.

5. 4989 Cannabinoid receptor 2 and C-X-C chemokinereceptor 4 interact to abrogate CXCL12-mediated cellularresponse. Christopher Coke, Ahriea Johnson, Kia Jones,Cimona Hinton.

6. 4990 The RET receptor Y791F variant activates thekinase but diminishes ligand responsiveness. Andrew Fetz,Mathieu J. Crupi, Eric Lian, Brandy D. Hyndman, Lois M.Mulligan.

7. 4991 RET and integrins cooperate in cell-microenvironment response. Eric Lian, Mathieu J. Crupi,Jessica G. Cockburn, Simona M. Wagner, Anirudh Goel, LoisM. Mulligan.

8. 4992 Nicotinic acetylcholine receptor �5 mediateslow-dose nicotine-dependent regulation of tumorigenesisin lung adenocarcinoma cells. Mong-Lien L. Wang, Yi-FanHsu, Chih-Hsuan Liu, Cheng-Wen Wu.

9. 4993 �-arrestin-2 regulates CXCR7-mediated EGFRtransactivation and tumor cell proliferation in prostatecancer cells. Georgios Kallifatidis, Daniel Munoz, Rajendra K.Singh, Bal L. Lokeshwar.

10. 4994 RET isoforms differentially contribute to focaladhesion formation. Piriya Yoganathan, Eric Lian, Lois M.Mulligan.

11. 4995 HO1 induction interrupts the glucocorticoidreceptor signaling in prostate cancer cells. Daiana B.Leonardi, Alejandra V. Paez, Federico Schuster, NicolasAnselmino, Javier N. Brandani, Mercedes Abbate, GeraldineGueron, Javier H. Cotignola, Elba S. Vazquez.

12. 4996 Expression of the estrogen receptor,progesterone receptor and PTEN in endometrial cancersfrom women with type II diabetes mellitus. Dario R. Roque,Arthur M. Dizon, Brooke Rambally, Siobhan O’Connor, PaolaA. Gehrig, Sheri A. Denslow, Victoria L. Bae-Jump.

13. 4997 Phosphorylation of SLAP by the KIT-D816Voncogenic mutant suppresses SLAP-mediated negativeregulation of KIT signaling. Julhash U. Kazi, Jianmin Sun,Lars Rönnstrand.

14. 4998 Novel N-glycosilation inhibitor blocksproliferation of EGFR-dependent NSCLC. Cecilia LopezSambrooks, Joseph N. Contessa.

15. 4999 Signaling-associated complexes to definetargetable vulnerabilities in lung cancer. Matthew Smith,Thomas Licata, Yun Bai, Guolin Zhang, Vincent Vuaroqueaux,Heinz-Herbert Fiebig, Eric B. Haura.

16. 5000 The heterogeneous expression and functionalrelationship of ALK and NLRR1 in neuroblastoma. ShunpeiSatoh, Atsushi Takatori, Atsushi Ogura, Miki Ohira, ShamimM. Hossain, Katsuyoshi Koh, Hiroshi Kishimoto, Ryoji Hanada,Akira Nakagawara.

17. 5001 High dose IL-2 (HDIL-2) results in increased PD-1expression on CD45RA-CCR7-CD8+ and CD45RA-CCR7-CD4+ T cells in melanoma patients. Maggie L. Diller, SusanMaio, Cabell E. Eysmans, David Lawson, Keith A. Delman,Ragini R. Kudchadkar, Mandy L. Ford.

18. 5002 Abstract Submission. Swati Acharya, Kira Y.Petersen, Vladislav Golubkov, Mandy Kwong, Christopher M.Adams, Peter K. Jackson, David B. Lewis.

19. 5003 Differential expression of lysophosphatidic acidreceptors (LPARs) between benign and malignant tissuesin humans. Andrew Bingham, Jinghe Mao, Chunyi Wang,Janice Lage, Xinchun Zhou.

20. 5004 Expression profiling of receptor tyrosine kinasesin high-grade neuroendocrine carcinoma of the lung: Acomparative analysis with adenocarcinoma and squamouscell carcinoma. Yuki Matsumura, Shigeki Umemura,Genichiro Ishii, Koji Tsuta, Shingo Mastsumoto, Keiju Aokage,Tomoyuki Hishida, Junji Yoshida, Yuichiro Ohe, HiroyukiSuzuki, Atsushi Ochiai, Koichi Goto, Kanji Nagai, KatsuyaTsuchihara.

21. 5005 Androgen-mediated genomic and non-genomicregulation of TRPM8 in prostate cancer. Swapna Asuthkar,Eleonora Zakharian.

22. 5006 Elucidating the mechanism of bile acid-inducedactivation of estrogen receptor � in colorectaladenocarcinoma. Jesse Trujillo.

23. 5007 A novel polyisoprenylated cysteinyl amideinhibitor, NSL-BA-055, selectively inhibits proliferation ofhepatocellular carcinoma cells. Michelle K. Naidoo, NazariusLamango, Olorunseun O. Ogunwobi.

24. 5008 The H1047R point mutation in p110 alpha of PI3Kdecrease Bcl2 expression in human colon cancer HCT116cells. Guanghua Wan, Ashwani Rajput.

1010



Poster ImmunologyTherapeutics and Therapeutic Models(not eligible for CME credit)


1. 5009 NKG2D receptor stimulation of effector CD8+ Tcells alters the transcriptome and activation of mTOR toenhance anti-tumor immunity. Kelsey Trace, Sara Jacobson,Amorette E. Barber.

2. 5010 A versatile tool to study immune checkpointtherapeutics: Syngenic tumor mouse models in vivo.Cynthia Schaefer-Obodozie, Peter Jantscheff, Sandra Moor,Steffen Hoffmann, Tihomir Saso, Christoph Schaechtele,Holger Weber.

3. 5011 Generation of rejuvenated murine antigen-specific T cells by reprogramming to pluripotency andredifferentiation. Fumito Ito, Noemi Fusaki, HidehitoSaito.

4. 5012 Establishment of a transplantable, NY-BR-1expressing breast cancer model in HLA-transgenic mice.Krishna Das, Adriane Gardyan, Mathias Vormehr, KarinMueller-Decker, Inka Zörnig, Dirk Jäger, Wolfram Osen,Stefan B. Eichmüller.

5. 5013 Toward better selection of PD-1 blockaderesponders through direct markers of adaptive immuneresistance. Daniel S. Shin, Angel Garcia-Diaz, Helena Escuin-Ordinas, Nicolaos J. Palaskas, Sara M. Komenan, Thomas G.Graeber, Begonya Comin-Anduix, Antoni Ribas.

6. 5014 Neutrophils protect B-cell lymphomas againstchemotherapy via cell-cell interactions mediated by CD44and ICAM1 receptors. Taghreed Hirz, Justine Esmenjaud,Anne Evesque, Doriane Mathe-Poloni, Charles Dumontet.

7. 5015 Tumor dependence on HER2 signaling as a playerin immune infiltration required for trastuzumab activity.Tiziana Triulzi, Viola Regondi, Loris De Cecco, Gaia Ghedini,Maria Luisa Carcangiu, Serenella M. Pupa, Elda Tagliabue.

8. 5016 Short-term blockade of EGF signaling improvesimmune-mediated cytotoxicity of NSCLC cells. CharliDominguez.

9. 5017 The discovery of novel therapeutics that restoreantigen processing pathways in immune-editedmetastatic cancers. Lilian Nohara, Reinhard Gabathuler, PaulAhn, Ping Cheng, David Williams, Raymond Andersen,Wilfred A. Jefferies.

10. 5018 HLA class I expression in a tumor is higher thanthat out of a tumor: Promising new findings for antigen-specific cancer immunotherapy. Daisule Nobuoka, MariTakahashi, Toshiaki Yoshikawa, Takahito Yagi, ToshiyoshiFujiwara, Tetsuya Nakatsura.

11. 5019 Characterization of sentinel node-derivedantibodies from breast cancer patients. Girja S. Shukla,Stephanie C. Pero, Yu-Jing Sun, Chelsea L. Carman, David N.Krag.

12. 5020 Neutrophils in the bone marrow niche promotemultiple myeloma chemoresistance. Indu Ramachandran,Cindy Lin, Thomas Condamine, Maria Ozerova, Alfred Garfall,Dan Vogl, Dmitry Gabrilovich, Yulia Nefedova.

13. 5021 Histopathologic and gene expression analysis inmouse models of long-term chronic prostaticinflammation using human prostate cancer-derivedbacterial isolates. Gretchen K. Hubbard, Shu-Han Yu, DebikaB. Shinohara, Ajay Vaghasia, William G. Nelson, SrinivasanYegnasubramanian, Angelo M. De Marzo, Karen S. Sfanos.

14. 5022 Generation of T regulatory-cell specific RNAaptamers. Suresh Veeramani, Sue E. Blackwell, William H.Thiel, Paloma H. Giangrande, George J. Weiner.

15. 5023 NSCLC PDX model for the evaluation of immuno-oncological treatment strategies. Eva Oswald, KerstinKlingner, Dorothee Lenhard, Gabriele Niedermann, Julia B.Schüler.

16. 5024 Implications of MAPK pathway inhibition onmonocytes and tumor-associated macrophages inmelanoma. Gabriela Gremel, Maria Romina Girotti, AmayaViros, Garry Ashton, Helen Bradley, Elena Galvani, RebeccaLee, Alberto Fusi, Paul Lorigan, Richard Marais.

17. 5025 Immune expression profiling of MAPK inhibitorresistant tumors based upon mechanisms of resistance.James S. Wilmott, Hojabr Kakavand, Alexander M. Menzies,Ricardo Vilain, Gulietta M. Pupo, John F. Thompson, RichardF. Kefford, Matteo S. Carlino, Helen Rizos, Georgina V. Long,Richard A. Scolyer.

18. 5026 Tumor associated targeting with Manocept: HIVassociated Kaposi’s sarcoma as a model system. RongzhenZhang, Frederick O. Cope, Paige M. Bracci, Michael S.McGrath.

19. 5027 Interleukin-17B promotes chemoresistance ofbreast tumors through ERK1/2 anti-apoptotic pathway.Emilie Laprevotte, Jeremy Bastid, Stéphanie Cochaud,Jerôme Giustiniani, Marion Philippe, Kathryn A. Frewer,Andrew J. Sanders, Wen G. Jiang, Armand Bensussan, GillesAlberici, Jean-François Eliaou, Nathalie Bonnefoy.

20. 5028 CXCL10 within the tumor microenvironmentinduces gemcitabine resistance in pancreatic cancer cells.Daniel Delitto, Chelsey Perez, Brian S. Black, Heather L.Sorenson, Andrea E. Knowlton, Song Han, Dongyu Zhang,George A. Sarosi, Lyle L. Moldawer, Kevin E. Behrns, Chen Liu,Thomas J. George, Ryan M. Thomas, Jose G. Trevino,Shannon M. Wallet, Steven J. Hughes.

21. 5029 Microglia differentiated from induced pluripotentstem cells treat glioma tumors in mice. Hetal Pandya, DavidM. Ichikawa, Michael J. Shen, Andrea B. Sedlock, Kory R.Johnson, Dragan Maric, Dorian B. McGavern, Harry L. Malech,John K. Park.

22. 5030 Polarizing tumor associated macrophages (TAMs)towards an anti-tumor phenotype with a novel compoundreveals a new subset of TAMs within breast tumors whichfacilitate tumor regression. Alaba O. Sotayo, Jennnifer L.Guerriero, Holly E. Ponichtera, Anthony G. Letai.

23. 5031 A humanized mouse model for translationalassessment of targeted immune checkpoint blockade.Gilson Baia, David Vasquez-Dunddel, Daniel Ciznadija, DavidSidransky, Amanda Katz, Keren Paz.

24. 5032 Acute phase liver graft injury mobilizes regulatingB cells after transplantation for HCC patients throughTLR4/CXCL10/CXCR3 signaling. Kwan Man, Yan Shao,Chang Xian Li, Chung Mau Lo.

25. 5033 Azacitidine pretreatment sensitizes NSCLC cells tointerferon-�. Kai He, Xin Zhang, Ludmila Danilova, XiaoyuPan, Julie Brahmer, Drew Pardoll, Malcolm Brock, StephenBaylin, James Herman, John Wrangle.

26. 5034 Imprime PGG decreases regulatory T cellsuppression and enhances T cell proliferation anddifferentiation revealing additional mechanisms for itsanti-tumor activity. Steven M. Leonardo, Keith Gorden, RossFulton, Lindsay Wurst.

27. 5035 Effect of FXR agonist on colitis and colorectalcarcinogenesis in mice. Tsuneyuki Miyazaki, Takahiro Kochi,Hiroyasu Sakai, Yohei Shirakami, Masahito Shimizu, TakujiTanaka, Hisataka Moriwaki.

28. 5036 Tumor-induced activation of the Wnt/�-catenin/TCF4 pathway in dendritic cells promotes immunetolerance. Yuan Hong, Indumathi Manoharan, AmolSuryawanshi, Santhakumar Manicassamy.

29. 5037 Immunotherapy meets epigenetics: GP96-Igcellular vaccine genetic signature is modulated by theinhibition of histone modifications. George J. Fromm, NealSchilling, Taylor H. Schreiber.

1111



Poster EndocrinologyMolecular Endocrinology of Cancer 2(not eligible for CME credit)


1. 5038 Role of the short isoform of the progesteronereceptor in hormone-regulated invasiveness of breastcancer cells at pre- and post-menopausal levels ofestrogen and progesterone. Thomas B. McFall, MugdhaPatki, Rayna Rosati, Manohar Ratnam.

3. 5040 Calcium channels: Potential new therapeutictargets for hormone independent and resistant breastcancers. Kedra Cyrus, Mudit Kaushal, Zeina Sharawi, GlynNoguchi, Tiffany Chang, William Rydzewski, Fatima Gibrel,William Yeguech, Bassam Haddad, Mary Beth Martin.

4. 5041 The ER� downregulation mediated by MTA1 insalivary gland cancer cells. Kazufumi Ohshiro, RakeshKumar.

5. 5042 Dynamic transcriptional regulation of ER�targets in prostate cancer. Kellie Cotter, DimpleChakravarty, Andrea Sboner, Mark A. Rubin.

6. 5043 ER� decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53gain-of-function. Igor Bado, Fotis Nikolos, GayaniRajapaksa, Jan-Ake Gustafsson, Christoforos Thomas.

7. 5044 Reducing breast cancer risk with hormonereplacement therapy. Anna Dembo, Geoffrey Greene.

8. 5045 Characterization of estrogen receptor alphaphosphorylation sites as a marker for tamoxifen resistantbreast cancer. Wayne A. Speckmann, Robert Brockett, ChunYang, Chandra Mohan, Kevin Long, Michele Hatler, Xiaoyi Xu.

9. 5046 Amphiregulin is a key effector of estrogenreceptor in breast cancer. Esther A. Peterson, NatashaChandiramani, Evelyn J. Aranda Jaque, E. C. Jenkins, ParaicA. Kenny.

10. 5047 Role of estrogen receptors alpha and beta in thebalance between proliferation and surveillance. D. J. Jerry,Karen A. Dunphy, Amy L. Roberts, Margarita Brown.

11. 5048 The cholesterol metabolite, 27-hydroxycholesterol stimulates cell proliferation in prostateepithelial cell lines via estrogen receptor beta. ShaneabbasRaza, Jared Schommer, Megan Meyer, Bin Guo, KimberlyHammer, Othman Ghribi.

12. 5049 Checkpoint kinase 2 is a novel regulator ofprostate cancer cell growth. Huy Q. Ta, Melissa L. Ivey,Henry F. Frierson, Mark R. Conaway, Jaroslaw Dziegielewski,James M. Larner, Daniel Gioeli.

13. 5050 Proteome-based combined treatment strategiessynergizing antagonism of androgen receptor function inprostate cancer. Joo Hyoung Lee, James A. Mobley,Selvarangan Ponnazhagan.

14. 5051 Androgen receptor-mediated regulation ofp14ARF transcription in prostate tumor cells. Maria Mudryj,Salma Siddiqui, Stephen J. Libertini, Alan P. Lombard,Benjamin Mooso, Leandro D’Abronzo, Frank Melgoza,Alexander Borowsky, Christiana Drake, LiHong Qi, ParamitaM. Ghosh.

15. 5052 The association between estrogen receptor alphaand platinum sensitivity in ovarian cancer cells. SoheiMatsumura, Tsuyoshi Ohta, Toshifumi Takahashi, KazuhiroTakahashi, Satoru Nagase.

16. 5053 Discovery of GDC-0810 a novel, non-steroidalselective estrogen receptor degrader with robust activityin pre-clinical models of endocrine-resistant breast cancer.James Joseph, Steven Govek, Beatrice Darimont, DanielBrigham, Anna Aparicio, Eric Bischoff, Mehmet Kahraman,Michelle Nannini, Joshua Kaufman, Andily Lai, Kyoung-JinLee, Jason Oeh, Nhin Lu, Wei Zhou, Michael Moon, Jing Qian,John Sensintaffar, Gang Shao, Deepak Sampath, Lori S.Friedman, Peter Rix, Richard A. Heyman, Nicholas Smith,Jeffrey H. Hager.

17. 5054 Discerning the PARP-dependent AR cistrome/transcriptome in prostate cancer. Matthew J. Schiewer,Sumin Han, Joseph Evans, Michael A. Augello, Lisa Berman-Booty, Theodore Parsons, Ruth Birbe, Adam P. Dicker,William K. Kelly, Leonard G. Gomella, Felix Feng, Karen E.Knudsen.

18. 5055 Role of insulin-like growth factor 1 receptor inpancreatic cancer pathogenesis. Ramadevi SubramaniReddy, Arunkumar Arumugam, Sushmita B. Nandy, ElizabethGonzalez, Viviana Gonzalez, Sandrine Bonkoungou, AndrewOrtega, Rajkumar Lakshmanaswamy.

19. 5056 PIM-1 kinase regulates vitamin D receptorsignaling in human renal carcinoma cells. Wei Luo, YingyuMa, Carmen Baldino, Justin Caserta, Swathi Ramakrishnan,Pili Roberto, Candace Johnson, Donald Trump.

20. 5057 Single-cell RNA-seq analysis of heterogeneouspopulations within gastroenteropancreaticneuroendocrine tumors: the role of Sox transcriptionfactors. Haydee Lara, Tamara Matysiak-Budnik, Scott T.Magness.

21. 5058 Silencing of NOTCH signaling enhances thesensitivity of ERG positive prostate cancer cells to ARinhibitors. Ahmed A. Mohamed, Shyh-Han Tan, Shilpa Katta,Charles P. Xavier, Lakshmi Ravindranath, Wei Huang, Hua Li,Meera Srivastava, Shashwat Sharad, Taduru Sreenath,Gyorgy Petrovics, Albert Dobi, Shiv Srivastava.

22. 5059 Androgenic signaling influences SOCS-3 inprostate cancer cells. Florian Handle, Holger H. Erb, BirgitLuef, Frédéric R. Santer, Zoran Culig.

1212



Poster Tumor BiologyBiomarkers and Clinical Implications of the Tumor Microenvironment(not eligible for CME credit)


1. 5060 Exosome transfer from ovarian cancer cells tomesothelial cells promotes cell invasion by upregulatingMMP-9 secretion and increasing clearance of mesothelialcells. Koji Nakamura, Kenjiro Sawada, Yasuto Kinose, AkihikoYoshimura, Erika Nakatsuka, Seiji Mabuchi, Tadashi Kimura.

2. 5061 Astrocytes promote medulloblastomatumorigenesis via sonic hedgehog secretion. Larra W.Yuelling, Fang Du, Eric Lee, Renata Muradimova, Peng Li,Zeng-jie Yang.

3. 5062 Ovarian cancer cells induce themicroenvironment changes and subsequently promotedisease propagation and dissemination through epithelial-mesenchymal transition and enrichment of tumorigeniccells. Nanni Huser, Zhengming Yan, Jing Yuan, Cathy C.Zhang.

4. 5063 Lysyl oxidase-like 2 (LOXL2) from cancer-associated fibroblasts stimulates the progression ofgastric carcinoma. Hiroaki Kasashima, Masakazu Yashiro,Kisyu Kitayama, Go Masuda, Haruhito Kinoshita, KatsunobuSakurai, Takahiro Toyokawa, Naoshi Kubo, Hiroaki Tanaka,Kazuya Muguruma, Masaichi Ohira, Kosei Hirakawa.

5. 5064 EGFR and HER3 are important in the interactionbetween lung cancer cells and fibroblasts. ChristinaDemuth, Kristine R. Jakobsen, Peter Meldgaard, Anders L.Nielsen, Boe S. Sorensen.

6. 5065 Interleukin-1� secreted into the bone metastaticniche by androgen receptor-negative prostate cancer cellsenables skeletal metastasis. Kristina S. Shahriari, Fei Shen,QingXin Liu, Danielle L. Jernigan, Ramanpreet Kaur,Alessandro Fatatis.

7. 5066 Reprogramming the TGF-beta signaling incancer-associated fibroblasts inhibits ovarian cancerprogression. Tsz-Lun Yeung, Cecilia S. Leung, Kwong-KwokWong, Samuel C. Mok.

8. 5067 Preadipocyte exosomes promote early stagebreast cancer formation by enhancing cancer stem cellrenewal signaling. Benjamin Wolfson, RamkishoreGernapudi, Nadire Duru, Qun Zhou.

9. 5068 Treatment with regorafenib inhibits the tumor-promoting effect of bone marrow-derived mesenchymalstem cells in an orthotopic nude mice model of coloncancer. Kei Shinagawa, Yasuhiko Kitadai, Ryo Yuge, MiekoOnoyama, Shinji Tanaka, Wataru Yasui, Kazuaki Chayama.

10. 5069 IL-33 secreted by cancer-associated fibroblastsmediates epithelial-stromal interactions and promotesgastric cancer invasion via ERK signaling pathway. LipingSu, Quan Zhou, Chenchen Wang, Xiongyan Wu, XiaofengWang, Jianfang Li, Zhenggang Zhu, Bingya Liu.

11. 5070 Inhibition of collagen receptor discoidin domainreceptor-1 (DDR1) reduces colon cancer cell migration andmetastasis. Ryo Yuge, Yasuhiko Kitadai, Kei Shinagawa, MiekoOnoyama, Shinji Tanaka, Wataru Yasui, Kazuaki Chayama.

12. 5071 Inhibition of Porcupine reduces Wnt-dependentcolony formation and/or proliferation in both autocrineand paracrine cell models. Ben A. Thompson, Kate J.Messenger, Emily Linnane, Sarah E. Coupland, Peter J. Calcraft.

13. 5072 Mesenchymal stem cells promote osteogenesisand the evolution of apoptosis resistant bone metastaticprostate cancer. Jeremy J. McGuire, Leah Cook, JeremyFrieling, Conor Lynch.

14. 5073 Role of TIMP-1 glycosylation in lung carcinoma.Byung R. Lee, Ammar Kutiyanawalla, Sampa Ghosal-Gupta,Amyn M. Rojiani, Mumtaz V. Rojiani.

15. 5074 Activation of TGF �-IL6 axis mediateschemoresistance in non-small cell lung cancer byincreasing epithelial-mesenchymal transition signaling.Yasushi Shintani, Soichiro Funaki, Toru Kimura, AyakoFujiwara, Tomohiro Kawamura, Toshiya Bessho, MasayoshiInoue, Masato Minami, Meinoshin Okumura.

16. 5075 The composition and interactions in themicroenvironment of human prostate cancer. MoniqueMelis, Bianca Cioni, Ekaterina Nevedomskaya, Johan vanBurgsteden, Emma Hodel, Annegien Broeks, Henk van derPoel, Jeroen de Jong, Andre Bergman.

17. 5076 Tumor cell-derived exosomes educate bonemarrow mesenchymal stromal cells toward aprotumorigenic function. Rie Nakata, Lucia Borriello, MullerFabbri, Hiroyuki Shimada, Yves A. Declerck.

18. 5077 Metastasis suppressors regulate the tumormicroenvironment by blocking recruitment of pro-metastatic TAMs. Daniel C. Rabe, Casey Frankenberger,Russell Bainer, Devipriya Sankarasharma, Kiran Chada,Thomas Krausz, Yoav Gilad, Lev Becker, Marsha R. Rosner.

19. 5078 Human breast carcinoma-associatedmesenchymal stem cells promote breast cancer cellproliferation, irreversible EMT and invasion throughCollagen I. Maria E. Gonzalez, Emily E. Martin, Celina G. Kleer.

20. 5079 Parasympathetic signaling suppresses pancreaticcancer development. Bernhard W. Renz, Marina Macchini,Yoku Hayakawa, C. B. Westphalen, Michael Churchill, SuchetakKar, Xiaowei Chen, Karan Nagar, Yagnesh Tailor, Daniel L.Worthley, Alina C. Iuga, Ken P. Olive, Timothy C. Wang.

21. 5080 HIF-1 is responsible for the induction of cancer-associated fibroblasts in hypoxic tumormicroenvironment. Koji Teramoto, Yoko Kataoka, TomoyukiIgarashi, Yasuhiko Ohshio, Jun Hanaoka, Yataro Daigo.

22. 5081 The IGF axis regulates hepatic stellate cellrecruitment and activation during colorectal carcinomaliver metastasis. Maria C. Fernandez, Roni F. Rayes, Jun Xu,Tatiana Kisseleva, Shoshana Yakar, Pnina Brodt.

23. 5082 Impact of HGF knockin microenvironment onepithelial-mesenchymal transition and cancer stem cells ina non-small cell lung cancer xenograft model. Tony Navas,Thomas D. Pfister, Scott M. Lawrence, Apurva K. Srivastava,Robert J. Kinders, Suzanne Borgel, Melinda G. Hollingshead,Lindsay M. Dutko, Brad A. Gouker, Donna Butcher, ElinorNg-Eaton, Naoko Takebe, Ralph E. Parchment, Joseph E.Tomaszewski, James H. Doroshow.

24. 5083 Adipocytes promote pancreatic cancer cellproliferation and progression. Roopali Roy, Marsha A.Moses.

25. 5084 A multifaceted role of the Hedgehog pathway inmodulating pancreatic ductal adenocarcinoma biology.Dafydd H. Thomas, Albert Lee, Carmine Palermo, StephenSastra, Raul Rabadan, Kenneth Olive.

26. 5085 Acute myeloid leukemia cells induce osteogenicdifferentiation in mesenchymal stem cells through bonemorphogenetic protein- and RUNX-2- mediated signaling.Venkata Lokesh Battula, Phuong M. Le, Jeff Sun, ChristopherB. Benton, Teresa Mc.Queen, Elizabeth J. Shpall, Carlos E.Bueso-Ramos, Marina Konopleva, Michael Andreeff.

27. 5086 De-differentiation of CD45+ hematopoietic cellsto CD45- stromal cells in vitro. Yang Jo Chung, Suntae Kim,Peter Aplan.

28. 5087 Precise characterization of macrophage secretoryexosomes can lead to novel therapeutic approaches.Robert B. Bednarczyk, Yuki Kitadai, Neha Y. Tuli, Elyse K.Hanly, Ghada Benrahoma, Abraham Mittelman, Raj K. Tiwari.

29. 5088 Glioblastoma stem cell-secreted exosomes caninduce a tumor supportive M2 response. KonradGabrusiewicz, Yuuri Hashimoto, Jun Wei, Maiti Sourindra,John Yu, Shinji Yamashita, Anna Zal, Tomasz Zal, LaurenceCooper, Amy B. Heimberger.

30. 5089 Desmoplastic stroma affects growth and invasionof progressively mutated human pancreatic cancer cells invitro. Ruchi Malik, Tiffany Luong, Seda Karamil, Peter Lelkes,Edna Cukierman.

1414



Poster Tumor BiologyFactors Regulating Motility and Invasion(not eligible for CME credit)


1. 5090 Targeting metastatic prostate cancer withpolyisoprenylated cysteinyl amides. Rosemary A. Poku,Augustine Nkembo, Olufisayo Salako, Felix Amissah, HernanFlores-Rozas, Tryphon Mazu, Nazarius S. Lamango.

2. 5091 Inhibiting endothelium directed tumor cellstreaming by targeting the HGF/C-Met and EGF/CSF-1signaling pathways. Edison Leung, Yarong Wang, BryanSmith, Daniel Flynn, John Condeelis.

3. 5092 Midkine as a potential target for combating drugresistance and invasion in melanoma. Amanpreet Kaur,Michael O’Connell, Marie Webster, Reeti Behera, VanessaDang, Abibatou Ndoye, Ashani Weeraratna.

4. 5093 Pre-clinical assessment of a novel anti-invasionnanoparticle therapeutic in combination withbevacizumab for the treatment of glioblastoma. David W.Murray, Philip O’Halloran, Monika Jarzabek, Brian MacCarthy,Jann N. Sarkaria, Raymond M. Schiffelers, Marc Symons,Annette T. Byrne.

5. 5094 Capsaicin inhibits invasion of human non-smallcell lung cancer cells in a TRPV1 receptor independentmanner. Matthew N. Eskew, Kathleen C. Brown, PiyaliDasgupta.

6. 5095 1,25D3 inhibits migration and invasion throughmiR-101-3p in human bladder cancer cells. Yingyu Ma, WeiLuo, Rachel Pratt, Donald L. Trump, Candace S. Johnson.

7. 5096 ALIBI: a novel, truncated tubulin isotype in AMLand stem cells. Paul Basciano, Xi Li, Jason Matakas, SusannaLiu, Silvana Di Giandomenico, Siddhartha Sen, Todd Evans,Joseph Scandura, Monica Guzman, Paraskevi Giannakakou.

8. 5097 APE1/Ref-1 promotes cell adhesion andmigration in cervical cancer cells. Mihwa Kim, Ho J. You,Dae J. Kim.

9. 5098 Participation of Crk-associated substrate (CAS) inhuman pancreatic cancer cell migration, invasion andmetastatic processes. Hirotaka Okamoto, Hideki Fujii.

10. 5099 Abrogation of cancer cell extravasation in renalcell carcinoma PDX lines via invadopodia dysregulationmediated by PAK1 inhibitors. Karla Williams, ClarisseMazzola, James Brugarolas, Nicholas Power, Ann Chambers,Hon Leong.

11. 5100 Aerobic glycolysis is the primary metabolicpathway used for prostate cancer cell motility andinvasion processes regardless of androgen sensitivity.James E. Verdone, Jelani C. Zarif, Kenneth J. Pienta.

12. 5101 The control of migration and invasion processesin colorectal adenocarcinoma is modulated by prionprotein and its ligand STI1/HOP. Tonielli S. Lacerda, MarcosVinicius S. Dias, Fernanda S. Giudice, Bianca Luise Teixeira,Vilma Regina Martins.

13. 5102 Differential levels of mutated Kras drive lungcancer cell motility and morphology via a hypoxia-sensitive FAK/Erk/Myosin II signaling pathway. Anette C.Schafer, Meghan Discoll, Ashwathi Mohan, Andrew Ludlow,Wesley Burford, Jerry W. Shay, Gaudenz Danuser.

14. 5103 Loss of p27 upregulates MnSOD in a STAT3-dependent manner, disrupts intracellular redox activityand enhances cell migration. Jing An, Dongyun Zhang,Chuanshu Huang.

15. 5104 Isorhapontigenin (ISO) inhibits cancer invasionby enhancing FOXO1 transcription through targetingSTAT1 phosphorylation at Tyr701. Lei Xue, Guosong Jiang,Jingxia Li, Chuanshu Huang.

16. 5105 The imprinted tumor suppressor gene NDNinhibits cell motility in ovarian cancer by reactivating FAKand RhoA. Hailing Yang, Partha Das, Weiqun Mao, Rebecca T.Marquez, Zhen Lu, Robert C. Bast.

17. 5106 Influence of chloride flux on cell motility in headand neck squamous cell carcinoma. Nayel Khan, KevinSteehler, Carolyn Kemp, Sucheta Kulkarni, Kara Davis,Umamaheswar Duvvuri.

18. 5107 Divergent behaviors and underlying mechanismsof cell migration and invasion in non-metastatic T24 andits metastatic derivative T24T bladder cancer cell lines.Honglei Jin, Jingxia Li, Chuanshu Huang.

19. 5108 Oscillatory calcium signal drives melanomainvasion and metastasis. Jianwei Sun, Fujian Lu, Huifang He,Heping Cheng, Shengyu Yang.

20. 5109 The CARMA3-Bcl10-MALT1 signalosome mediatesNF-�B activation and cellular invasion in AGTR1-positivebreast cancer. Prasanna Ekambaram, Nathaniel Hubel, Jia-Ying Lee, Linda Klei, Vincent Concel, Philip Delekta, ScottTomlins, Linda McAllister-Lucas, Peter Lucas.

1515



Poster Tumor BiologyImaging of Molecular and Cellular Events in Tumors and Tumor Cells(not eligible for CME credit)


1. 5110 Initial characterization of an optical reportermyoblast cell line for non-invasive imaging in a cancercachexia model in mice. Paul T. Winnard, Marie-FrancePenet, Yelena Mironchik, Flonne Wildes, Anirban Maitra,Zaver M. Bhujwalla.

2. 5111 Bio-distribution and tumor targeting of a P-cadherin x CD3 bi-specific redirected T-cell molecule usingfluorescence molecular tomography imaging. AnandGiddabasappa, Vijay Gupta, Timothy S. Fisher, John David,Norberg Rand, Allison Rohner, Justin Cohen, Tracey Clark,Nahor Haddish-Berhane, Adam Root, Chad May.

3. 5112 In vivo molecular imaging of HIF-1� and septin 9interaction by bimolecular fluorescence complementation.Maya Golan, Nicola J. Mabjeesh.

4. 5113 Rapid cancer imaging by GGT-targetedfluorescence probe for primary lung cancer. Haruaki Hino,Mitsuaki Kawashima, Tomonori Murayama, Junji Ichinose,Kentaro Kitano, Kazuhiro Nagayama, Jun-ichi Nitadori,Masaki Anraku, Tomohiro Murakawa, Kasue Mizuno, SayakaTanaka, Mako Kamiya, Nobuhiro Nishiyama, KazunoriKataoka, Kohei Miyazono, Yasuteru Urano, Jun Nakajima.

5. 5114 Multispectral optoacoustic tomography (MSOT)as a novel approach for dynamic, noninvasive assessmentof tumor therapy response and chronic inflammation.Wouter H. Driessen, Neal Burton, Christian Schwöppe,Wolfgang E. Berd, Toni Weinhage, Georg Varga, ChristianeGeyer.

6. 5115 An orthotopic lung tumor model for image-guided microirradiation in rats. Zhang Zhang, MichelleWodzak, Olivier Belzile, Heling Zhou, Ralph Mason, RolfBrekken, Rajiv Chopra, Michael D. Story, Robert Timmerman,Debabrata Saha.

7. 5116 Detection of pancreatic cancer using acidic pHtargeted probes detected using multispectral optoacoustictomography. Matthew Zeiderman, Anil Khanal, Charles W.Kimbrough, Jorge Gomez, William E. Grizzle, Kelly M.McMasters, Lacey R. McNally.

8. 5117 Fluorescence-guided surgery of liver metastasisin orthotopic nude-mouse models. Takashi Murakami,Yukihiko Hiroshima, Shinji Miwa, Yano Shuya, Makoto Toneri,Mako Yamamoto, Masashi Momiyama, Takashi Chishima,Kuniya Tanaka, Michael Bouvet, Satoshi Hasegawa, ItaruEndo, Robert M. Hoffman.

9. 5118 In-vivo non-invasive mitochondrial evaluation of3D human skin. Dimitra Pouli, Mihaela Balu, Bruce Tromberg,Irene Georgakoudi.

10. 5119 Mechanisms associated with blood flowmodifying effects of electric pulses used forelectrochemotherapy on normal and tumor blood vessels.Bostjan Markelc, Elisabeth Bellard, Gregor Sersa, TanjaDolinsek, Justin Teissie, Muriel Golzio, Maja Cemazar.

11. 5120 Using flow-proteometric platform to analyzeindividual signaling complexes in tumor tissue. Chao-KaiChou, Heng-Huan Lee, Pei-Hsiang Tsou, Chun-Te Chen, Jung-Mao Hsu, Hirohito Yamaguchi, Ying-Nai Wang, Jennifer L.Hsu, Jin-Fong Lee, Jun Kameoka, Mien-Chie Hung.

12. 5121 Study of a synthetic peptide probe for apoptosisimaging. Shen Yang, Jie Meng, Huike Liu, Chuan Wang,Yanlian Yang, Hua Guo, Jian Liu, Chen Wang, Haiyan Xu.

13. 5122 In vivo imaging models of bone and brainmetastases and pleural carcinomatosis developed using anovel human EML4-ALK lung cancer cell line, A925LPE3.Shigeki Nanjo, Shinji Takeuchi, Kenji Kita, Koji Fukuda,Mitsutoshi Nakada, Hiroshi Nishihara, Seiji Yano.

14. 5123 Curative fluorescence-guided surgery ofpancreatic cancer in combination with UVC irradiation inorthotopic mouse models. Yukihiko Hiroshima, Ali Maawy,Yong Zhang, Sho Sato, Takashi Murakami, Mako Yamamoto,Fuminari Uehara, Shinji Miwa, Shuya Yano, MasashiMomiyama, Takashi Chishima, Kuniya Tanaka, MichaelBouvet, Itaru Endo, Robert M. Hoffman.

15. 5124 Molecular imaging of tumor energy metabolismas an early indicator of anticancer drug efficacy in smallanimal models. Jen-Chieh Tseng, Jeffrey Peterson.

16. 5125 Imaging the tumor microenvironment ofmetastasis reveals the mechanism of transient bloodvessel permeability and tumor cell intravasation. Allison S.Harney, Esther N. Arwert, David Entenberg, Yarong Wang,Peng Guo, Bin-Zhi Qian, Bryan D. Smith, Jeffrey W. Pollard,Joan G. Jones, Daniel L. Flynn, John S. Condeelis.

1616



Poster Tumor BiologyOther Animal Species and Cell Models of Cancer(not eligible for CME credit)


1. 5126 Establishment of an esophageal smallcell carcinoma cell line (TYUC-1). Yutaka Shimada,Tomoyuki Okumura, Yoshinori Takei, Kazuaki Watanabe,Akira Hirasawa, Arito Yamane, Masahiko Nishiyama,Takuya Nagata, Kazuhiro Tsukada, Kazuharu Shimizu.

2. 5127 The most common mistakes in cancer cellpharmacology. Guido Lenz, Andrew O. Silva.

3. 5128 Changes in mitochondrial background affectnuclear DNA methylation. Carolyn J. Vivian, Amanda E.Brinker, Gerald C. Gooden, Christophe Legendre, BodourSalhia, Danny R. Welch.

4. 5129 Model osteosarcoma by Li-Fraumeni syndromepatient-specific induced pluripotent stem cells. Dung-FangLee, Jie Su, Huen Suk Kim, Betty Chang, Ruiying Zhao, DmitriPapatsenko, Ye Yuan, Julian Gingold, Weiya Xia, Henia Darr,Christoph Schaniel, Razmik Mirzayans, Mien-Chie Hung, IhorR. Lemischka.

5. 5130 Assessment of the antitumor activity of leech(huridinaria manillensis) saliva extract in prostate cancer.Amr E. Ammar, Mohamed H. Hassona, Gray R. Meckling,Leslie G. Chan, Mei Y. Chin, Abdulrahman Abdualkader,Mohamed Alaama, Ahmed Merzouk, Abulbashar Helaluddin,Abbas Ghawi, Omer Kucuk, Emma S. Guns.

6. 5131 Establishment of uterine carcinosarcomaprimary cell lines for chemosensitivity testing andevaluation of targeted therapy. Jurriaan Brouwer-Visser,Eirwen Scott, Shijun Mi, Maria J. Cossio, Tiffany Hebert,Gloria S. Huang.

7. 5132 Evaluation of multi-marker in tissue-derivedcancer cells from patients with epithelial ovariancarcinoma. Shin-Wha Lee, Sang-Eun Lee, Ha-Young Lee,Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-TakKim, Joo-Hyun Nam.

8. 5133 The RNA-binding protein HuR facilitatesproliferation and metastasis in human pancreatic ductaladenocarcinoma. Masaya Jimbo, Fernando F. Blanco, BradScrenci, Gabriela Cosma, Vitali Alexeev, Yu-Hung Huang,Jordan M. Winter, Charles J. Yeo, Janet A. Sawicki, JonathanR. Brody.

9. 5134 Pharmaceutical effect of vitamin C (ascorbate) onB16 melanoma in vitro and in vivo. Pierre-Christian Violet,Nermi L. Parrow, Serrano L. Oscar, Jacqueline Yang, Mark A.Levine.

10. 5135 Study of a new splice variant of Neuropilin-1:Antagonistic functions in the regulation of tumorprogression. Céline Hendricks, Lauriane Janssen, RomainDelcombel, Johanne Dubail, Christophe Deroanne, AlainColige.

11. 5136 The Flint Animal Cancer Center (FACC) caninetumor cell line panel: A resource for comparative andtranslational oncology. Daniel L. Gustafson, Jared S.Fowles, Douglas H. Thamm, Rodney L. Page, Dawn L.Duval.

12. 5137 IQGAP1, an ERK1/2 MAPK scaffold, is anoncogenic target in canine melanoma. Ashley Zehnder,Becky Lee, Poornima Neela, Paul Khavari.

13. 5138 New technique generates cell cultures from rareadenoid cystic carcinomas of the salivary gland. ChenChen, Sujata Choudhury, Xuefeng Liu, Richard Schlegel,Seema Agarwal.

14. 5139 Cell sorting strategies for the isolation of cancercells and associated fibroblasts from tumor biopsies,surgical resections, and patient-derived xenografts. LukeH. Stockwin, Michael Mullendore, Carrie Bonomi, KellyDougherty, James H. Doroshaw, Melinda G. Hollingshead,Dianne L. Newton.

15. 5140 TALEN mediated mutation of apc and �-cateninin Xenopus tropicalis as powerful models for Wnt drivencancer and Familial Adenomatous Polyposis (FAP). TomVan Nieuwenhuysen, Thomas Naert, David Creytens, FransVan Roy, Kris Vleminckx.

16. 5141 A comprehensive system of congenic mousemelanoma models for evaluation of immune therapies.Katrina M. Meeth, William E. Damsky, Marcus Bosenberg.

17. 5142 A naturally occurring model for gastric cancer.Manar A. AbdelMageed, Monica Betancur-Boissel, ParthenaFoltopoulou, Sureshkumar Muthupalani, James G. Fox,Elizabeth A. McNiel.

18. 5143 Rats heterozygous for Pten developfibroadenoma and adenocarcinoma arising from themammary gland. Aaron M. McCoy, Bala Manickam, LaraReid, Edward Weinstein, Xiaoxia Cui.

19. 5144 Low dose sorafenib delays hepatocellular cancer(HCC) development in the woodchuck model of hepatitis Brelated HCC. Renuka V. Iyer, Sandra Sexton, Leslie Curtin,Gerald Fetterly, Orla Maguire, Hans Minderman, Ilia Toshkov,Bud Tennant, Alan Hutson, Donald L. Trump, CandaceJohnson.

20. 5145 Y-27632 inhibits Myc-induced apoptosis andcooperates with Myc to immortalize human keratinocytes.Aleksandra Dakic, Kyle Divito, Shuang Fang, Nancy Palechor-Ceron, Vera Simic, Sujata Choudhury, Songtao Yu, Cynthia M.Simbulan-Rosenthal, Dean Rosenthal, Richard Schlegel,Xuefeng Liu.

21. 5146 Establishment of an orthotopic bladder cancermodel to evaluate continuous intravesical delivery of smallmolecule inhibitors in the nude rat. Leigh J. Williams,Stephanie K. Klein, Danielle Greenawalt, Dawn Trueman,Helen Musgrove, Helen Jones, Linette Ruston, Barry R.Davies.

22. 5147 Canine spontaneous head and neck squamous cellcarcinomas represent their human counterparts at themolecular level. Deli Liu, Huan Xiong, Angela E. Ellis, NicoleC. Northrup, Dong M. Shin, Shaying Zhao.

23. 5148 NR5A2 is essential for pancreas developmentand affects pancreas carcinogenesis. Sahar Nissim, OliviaWeeks, John Hedgepeth, Julia Wucherpfennig, Xiao-XuWang, Alec Kimmelman, Wolfram Goessling.

24. 5149 An orthotopic model of human chordoma in rats.Rachel Sarabia-Estrada, Alejandro Ruiz-Valls, Courtney R.Goodwin, Sagar Sha, Alfredo Quiñones-Hinojosa, Ziya L.Gokaslan, Daniel M. Sciubba.

25. 5150 Drosophila models of Ret fusions in papillarythyroid carcinoma. Sarah Levinson, Ross Cagan.

26. 5151 Yap reprograms glutamine metabolism andsupports growth during liver development andtumorigenesis. Andrew G. Cox, Katie L. Hwang, KimberleyEvason, Kristin K. Brown, Sebastian Beltz, Keelin O’Connor,Giorgio G. Galli, Dean Yimlamai, Sagar Chhangawala, EvanLien, Fernando D. Camargo, John Asara, Yariv Houvras, DidierY. Stainier, Wolfram Goessling.

27. 5152 Zebrafish models of myeloid malignanciesproduced through tet2 and asxl1 genomic editing. EvisaGjini, Marc Mansour, Jeffry Sander, Shuning He, MyunggonKo, Yi Zhou, Scott Rodig, Keith Joung, Leonard Zon, AnjanaRao, Thomas Look.

28. 5153 Myogenic regulatory factors and their role inembryonal rhabdomyosarcoma. Ines M. Tenente, MyronIgnatius, Eleanor Chen, Madeline Hayes, David M.Langenau.

1717



Poster Tumor BiologyPredicting, Profiling, and Imaging Prospective and Established Metastases(not eligible for CME credit)


1. 5154 Diagnostic serum markers for metastatic braintumors identified by cross-species hybridization ofmicroarrays in animal models. Ho Jeong Lee, Sun Jin Kim,Hyun Kyung Yu, Seung Wook Kim, Qiuyu Wu, Junqin He,Isaiah J. Fidler.

2. 5155 Status and clinical relavence of G1/S cell cycleregulatory proteins in Ocular Surface Squamous Neoplasia.Sheetal Chauhan, Seema Sen, Anjana Sharma, SeemaKashyap, M. Vanathi, Neelam Pushker, Radhika Tandon.

3. 5156 Establishment of a FISH based analysis forindividual risk assessment of ccRCC patients on tissuemicroarrays. Julia Grimm, Arndt Hartmann, Christine Stoehr,Martin Janssen, Frank Kunath, Michael Stöckle, KerstinJunker.

4. 5157 Elevated uptake of free fatty acids via CD36promotes epithelial-mesenchymal transition inhepatocellular carcinoma. Aritro Nath, Irene Li, ChristinaChan.

5. 5158 CD44 cleavage promotes anoikis resistance andmetastasis in Ewing sarcoma. Nikolina Dioufa, Guang Li,Maria Tsokos.

6. 5159 Identification of ARv567es expression profile inthe prostate cancer clinical samples with a newlydeveloped antibody. Gang Liu, Aihua Li, Shihua Sun, CynthiaSprenger, Eva Corey, Colm Morrisey, Scott Dehm, StephenPlymate.

8. 5161 Discovery of a matrix metalloproteinase MMP10as a clinically relevant biomarker to predict lymph nodemetastasis in tongue squamous cell carcinoma. PawanUpadhyay, Nilesh L. Gardi, Hemant R. Dhamne, KavithaSonawane, Anil D’Cruz, Sudhir Nair, Amit Dutt.

9. 5162 Phosphatidylinositol 4-Kinase type IIIa (PI4KA)expression in prostate cancer. Diego Sbrissa, Louie Semaan,Li Yanfeng, Assia Shisheva, Sreenivasa R. Chinni.

10. 5163 A high level of circulating CXCL10 at initialdiagnosis is associated with poor prognosis ofosteosarcoma patients. Ricardo J. Flores, Aaron J. Kelly,Yiting Li, Manjula Nakka, Ching C. Lau, John Hicks, Tsz-KwongMan.

11. 5164 Primary tumor subclones carry somatic mutationsignatures of metastasis. Noemi Andor, Hanlee P. Ji.

12. 5165 Cancer associated macrophage-like cells as ablood-based biomarker for the screening of solid tumors.Daniel Adams, Katherine Alpaugh, Massimo Cristofanilli,Stuart Martin, Saranya Chumsri, Raymond C. Bergen, SusanTsai, Martin Edelman, Peixuan Zhu, Shuhong Li, Olga V.Makarova, Platte T. Amstutz, Cha-Mei Tang, Jeffrey R. Marks.

13. 5166 The Wnt signaling pathway in the ovariancarcinoma. Michal Chehover, Claes Tropé, Reuven Reich, BenDavidson.

15. 5168 Tumor metabolism as a driver of lethal prostatecancer. Rachel S. Kelly, Jennifer A. Sinnott, Jennifer R. Rider,Ericka Ebot, Travis Gerke, Kathryn Penney, Michaela Bowden,Massimo Loda, Philip W. Kantoff, Neil E. Martin, Edward L.Giovannucci, Andreas Pettersson Pettersson, SvitlanaTyekucheva, Kathryn M. Wilson, Matthew Vander Heiden,Lorelei A. Mucci.

16. 5169 Omics approach to identify driver genes forperitoneal dissemination of gastric cancer cells. ShoNambara, Junji Kurashige, Tomoko Saito, Hisateru Komatsu,Masami Ueda, Shotaro Sakimura, Hidenari Hirata, RyutaroUchi, Yuki Takano, Yoshiaki Shinden, Tomohiro Iguchi,Hidetoshi Eguchi, Keishi Sugimachi, Yoshihiko Maehara, KoshiMimori.

17. 5170 The autotaxin-lysophosphatidic acid signalingpathways in ovarian carcinoma. Hadil Onalla, Claes Tropé,Reuven Reich, Ben Davidson.

18. 5171 EpCAM expression governs tumor growth ordistant metastasis of human endometrial cancer: grow orgo theory. Kuo-Chang Wen, Peng-Hui Wang, Pi-Lin Sung,Mong-Hong Lee, Cheng-Wen Wu.

19. 5172 Developing a lung metastasis gene signatureusing a lung tropism model in melanoma. Yu Wen, MaungNaing Lin Shan, Jiadong Li, James Goydos.

20. 5173 Androgen receptor status is highly conservedduring tumor progression of breast cancer. André Grogg,Katrin Pfaltz, Claudia Lädrach, Nikola Cihoric, Martin Zweifel,Coya F. Tapia.

21. 5174 Imaging of tissue factor expression in anorthotopic pancreatic tumor mouse model using smallanimal PET/CT and MRI. Carsten H. Nielsen, Troels E.Jeppesen, Lotte K. Kristensen, Laura H. Larsen, JacobMadsen, Bo Wiinberg, Lars C. Petersen, Andreas Kjaer.

22. 5175 Preclinical monitoring of prostate cancer lesionsin bone by intravital multiphoton microscopy. EleonoraDondossola, Stephanie Alexander, Steve Alexander, BorisHolzapfel, Christopher Logothetis, Dietmar Hutmacher, PeterFriedl.

23. 5176 Chemotherapy alters the natural history ofmetastatic progression. Nicole M. Aiello, David L. Bajor,Minh N. Pham, Robert H. Vonderheide, Ben Z. Stanger.

24. 5177 Heterogeneity of pancreatic ductaladenocarcinoma visualized. Veronique Veenstra, HeleneDamhofer, Tom van Leusden, Jan Kessler, Jan Paul Medema,Hanneke van Laarhoven, Louis Vermeulen, Maarten Bijlsma.

25. 5178 Chitinase-3-like-1 (CHI3L1) expressed duringallergic pulmonary inflammation alters lungmicroenvironment accelerating breast cancer metastasis.Nathalia Gazaniga, Camilla S. Castro, Stephania Libreros,Ramon Garcia-Areas, Vijaya Iragavarapu-Charyulu.

26. 5179 An endothelial-mesenchymal transition of brainendothelial cells is required for metastatic extravasation.Istvan A. Krizbai, Akos Gasparics, Peter Nagyoszi, CsillaFazakas, Imola Wilhelm, Rita Bencs, Laszlo Rosivall, AttilaSebe.

27. 5180 Allergic pulmonary inflammation acceleratesbreast cancer metastasis via increase of MDSCs in the lungmicroenvironment. Stephania Libreros, Ramon Garcia-Areas, Nathalia Gazaniga, Philip Robinson, VijayaIragavarapu-Charyulu.

29. 5182 Characterization of miRNA expression patternfrom in-vitro obtained exosomes of different urinarybladder cancer cell lines. Sophie Baumgart, JoanaHeinzelmann, Michael Stoeckle, Marie Stampe Ostenfeld,Kerstin Junker.

30. 5183 Identification and characterization of wild typekinases driving prostate cancer metastasis. ClaireFaltermeier, Justin Drake, Peter Clark, Bryan Smith, ColleenMathis, Yang Zong, Carmen Volpe, Owen Witte.

1818



Poster Tumor BiologyTumor Metastasis(not eligible for CME credit)


1. 5184 Synaptonemal complex protein 3 is associatedwith lymphangiogenesis in non-small cell lung cancer.Haruhisa Kitano, Joon-Yong Chung, Jun Hanaoka, ShuheiInoue, Doki Yoshinori, Junya Fukuoka, Stephen M. Hewitt.

2. 5185 Identification of BRIP1 as a novel marker ofbreast tumor malignancy in the Omani population. IshitaGupta, Allal Ouhtit, Marwa Al-Riyami, Adil Al Ajmi.

3. 5186 Label-free imaging identification of white bloodcells using quantitative phase microscopy for negativeselection of circulating tumor cells. Yusuke Ozaki, HidenaoIwai, Hirotoshi Kikuchi, Tomohiro Matsumoto, ShinichiroMiyazaki, Toshiki Kawabata, Yoshihiro Hiramatsu, ManabuOhta, Kinji Kamiya, Megumi Baba, Kentaro Goto, ToyohikoYamauchi, Yukio Ueda, Shigetoshi Okazaki, Hiroyuki Konno.

4. 5187 Expression of metastasis-related miRNAs inEpCAM-positive CTC fraction in corresponding plasma andFFPEs of breast cancer patients with verified metastasis.Athina Markou, Martha Zavridou, Ioanna Sourvinou, NikosMalamos, Vasilis Georgoulias, Evi S. Lianidou.

5. 5188 Immunostaining of MRP-1 protein in circulatingtumor cells predicts shorter progression free survival inmetastatic colorectal cancer patients. Emne A. Abdallah,Ludmilla T. Chinen, Virgílio S. Silva, Natalia B. Mingues,Marcelo C. Machado Netto, José Luiz Gasparini Júnior, BrunaM. Rocha, Juliana V. Romero, Marcilei E. Buim, Mitzi Brentani,Marcello F. Fanelli.

6. 5189 Inhibitory effect of phytochemicals ononcostatin-M-induced tumor invasion and migration inhuman esophageal carcinoma. Eijin Naka, Yuko Takahashi,Hisahiro Matsubara, Kazunori Kato.

7. 5190 CCR6-mediated molecular mechanisms involvedin colon cancer. Neeraj Kapur, Hina Mir, Rajesh Singh,Shailesh Singh.

8. 5191 Missense mutants of p53 tumor suppressorcontributes to drug-resistance and epithelial-mesenchymal transition in colon cancer cells. Salman B.Hosain, Yong Y. Liu.

9. 5192 TGM-2 mediated downregulation of fibronectinduring TGFb-induced epithelial-mesenchymal transition inlung cancer NCI-H358 cells. Thung S. Lai, Pin-Tsen Lin,Charles S. Greenberg, Harry A. Drabkin, Robert Gemmill.

10. 5193 Ataxia telangiectasia mutated relates toepithelial-mesenchymal transition in colorectal cancer.Hidena Takahashi, Masashi Tsuruta, Hirotoshi Hasegawa, KojiOkabayashi, Ryo Seishima, Shimpei Matsui, Toru Yamada,Takayuki Kondo, Takehiro Shimada, Mutsuhito Matsuda,Masashi Yahagi, Yusuke Yoshikawa, Yusuke Asada, KiyoakiSugiura, Yoshiyuki Suzuki, Yuki Tajima, Junpei Nakadai, YukoKitagawa.

12. 5195 A novel, multimodal theranostic nanoprobe iseffectively incorporated into melanoma brain metastaticcells. Synnøve N. Aasen, Tilo W. Eichler, Martin Hruby, AnetaPospisilova, Petr Stepanek, Endy Spriet, Daniel Jirak, Kai OveSkaftnesmo, Frits Thorsen.

13. 5196 Histologic and whole slide quantitative imageanalysis of lung metastases in a mouse breast cancermodel using carboplatin and Nutlin 3A alone and incombination. Margaret Strack, Eva Tonsing-Carter, TonySinn, Tiaishia Spragin, Kacie Peterson, Barbara Bailey, KarenPollok, George Sandusky.

14. 5197 Claudin-1 enhances tumor proliferation andmetastasis by regulating cell anoikisin gastric cancer.Jiangfang Li, Jie Huang, Bingya Liu, Zhenggang Zhu.

15. 5198 Contribution of inflammatory cytokines to CD44-mediated breast cancer metastatic potential. HunterCovert, Liliana Mellor.

16. 5199 A second round for concomitant resistance inhuman cancer: A restraint upon metastasis. GeraldineGueron, Nicolás Anselmino, Damian Manchuca, Emiliano G.Ortiz, Maria Noelia Carabelos, Federico Schuster, PaulaChiarella, Alejandra Paez, Felipe M. Jaworski, JavierCotignola, Roberto Meiss, Raul Ruggiero, Elba S. Vazquez.

17. 5200 Significance of SPARC expression as the predictfactor of the therapeutic effect of nab-PTX in gastriccancer. Yuki Kiyozumi, Junji Kurashige, Shiro Iwagami,Kenichi Nakamura, Mayuko Ohuchi, Daisuke Izumi, KeisukeKosumi, Kazuto Harada, Ryuma Tokunaga, Yukiharu Hiyoshi,Yoshifumi Baba, Yasuo Sakamoto, Yuji Sakamoto, NaoyaYoshida, Hideo Baba.

18. 5201 Antimetastatic effect of a Dializable LeucocyteExtract in a murine model of prostate cancer. Miguel A.Hernandez-Esquivel, Sonia M. Perez-Tapia, Richard G. Pestell,Marco A. Velasco-Velazquez.

19. 5202 Magnolin suppresses cell migration by abrogationof ERK-mediated RSK2/NF-�B signaling pathway. Cheol-Jung Lee, Mee-Hyun Lee, Ji-Hong Song, Sun-Mi Yoo, Yong-Yeon Cho.

20. 5203 Differential response to retinoid treatment inmouse and human mammary tumor cell lines withalterations in protein kinase C (PKC) expression. Maria I.Diaz Bessone.

21. 5204 Parameters associated with metastaticdissemination are differentially modulated by specificisotypes of the retinoic acid receptor. Carolina Flumian,Damián E. Berardi, Stefano M. Cirigliano, María I. DíazBessone, Elisa D. Bal de Kier Joffé, Alejandro J. Urtreger,Laura B. Todaro.

1919



Poster Tumor BiologyTumor-Host Interactions(not eligible for CME credit)


1. 5205 Docosahexaenoic acid (DHA) alters breast cancerexosome-mediated microRNA signaling. Bethany N.Hannafon, Karla Carpenter, William Berry, Ralf Janknecht,William Dooley, Wei-Qun Ding.

3. 5207 Vascular remodeling is associated with increasedpermeability of experimental brain metastases of breastcancer. Kaci A. Bohn, Tori B. Terrell-Hall, Chris E. Adkins,Rajendar K. Mittapalli, Mohamed I. Nounou, Afroz S.Mohammad, Paul R. Lockman.

4. 5208 Neovascularization in brain metastasis is throughboth angiogenesis and vasculogenesis. Stephanie Mok,Lee-Cyn Ang, Christopher J. Howlett, Zia A. Khan.

5. 5209 Non-tumoral autotaxin stored into platelet �-granules promotes breast cancer cell metastasis. RaphaelLeblanc, Sue-Chin Lee, Dereck Norman, Johnny Ribeiro,Gabor Tigyi, Olivier Peyruchaud.

6. 5210 Creation of endothelial-targeted adenoviralvectors for genetic engineering of the metastatic tumormicroenvironment. Zhi Hong Lu, Sergey Kaliberov, LyudmilaKaliberova, Rebecca E. Sohn, Yingqui Du, David T. Curiel,Jeffrey M. Arbeit.

7. 5211 In vivo fluorescence and spectral microscopy ofthe effects of aerobic exercise on tumor oxygenation andperfusion in breast cancer. Jennifer A. Lee, Jennifer M.Wiggins, Lori P. Rice, Dietmar W. Siemann.

8. 5212 GM-CSF and MMP9, targets of metformin, arecrucial mediators of the tumor-promoting role of adiposetissue cells in breast cancer. Francesca Reggiani, PatriziaMancuso, Cristina Rabascio, Stefania Orecchioni, GiovannaTalarico, Cinzia Massaro, Valentina Labanca, Angelica Calleri,Francesco Bertolini.

9. 5213 RUNX2 modulates the angiogenic potential ofhuman neuroblastoma cells. Manu Gnanamony, IndraMohanam, Sanjeeva Mohanam.

10. 5214 Synergistic activity of aspirin, atenolol andmetformin in the inhibition of angiogenesis, local andmetastatic growth of breast cancer by targeting bothneoplastic and microenvironment cells. Giovanna Talarico,Francesca Reggiani, Stefania Orecchioni, Patrizia Mancuso,Angelica Calleri, Giuliana Gregato, Valentina Labanca,Douglas M. Noonan, Katiuscia Dallaglio, Adriana Albini,Francesco Bertolini.

11. 5215 Loss of Rpl22 promotes tumor progressionthrough regulation of angiogenesis. Shuyun Rao, Jason E.Stadanlick, Kathy Q. Cai, David L. Wiest.

12. 5216 Potential use of saliva and hair samples toidentify genetic markers for anti-VEGF therapy. Gloria R.Xue, Crystal R. Xue, Fei Shen, Bryan P. Schneider.

13. 5217 Microenvironmental influences on glioma stemcell migration. Monica J. Chau, Myles R. McCrary, SubhasMukherjee, Daniel J. Brat.

15. 5219 Circulating hTERT (human telomerase) mRNA:mechanism of action and potential use for early diagnosisof malignancy. Orit Uziel, Anna Gutkin, Einat Beery, JardenaNordenberg, Hadar Goldvaser, Yair Zloof, Steven Henick, MeirLahav.

16. 5220 Inflamed and wound recovered tumormicroenvironment contributions to lymphatic-mediatedmetastasis. Darci M. Fink, Alicia L. Connor, Philip M. Kelley,Richard M. Tempero, Michael A. Hollingsworth.

17. 5221 Mammary tumor aggressiveness is exacerbatedby endothelial HoxA5 expression. Josette Northcott, HansLayman, Nancy Boudreau.

18. 5222 Endothelial plasticity generates aberrantangiogenesis and therapy resistance in glioblastoma.Menggui Huang, Yi Fan.

19. 5223 A novel pro-angiogenic role for IDO1 ininflammatory tumor promotion. Arpita Mondal, James B.DuHadaway, Erika Sutanto-Ward, Courtney Smith, George C.Prendergast, Arturo Bravo-Nuevo, Alexander J. Muller.

20. 5224 Non-canonical activity of threonyl-tRNAsynthetase promotes angiogenesis and invasion in amouse model of ovarian cancer. Peibin Wo, TheresaWellman, Alan Howe, Christopher Francklyn, Karen M.Lounsbury.

21. 5225 Endothelial-specific Jagged1 blockade preventssolid tumor growth in pre-clinical models. Antonio Duarte,Ana-Rita Pedrosa, Alexandre Trindade, Catarina Carvalho,José Graça, Sandra Carvalho, Maria C. Peleteiro, Ralf H.Adams.

22. 5226 Glioma stem cells internalize perivascularbevacizumab via a non-canonical pathway and target it forrecycling or degradation. Gaelle Muller-Greven, CathleenCarlin, Justin Lathia, Richard Prayson, Manmeet Ahluwalia,Steven Toms, Markus Bredel, Jeremy Rich, Petra Hamerlik,Candece L. Gladson.

23. 5227 Endothelial-targeted fumagillin nanoparticlesand zoledronic acid additively reduce tumor angiogenesis.Alison Esser, Anne Schmieder, Jingyu Xiang, Michael Ross,Xinming Su, Huiying Zhang, Grace Cui, Stacy Allen, XiaoXiaYang, Dipanjan Pan, Greg Lanza, Kathy Weilbaecher.

24. 5228 mTORC2 mediates SDF-1�/CXCL12-inducedangiogenesis. Mary E. Ziegler, Michaela M. Hatch,Christopher C. Hughes.

25. 5229 Disruption of the acetylcholine signaling pathwaysuppresses the growth and angiogenesis of human lungcancers. Piyali Dasgupta, Kathleen C. Brown, Jamie K. Lau,Aaron M. Dom, Brent A. Thornhill, Clayton M. Crabtree,Theodore R. Witte, W. E. Hardman, Cody A. Stover, A. B.Carpenter, Yi C. Chen.

2020



Poster Clinical ResearchCirculating Free DNA 2(not eligible for CME credit)


1. 5230 Circulating tumor DNA as a ‘liquid biopsy’ in headand neck cancer. Sandra Perdomo, DevasenaAnantharaman, James Mckay, Paul Brennan.

2. 5231 Plasma genetic and genomic abnormalitiespredict treatment response and clinical outcome inadvanced prostate cancer. Liang Wang, Shu Xia, Meijun Du,Rachel Ditmar, Tiezheng Yuan, Yongchen Guo, Yuan Wang,Adam Lee, Michael Tschannen, Elizabeth Worthey, HowardJacobs, Chiang-Ching Huang, Manish Kohli.

3. 5232 Changes in plasma circulating DNA compositionduring focal ablative therapy for liver cancer. Maarit I.Tiirikainen, Karolina Peplowska, Min-Ae Song, Kyle Miyazaki,Linda L. Wong, Sandi A. Kwee.

4. 5233 Prediction and response evaluation of EGFRblockade for colorectal cancer by using circulating cell-free DNA. Takuma Iwai, Takeshi Yamada, Hatato Kan,Michihiro Koizumi, Seiichi Shinji, Goro Takahashi, AtushiWatanabe, Satoshi Matumoto, Akihisa Matuda, AyaYamagishi, Yasuyuki Yokoyama, Eiji Uchida.

5. 5234 Tumor-unique mutation detection in cell-freeDNA to monitor colorectal tumor burden using a cancer-associated gene sequencing panel. Kei A. Sato, Satoshi S.Nishizuka, Takeshi Iwaya, Kohei Kume, Koki Otsuka, GoWakabayashi.

6. 5235 Circulating tumor DNA as a prognostic marker incolorectal cancer: Preliminary results of a prospectivetrial. Pierre Laurent-Puig, Olivier Bouché, Ralph Niarra,Pascaline Aucouturier, Leonor Benhaim, Bruno Landi, AnneBerger, Thierry Lecomte, Corinne Normand, Delphine LeCorre, Audrey Didelot, Karine Mallet, Karla Perez Toralla,Thevy Hor, Zakaria El Harrak, Gilles Chatellier, BrianHutchison, Darren Link, Valerie Taly.

7. 5236 Prospective clinical application of circulatingcell-free DNA sequencing in metastatic colorectal cancer.Maria Pia Morelli, Michael Overman, Eduardo Vilar, VanMorris, David Fogelman, Imad Shureiqi, Chris Garret, RaghavKanwal, Cathy Eng, Brian Kee, Shanequa Manuel, RobertWolff, Dragon Sebisanovic, LaiMun Sew, Aubey Zapanta, BenShiller, Gangwu Mei, Helmy Eltoukhy, AmirAli Talasaz, ScottKopetz.

8. 5237 Monitoring minimal residual disease by urinary orplasma circulating tumor DNA of KRAS mutation burden incolorectal cancer patients with resectable livermetastases. Vlada Melnikova, Jason C. Poole, Cecile Rose T.Vibat, Lucie Benesova, Barbora Belsanova, Saege Hancock,Latifa Hassaine, Errin Samuelsz, Timothy T. Lu, Mark G.Erlander, Marek Minarik.

9. 5238 Methodology for single copy detection andquantitative monitoring of clinically actionable circulatingtumor DNA mutations in urine from cancer patients.Karena Kosco, Jason C. Poole, Saege Hancock, ErrinSamuelsz, Timothy T. Lu, Erin Clark, Latifa Hassaine, ShilohGuerrero, Cecile Rose T. Vibat, Vlada Melnikova, Mark G.Erlander.

10. 5239 KRAS wild-type status as detected by circulatingtumor DNA analysis may be a prognostic or predictivefactor for clinical benefit in patients with unresectable,locally advanced or metastatic pancreatic cancer (PC)treated with the MEK inhibitor refametinib (BAY 86-9766)and gemcitabine. Michael Teufel, Jean-Luc Van Laethem,Hanno Riess, Marius Giurescu, Vittorio L. Garosi, Anke Schulz,Richardus Vonk, Henrik Seidel, Joachim Reischl, Barrett H.Childs.

11. 5240 Comparative levels of KRAS mutations circulatingtumor DNA for association with overall survival in patientswith non-resectable pancreatic cancer. Julia S. Johansen,Cecile Rose T. Vibat, Saege Hancock, Latifa Hassaine, ErrinSamuelsz, Inna Chen, Eric A. Collisson, Dan Calatayud, BennyV. Jensen, Jane P. Hasselby, Timothy T. Lu, Jason C. Poole,Vlada Melnikova, Mark G. Erlander.

12. 5241 Clinical relevance of circulating tumor DNA inplasma from pancreatic cancer patients. Kjersti Tjensvoll,Morten Lapin, Tove Buhl, Satu Oltedal, Katrine S. Berry,Bjørnar Gilje, Jon Arne Søreide, Millind Javle, OddmundNordgård, Rune Smaaland.

13. 5242 Utilization of next-generation sequencing toidentify clinically-relevant mutations in cell-freecirculating tumor DNA from patients with advancedpancreatic cancer. Clifford G. Tepper, Ryan R. Davis,Stephenie Y. Liu, Rebekah A. Tsai, Irene M. Hutchins, Philip C.Mack, Thomas J. Semrad.

14. 5243 Copy number variation in cell free DNA inpancreatic cancer patients undergoing neoadjuvanttherapy. Karthika Divakaran, Xia Shu, Rachel L. Dittmar,Jenny Grewal, Kathleen K. Christians, Fabian M. Johnston,Douglas B. Evans, Spencer Huang, Liang Wang, Susan Tsai.

15. 5244 Next-generation sequence analysis of cell-freeDNA in patients with chemotherapy-refractory advancedpancreatic adenocarcinoma (PDAC) treated withselumetinib (AZD6244) and erlotinib. Andrew H. Ko, TaniosBekaii-Saab, Ryan Courtin, Olga K. Mirzoeva, Sharvina Ziyeh,Robin K. Kelley, Elizabeth Ditto, Anna Ong, ReginaLinetskaya, Margaret Tempero, Alan P. Venook, AmiraliTalasaz, Wolfgang M. Korn.

16. 5245 Identification and quantification of somaticstructural variations in tumor, urine and plasma frombladder cancer patients. Karin Birkenkamp-Demtröder, IverNordentoft, Emil Christensen, Søren Hoyer, Thomas Reinert,Søren Vang, Jørgen Bjerggaard Jensen, Torben F. Ørntoft,Lars Dyrskjøt.

17. 5246 Noninvasive detection of MET gene amplificationin the circulation of cancer patients. Mark Sausen, SamuelV. Angiuoli, Bryan Chesnick, Kevin Galens, Siân Jones, MauraKadan, Lisa Kann, Karli Lytle, Derek Murphy, MonicaNesselbush, Sonya Parpart-Li, David Riley, Manish Shukla,Theresa Zhang, Victor E. Velculescu, Luis A. Diaz.

18. 5247 Predominance of EGFR mutations responsible forresistance to tyrosine kinase inhibitors among tumor DNAsassessed by picoliter droplet digital PCR analysis of cell-free plasma DNAs. Yoshitaka Seki, Yutaka Fujiwara, TakashiKohno, Erina Takai, Kuniko Sunami, Hidehito Horinouchi,Shintaro Kanda, Hiroshi Nokihara, Noboru Yamamoto, Shun-ichi Watanabe, Kazuyoshi Kuwano, Yuichiro Ohe.

19. 5248 Non-invasive EGFR T790M detection usingdroplet digital PCR system. Shinsuke Hashida, KadoakiOhashi, Takehiro Matsubara, Tomoaki Ohtsuka, MototsuguWatanabe, Ken Suzawa, Yuho Maki, Hiromasa Yamamoto,Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, ShinichiroMiyoshi, Katsuyuki Kiura, Shinichi Toyooka.

20. 5249 Intratumor heterogeneity and the detection ofpotential driver mutations in cfDNA in a NSCLC cohortusing UltraSEEKTM. Mariam Jamal-Hanjani, Elza De Bruin,Gareth Wilson, Nicholas McGranahan, Andrew Rowan,Michael Mosko, Heath Metzler, Anders Nygren, CharlesSwanton.

21. 5250 Analysis of circulating plasma DNA on metastaticanimal model using human lung cancer cell lines. NaokoAragane, Akemi Sato, Naomi Kobayashi, Eisaburo Sueoka,Seiji Okada, Shinya Kimura.

22. 5251 TaqMan® rare mutation assays for QuantStudio®3D digital PCR system. Marion Laig, Brian Ho, Nivedita S.Majumdar, Le T. Lac, Frances Chan, Ramesh Sathiyaa, Iain Russel,Paco Cifuentes, Ted Straub, Kamini Varma, David Keys.

23. 5252 Liquid biopsies to prospectively select patientswith KRAS or NRAS mutant hepatocellular carcinoma(HCC) in two phase II studies with Refametinib. HeikoKrissel, Andrea Hennig, Danny Zhang, Rodrigo Ito, ChristineGonschorek, Fabricio Souza, Martina Poethig, KathleenSchostack, Joachim Reischl, Philipp Angenendt, Barrett H.Childs, Michael Teufel.

2222



Poster Clinical ResearchGenomics in the Clinic 2(not eligible for CME credit)


1. 5253 LT� receptor and NIK signaling activates thealternative NF-kB pathway in head and neck squamouscell carcinoma. Rita Das, Tsu-Fang Cheng, Jamie coupar,Anthony Saleh, Xingping Yang, jialing Zhang, shaleekaCornelius, Carter Van Waes, zhong Chen.

2. 5254 Sentinel lymph node detection and in vivo/exvivo assessment of melanin distribution by means ofmultispectral optoacoustic tomography (MSOT) inpatients with malignant melanoma. Stefan Morscher, IngoStoffels, Neal C. Burton, Jing Claussen, Thomas Sardella, IrisHelfrich, Uwe Hillen, Julia Leyh, Dirk Schadendorf, MatthiasGunzer, Joachim Klode.

3. 5255 miR-21 expression in HER2-positive breast cancer andprediction of resistance to adjuvant trastuzumab. Boye S. Nielsen, EvaBalslev, Tim S. Poulsen, Dorte Nielsen, Trine S. Moller, Christiane E. Mortensen, KimS. Holmstrom, Estrid Hoegdall.

4. 5256 MiRNA-31-5p expression in glioblastoma tissue and effectsof its replacement in glioblastoma cells. Jiri Sana, Andrej Besse, JakubOndracek, Marek Vecera, Pavel Fadrus, Leos Kren, Hana Mlcochova,Robert Illiev, Jitka Mlcochova, Petra Vychytilova, Renata Hezova, JaroslavJuracek, Ondrej Slaby.

5. 5257 Immunohistochemical analysis and comprehensive hormonereceptor profiling of uterine adenosarcomas at a single institution.Jenna R. Zechmeister, Gloria S. Huang, Rouzan Karabakhtsian, MelissaSchwartz, Eric R. Prossnitz, Gary L. Goldberg, Merieme Klobocista.

6. 5258 Expression analysis of STEAP1 in breast cancer patients astherapeutic target. Chidananda Mudalagiriyappa, Sreeraj Pillai, MarkWatson, Rebecca Aft.

8. 5260 Mitochondrial DNA phylogenetic analysis for localrecurrences and second primary tumors from patients with oral cavitysquamous cell carcinoma. Chih-Hsiung Lai.

9. 5261 Prognosis of baseline absolute lymphocyte count (ALC) andneutrophil to lymphocyte ratio (NLR) in patients with pancreaticadenocarcinoma. Kartik Anand, Erkut Borazanci, Sachin Pai, Runhua Shi, Syed H.Jafri, Glenn Mills.

10. 5262 Specific mtDNA variants and colorectal adenopolyps.LaShanale M. Wallace, Sharifeh Mehrabi, Xuebiao Yao, Felix O.Aikhionbare.

11. 5263 Assessment and targeting of the MDM2-p53 network in CLL.Laura Woodhouse, Clark Crawford, Scott Marshall, Nick Bown, JonathanWallis, Geoffrey Summerfield, Elaine Willmore, John Lunec.

12. 5264 A novel strategy for accuurate and unambiguous mutationdetection of the highly homologous PMS2 gene. Jianli Li, HongzhengDai, Yangming Feng, Jia Tang, Stella Chen, Xia Tian, Elizabeth Gorman, EricS. Schmitt, Jing Wang, Victor W. Zhang, Lee-Jun Wong.

14. 5266 RYBP expression predicts survival of patients withhepatocellular carcinoma, and regulates response to chemotherapy.Wei Wang, Jianwen Cheng, Jiang-Jiang Qin, Sukesh Voruganti, Subhasree Nag, JiaFan, Qiang Gao, Ruiwen Zhang.

15. 5267 Comorbidity and cause of death in patients with chroniclymphocytic leukemia (CLL). Paolo Strati, Kari Chaffe, Sara Achenbach,Timothy Call, Neil Kay, James Cerhan, Susan Slager, Tait Shanafelt.

16. 5268 Differences in ERG and ANXA2 expression betweenCaucasian Americans and African Americans highlight distinctpathologic features of prostate cancer progression. Shyh-Han Tan,Denise Young, Yongmei Chen, Albert Dobi, Jennifer Cullen, GyorgyPetrovics, Isabell A. Sesterhenn, Shiv Srivastava.

17. 5269 Myxofibrosarcoma: A move toward Precision Medicine.Chantal Pauli, Jonathan Pauwels, Theresa Y. MacDonald, Juan MiguelMosquera, Andrea Sboner, Olivier Elemento, Francesca Demichelis, DavidePrandi, David Rickman, Beata Bode, Himisha Beltran, Mark A. Rubin.

18. 5270 IDH mutation status and role of WHO grade and mitoticindex in overall survival in grade II-III diffuse gliomas. Adriana Olar,Khalida Wani, Kristin Diefes, Lindsey Heathcock, Hinke van Thuijl, MarkGilbert, Terri Armstrong, Erik Sulman, Daniel Cahill, Jaap Reijneveld, BaukeYlstra, Pieter Wesseling, Kenneth Aldape.

19. 5271 Hepatic hypoxia-activated intra-arterial therapy: effect ofselective targeting of hypoxia in a rabbit liver tumor model. RafaelDuran, Sahar Mirpour, Vasily Pekurovsky, Shanmugasundaram Ganapathy-Kanniappan, Cory F. Brayton, Toby C. Cornish, Boris Gorodetski, JuliusChapiro, Rüdiger Schernthaner, Constantine Frangakis, MingDe Lin, JessicaD. Sun, Charles P. Hart, Jean-François H. Geschwind.

20. 5272 The correlation between the change of future remnant livervolume and functional capacity in ALPPS (associating liver partitionand portal vein ligation for staged hepatectomy), and establishment ofALPPS model in rats. Daisuke Kawaguchi, Yukihiko Hiroshima, TakashiMurakami, Kenichi Matsuo, Chihiro Kosugi, Kiyohiko Syuto, AkimitsuYamada, Itaru Endo, Keiji Koda, Kuniya Tanaka.

21. 5273 Role of methylation of Wnt target genes in tumorigenesisand effect of re-expression with demethylating agent decitabine incolon cancer. Janneke Linnekamp, Raju Kandimalla, Louis Vermeulen,Hanneke van Laarhoven, Jan Paul Medema.

22. 5274 MSI, 18q LOH, and clinicopathological features in stage IIsporadic colon cancers: Biomarker study in a phase III study ofpostoperative adjuvant chemotherapy for stage II colon cancer(SACURA trial). Toshiaki Ishikawa, Hiroyuki Uetake, Megumi Ishiguro,Kenta Murotani, Hideki Ueno, Shigeyuki Matsui, Kenichi Sugihara, NaohiroTomita, SACURA study group.

23. 5275 Association of TERT polymorphism with acute myeloidleukemia risk and prognosis. Kourosh Lotfi, Mohamed Ali Mosrati, KerstinWillander, Ingrid Jakobsen Falk, Monica Hermanson, Martin Höglund, DickStockelberg, Yuan Wei, Peter Söderkvist.

24. 5276 Epithelial mesenchymal transition may contribute toanaplastic change of pancreatic ductal adenocarcinoma. Kotaro Miura,Kenjiro Kimura, Ryosuke Amano, Sadaaki Yamazoe, Go Ohira, Kohei Nishio,Masatsune Shibutani, Katsunobu Sakurai, Hisashi Nagahara, Takahiro Toyokawa,Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Hiroshi Otani, Masakazu Yashiro,Kiyoshi Maeda, Masaichi Ohira, Kosei Hirakawa.

25. 5277 ERG-based stratification of prostate cancer highlightsethnicity associated biological differences. Albert Dobi, Michael Degon,James Farrell, Wagner Baptiste, Denise Young, Yongmei Chen, GyorgyPetrovics, Jennifer Cullen, Jacob Kagan, Sudir Srivastava, Inger Rosner,David G. McLeod, Shiv Srivastava, Isabell Sesterhenn.

26. 5278 Mutation in protein tyrosine phosphatase receptor type K(PTPRK) enhances progression of colon cancer through WNT signaling.Masayuki Tojo, Kazuo Konishi, Keiko Shinjo, Fumiharu Ohka, KeisukeKatushima, Akira Hatanaka, Norihisa Ichimura, Hisako Nozawa, TomoeShimazaki, Hitoshi Yoshida, Yutaka Kondo.

27. 5279 Establishing robust pharmacodynamic (PD)immunofluorescence assays of clinical biopsies at the National CancerInstitute: Optimized quality control procedures for the evaluation ofDNA damage response and epithelial-mesenchymal transition (EMT)biomarkers. Katherine V. Ferry-Galow, Scott M. Lawrence, Tony Navas,Hala R. Makhlouf, Donna O. Butcher, Brad A. Gouker, William H. Yutzy,Jiuping Ji, Robert Kinders, Ralph E. Parchment, Shivaani Kummar, JosephE. Tomaszewski, James H. Doroshow.

28. 5280 A polymorphism of VEGFA is associated with susceptibilityto extrathyroidal invasion of papillary thyroid cancer. Young Gyu Eun,Young Chan Lee, Jung-Woo Lee.

29. 5281 Prognostic biomarkers for progression-free survival inglioblastoma multiforme: quantitative imaging and gene expressions.Kelvin K. Wong, Stephen T. Wong.

2323



Poster Clinical ResearchPrognostic Biomarkers 3: Breast, Central Nervous System, Gynecological, andHematological Cancer(not eligible for CME credit)


1. 5282 A 3q amplification gene signature associated with triplenegative breast cancer lung-specific metastasis. Jun Qian, Heidi Chen,Pierre P. Massion.

2. 5283 Vav2 oncoprotein up regulation may predict the aggressivesubtype of ductal carcinoma in situ. Marina A. Guvakova, Yun Qing Jiang,Indira Prabakaran, Fei Wan, Nandita Mitra, Paul J. Zhang, Douglas L.Fraker.

3. 5284 Triple-negative breast cancer in Algerian population:clinicopathological and molecular study. Farid Cherbal, Hadjer Gaceb,Chiraz Mehemmai, Insaf Saiah, Rabah Bakour, Abdelhalim Ould-Rouis,Tarek Touahria, Hassen Mahfouf, Samia Daoudi, Wassila Benbrahim, KadaBoualga.

4. 5285 Ki-67 expression and mitotic count in lymph nodemetastasis and their association with clinico-pathologic features andsurvival in aggressive breast carcinoma. Sura M. Aziz, Elisabeth Wik, GørilKnutsvik, Karin Collett, Lars A. Akslen.

5. 5286 Expression of cancer type amino acid transporter LAT1 is aprognosis prediction factor in breast carcinoma: comparison betweentriple-negative and non-triple-negative types. Masaaki Ichinoe, TetsuoMikami, Kiyomi Hana, Nobuyuki Yanagisawa, Hitoshi Endou, Isao Okayasu,Yoshiki Murakumo.

6. 5287 RNA DNA divergences: An unsuspected marker of cancergenomic instability accurately predicts triple-negative breast cancerseverity. Bernard E. Bihain, Stéphane Verdun, Julie Tomasina, BenoitHilselberger, Marie Brulliard, Lionel Bonnard, Marina Trarbach, OlivierRoitel, Sandrine Jacquenet, Virginie Ogier, Jean-Pierre Armand, BenoitThouvenot.

8. 5289 The role of the immune system in lymph node positive ER+breast cancer. Jessica G. Cockburn, Amy Gillgrass, Anita Bane.

9. 5290 Identification of novel prognostic genes associated with riskof recurrence in early breast cancer patients. Mi Jeong Kwon.

10. 5291 Prognosis within different breast cancer subtypes usingfunctional activity of signaling pathways. Henk van Ooijen, Márcia A.Inda, Ralf Hoffmann, Paul van de Wiel, Anja van de Stolpe, Wim Verhaegh.

11. 5292 Determination of the receptor for advanced glycation end-products in breast cancer patients previous chemotherapy. Jorge A.Guadarrama-Orozco, Erika B. Ruiz-García, Hector A. Maldonado-Martinez, LiliaP. Barron-Rodríguez, Fernando Mainero-Ratchelous, Horacio Astudillo-delaVega.

12. 5293 Redox imaging biomarkers for breast cancerdiagnosis/prognosis: a pilot study. He N. Xu, Julia Tchou, Min Feng,Huaqing Zhao, Nannan Sun, Sophia Zhang, Lily Moon, Lin Z. Li.

13. 5294 Biomarkers in residual disease after neoadjuvantchemotherapy of breast cancer predict long-term outcome. RichardBuus, Marie Klintman, Amna Sheri, Maggie Cheang, Mitch Dowsett.

14. 5295 Latent class longitudinal modeling of CTCs in ER+ metastaticbreast cancer patients. Terry Hyslop, Xuechan Li, Rui Duan, MarioGiuliano, Antonio Giordano, Marlana Orloff, Hallgeir Rui, James M. Reuben,Massimo Cristofanilli.

15. 5296 FOXP1 expression is associated with tumor progression andpoor prognosis in cervical cancer. Hanbyoul Cho, Woo Kyeom Yang, SolKim, Ha-Yeon Shin, Eun Ju Lee, Jae-Hoon Kim.

16. 5297 Chromosomal instability as a prognostic marker in cervicalcancer. Christine How, Jeff Bruce, Jonathan So, Melania Pintilie, BenjaminHaibe-Kains, Angela Hui, Blaise Clarke, David Hedley, Richard Hill, MichaelMilosevic, Anthony Fyles, Kenneth W. Yip, Fei-Fei Liu.

17. 5298 Serum angiogenic factors may predict prognosis in patientswith epithelial ovarian cancer. HIROAKI KOMATSU, Tetsuro Oishi, HiroakiItamochi, Akiko Kudoh, Michiko Nonaka, Seiya Sato, Jun Chikumi, ShinyaSato, Muneaki Shimada, Junzo Kigawa, Tasuku Harada.

18. 5299 Monitoring of ovarian cancer recurrence and progression viaLumipulse G CA125II assay. Rachel R. Radwan, Savitha S. Raju, Sara J.Gannon, John Le, Sharee D. Jones, Catherine Peacock, Katherine Falcone,Julianna T. Young, Zhong-Qian Li, Diana L. Dickson.

19. 5300 Loss of function of two closely linked tumor suppressorscontributes to biologic aggressiveness in endometrial cancers: Co-mutation of CTCF and ZFHX3. Christopher J. Walker, Mario A. Miranda,Matthew O’Hern, Kevin Coombes, Ralf Bundschuh, David G. Mutch, Paul J.Goodfellow.

20. 5301 Integrative protein-marker prognostic model for early-stageendometrioid endometrial carcinoma. Han Liang, UT MD AndersonRPPA/TCGA working group.

21. 5302 Genome-wide methylation analysis reveals multipleepigenetic subtypes of acute myeloid leukemia. Andrew D. Kelly, HeikeKroeger, Jumpei Yamazaki, Rodolphe Taby, Frank Neumann, Justin T. Lee,Rong He, Shoudan Liang, Yue Lu, Matteo Cesaroni, Sherry A. Pierce,Steven M. Kornblau, Carlos E. Bueso-Ramos, Farhad Ravandi, Hagop M.Kantarjian, Jaroslav Jelinek, Jean-Pierre J. Issa.

22. 5303 Correlative results from PRELUDE, a phase III study ofenzastaurin (ENZA) vs placebo (PBO) in patients (pts) with high-riskdiffuse large B-cell lymphoma (DLBCL) following a response to R-CHOPtherapy. Eric D. Hsi, Kerry J. Savage, Sonali M. Smith, Fritz Offner, Scott P.Myrand, Thomas M. Habermann, Donald E. Thornton, Boris K. Lin, Tuan S.Nguyen, Oday Hamid, Michael Crump.

23. 5304 A serum protein test for improved prognostic stratificationof patients with myelodysplastic syndrome (MDS). Joanna Roder, JudithLöffler-Ragg, Reinhard Stauder, Ulrich Germing, Wolfgang R. Sperr, PeterValent, Heinrich Roder, Arni Steingrimsson, Heinz Zwierzina.

24. 5305 Predicting relapse using CD138-independent strategy todetect residual myeloma plasma cells. Barbara Muz, Feda Azab, Pilar dela Puente, Justin King, Micah Luderer, Ravi Vij, Abdel Kareem Azab.

25. 5306 Microparticles as novel prognostic markers in multiplemyeloma. Sabna Rajeev Krishnan, Mary Bebawy, Ross D. Brown, FrederickLuk, Yiulam Kwan.

26. 5307 Analysis of telomere length in classic and variant hairy cellleukemia. Daniel C. Edelman, Evgeny Arons, Holly Stevenson, Allison Gomez,David Petersen, Hong Zhou, Yonghong Wang, Joshua J. Waterfall, Paul S.Meltzer, Robert Kreitman.

27. 5308 Distinct expression, activity, regulation and gene expressionsignature of NF-�B subunit c-Rel and the prognostic impact ofcrosstalk between p53, p63 and c-Rel in different subsets of diffuselarge B-cell lymphoma. Zijun Y. Xu-Monette, Ken H. Young.

28. 5309 The role of aquaporin-1 as the prognostic factor for triplenegative breast cancer. Young Ah Lim, Lee-Su Kim.

29. 5310 Prognostic and predictive biomarkers of clinical response toBevacizumab in recurrent WHO grade 3 malignant glioma patients.Anders Toft, Thomas Urup, Kirsten Grunnet, Ib J. Christensen, Signe R.Michaelsen, Helle Broholm, Vibeke A. Larsen, Michael Kosteljanetz, UlrikLassen, Hans S. Poulsen.

30. 5311 Studies of co-expression of cancer stem cell markers andgrowth factor receptors in human ovarian cancer cells and theirresponses to treatment with various tyrosine kinase inhibitors. SoozanaPuvanenthiran, Sharadah essapen, Alan M. Seddon, Helmout Modjtahedi.

2424



Poster Experimental and Molecular TherapeuticsApoptosis: Therapeutic Manipulation(not eligible for CME credit)


1. 5312 Biobran/MGN-3, arabinoxylan from rice bran,sensitizes breast adenocarcinoma tumor cells to paclitaxolin mice. Nariman K. Badr El-Din, Doaa A. Ali, Mai Alaa El-Dein, Mamdooh Ghoneum.

2. 5313 The anticancer effect of Vernonia amygdalina inthe MMTV-PyVT transgenic mouse model. Clement G.Yedjou, Paul B. Tchounwou, Lucio Miele, Ifedayo V. Ogungbe,Robert J. Brown, Marinelle Payton.

3. 5314 Evaluation of C-phycocyanin and anticancerdrug combination for inducing apoptosis in LNCaPprostate cancer cells. Amal Khallouki, Hasan Azad,Sivanesan Dhandayuthapani, Miroslav Gantar, AppuRathinavelu.

4. 5315 Hydroxychloroquine inhibits proliferation and S6phosphorylation in human renal carcinoma cells. Hyung-OkLee, Aladdin Mustafa, Gary R. Hudes, Warren D. Kruger.

5. 5316 Check point kinase 1 (Chk1) targeting as a noveltherapeutic strategy in small cell lung cancer (SCLC). AlyA. Valliani, Triparna Sen, Fatehmeh Masrorpour, Lixia Diao,Robert J. Cardnell, Jing Wang, Bonnie S. Glisson, HelenPiwnica-Worms, Don L. Gibbons, Lauren A. Byers.

6. 5317 Preclinical evaluation of IQS019, a novel BCRkinase inhibitor, in in vitro and in vivo models of non-Hodgkin lymphoma. Patricia Balsas, Jocabed Roldan, LauraJimenez, Vanina Rodriguez, Raimon Puig de la Bellacasa,Jordi Teixido, Alba Matas-Cespedes, Alexandra Moros,Antonio Martinez, Elias Campo, Jose I. Borrell, Patricia Perez-Galan, Dolors Colomer, Gael Roue.

7. 5318 Effect of C-phycocyanin on the anticancerproperties of taxol and topotecan in lung cancer implantedathymic nude mice. Sivanesan Dhandayuthapani, MiroslavGantar, Thanigaivelan Kanagasabai, Manasa Subbarao, AppuRathinavelu.

8. 5319 Apoptotic properties of platinum antitumoragents phosphaplatins. Homa Dezvareh.

9. 5320 Targeting HER3 and EGFR in NRG1 positive andHER3 mutated lung squamous cell carcinoma. Maria C.Pinzon-Ortiz, Xianhui Rong, Richard Versace, Qing Sheng, Z.Alexander Cao.

10. 5321 Preclinical validation for treatment with RG7787in ovarian cancer. Gwendlyn Kollmorgen, Klara Palme,Annette Seidl, Stefan Scheiblich, Christian Clemens, EdgarVoss, Martin Kaufmann, Klaus Hirzel, Pamela Wilfert, MoritzMarcinowski, Bernd Satzinger, Frank Herting, GerhardNiederfellner.

11. 5322 Englerin-A prevents invasive phenotypes of renalcell carcinoma by reprogramming mesenchymal toepithelial transition: A key mechanism of its anticancerproperties . Inamul Haque, Snigdha Banerjee, John A.Beutler, Sushanta K. Banerjee.

12. 5323 Targeting PIM1 and CDK4/6 kinases in renal cellcarcinoma. Jeffery S. Small, Sheldon L. Holder.

13. 5324 Selective Inhibition of HDAC6 regulatespreferential cytotoxicity in cancer cells by modulating p53and Hsp90 stability. So Hee Kwon.

14. 5325 A c-Kit targeting antibody-drug conjugate isefficiently metabolized and activated inside cancer celllines and xenograft tumors. Erica Hong, Qifeng Qiu, Rui Wu,Alan Wilhelm, Kathleen Whiteman, Jan Pinkas, HansErickson, Tinya Abrams, Siew Schleyer.

15. 5326 Intracellular bacterial delivery of a NIPP1-peptidekills tumor cells. Nele Van Dessel, Neil S. Forbes.

16. 5327 Simultaneous inhibition of ATR and PARP greatlysensitizes colon cancer cell lines to irinotecan. DavidDavidson, Atlal Abu-Sanad, Yunzhe Wang, FatemehHasheminasab, Justin Panasci, Raquel Aloyz, LawrencePanasci.

17. 5328 Protein phosphatase 2A activity is a majordeterminant of therapy response in cancer cells. OttoKauko, Susumu Imanishi, Amanpreet Kaur, Daniel Laajala,Evgeny Kulesskiy, Mikael Jumppanen, Garry Corthals, TeroAittokallio, Krister Wennerberg, Jukka Westermarck.

18. 5329 Development of small molecule activators ofprotein phosphatase 2A for the treatment of lung cancer.Jaya Sangodkar, Sudeh Izadmehr, Sahar Mahzar, Divya Hoon,Shen Yao, David Kastrinsky, Daniela Schlatzer, NeeleshSharma, Alain C. Borczuk, Michael Ohlmeyer, YiannisIoannou, Goutham Narla.

19. 5330 Methioninase-loaded erythrocytes: a promisingdrug for L-methionine restriction therapy in cancer. FabienGay, Julie Bes, Vanessa Bourgeaux, Yann Godfrin.

20. 5331 Targeting CA125 negative high grade serousovarian cancer stem cells can result in a dramaticreduction in tumor burden. Deanna Janzen, EkaterianTiourin, Justin Salehi, Jing Lu, Matteo Pellegrini, SanazMemarzadeh.

21. 5332 The Pim kinase inhibitor AZD1208 sensitizes acutemyeloid leukemia cells with fms-like tyrosine kinase 3internal tandem duplication (FLT3-ITD) to cytotoxiceffects of chemotherapy drugs. Kshama A. Doshi, KarthikaNatarajan, Benjamin Wolfson, Dennis Huszar, Maria R. Baer.

22. 5333 TH-302 potentiates the antitumor activity oftopotecan in neuroblastoma and rhabdomyosarcomapreclinical models. Libo Zhang, Bing Wu, Paula Marrano,Paul Thorner, Sylvain Baruchel.

23. 5334 Oncolytic Newcastle disease virus: armed but notdangerous. Danielle K. Carroll, James Harper, ShannonBurke, Jon Travers, Ruth Franks, Christel Navarro, XingCheng, Robert W. Wilkinson, Hong Jin.

24. 5335 Discovery and validation of new kinase targets fortherapy in ovarian clear cell cancer. Joseph J. Caumanns,Steven de Jong, G. Bea A. Wisman, Pieter Van der Vlies, RoelJ.C. Kluin, Lorenza Mittempergher, Katrien Berns, RenéBernards, Ate G.J. Van der Zee, The ovarian clear cell cancerconsortium.

25. 5336 Improved antitumor effect of combining WNT/beta-catenin inhibition with sorafenib in hepatocellularcarcinoma. Hsiao-Hui Lin, Wen-Chi Feng, Li-Chun Lu, Yu-YunShao, Ann-Lii Cheng, Chih-Hung Hsu.

26. 5337 An in silico platform for characterizing ADCbystander effects. Jackson Burton, Shu-Wen Teng,Christopher J. Zopf, Ryan Nolan, Arijit Chakravarty.

27. 5338 Preclinical study of telomerase-specific p53tumor suppressor gene overexpression in human scirrhousgastric cancer cells with different p53 status. Naoto Hori,Hiroshi Tazawa, Masahiko Nishizaki, Satoru Kikuchi, ShuyaYano, Michihiro Ishida, Megumi Watanabe, Yasuo Urata,Shunsuke Kagawa, Toshiyoshi Fujiwara.

28. 5339 Cytotoxic genes from traditional Chinesemedicine inhibit tumor growth both in vitro and in vivo.Yuanhui Zhang, Yuan Wang, Lina Wang, George Aslanidi,Arun Srivastava, Changquan Ling, Chen Ling.

29. 5340 Dual PI3K and Wnt pathway inhibition is asynergistic combination against triple-negative breastcancer. Jeffrey P. Solzak, Rutuja Atale, Brad Hancock, MilanRadovich.

2727



Poster Experimental and Molecular TherapeuticsDrug Discovery(not eligible for CME credit)


1. 5341 Bifunctional integrated molecules with combined retinoicacid receptor agonist/protein deacetylase inhibitory activities astherapeutic agents for breast cancer and neuroblastoma. David Cotnoir-White, Angela Miller, Bin Zhao, Isroel Weiss, James Gleason, DavidBettoun, Sylvie Mader.

2. 5342 Xanthohumol induces apoptosis and reduces notch inneuroblastoma. Mariappan Balamurugan, Selvi Kunnimalaiyaan, T.ClarkGamblin, Muthusamy Kunnimalaiyaan.

3. 5343 The effect of horizontal and vertical inhibition of nodeswithin the MAPK and PI3K-AKT pathways in NSCLC models. SophieBroutin, Adam Stewart, Parames Thavasu, Angelo Paci, Jean-MichelBidart, Udai Banerji.

4. 5344 Novel thioxodihydroquinazolinone small molecules forcombination with platinum drugs to reverse platinum resistancethrough inducing mitochondrial apoptosis independent of Bax and Bak.Wei Qian, Joseph Salamoun, Jingnan Wang, Vera Roginskaya, BennettVan Houten, Peter Wipf.

5. 5345 Enhanced inhibition of PC-3 xenograft prostate tumorgrowth by combination of green tea and quercetin with docetaxel.Piwen Wang, Susanne Henning, David Heber, Jaydutt Vadgama.

6. 5346 Notch3-mediated squamous cell differentiation shows anti-tumor effect on esophageal squamous cell carcinoma as well asreduces its resistance to 5-Fluorouracil. Osamu Kikuchi, Shinya Ohashi,Yukie Nakai, Yusuke Amanuma, Masahiro Yoshioka, Shin’ichi Miyamoto,Mitsuteru Natsuizaka, Hiroshi Nakagawa, Tsutomu Chiba, Manabu Muto.

7. 5347 SK053, a small molecule inhibitor of enzymes involved inallosteric disulfide bonds formation, shows potent anti-leukemiceffects and induces differentiation of human AML cells. Dominika Nowis,Justyna Chlebowska, Pawel Gaj, Michal Lazniewski, Malgorzata Firczuk,Karolina Furs, Radoslaw Sadowski, Pawel Leszczynski, Piotr Stawinski,Szymon Klossowski, Ryszard Ostaszewski, Krzysztof Giannopoulos, RafalPloski, Dariusz Plewczynski, Jakub Golab.

8. 5348 The extracellular domain of thrombomodulin induceserythroid differentiation and hampers proliferation of human leukemiacells in vitro and in vivo. Takayuki Ikezoe, Jing Yang, Chie Nishioka,Goichi Honda, Akihito Yokoyama.

9. 5349 Discovery of retinoic acids as low affinity inhibitors of theleukemia stem cell target NR2F6. Christine V. Ichim, Lap Shu A. Chan,Dzana Dervovic, David Koos, Richard A. Wells, Thomas Ichim.

10. 5350 Targeting Heparan Sulfated Proteoglycans by branchedpeptides for selective cancer imaging and therapy. Jlenia Brunetti,Lorenzo Depau, Chiara Falciani, Elisabetta Mandarini, Giulia Riolo, GiuliaRoscia, Alessandro Pini, Luisa Bracci.

11. 5351 Oral delivery of doxorubicin using bile enhancer formetronomic maintenance chemotherapy. Seho Kweon, Foyez K.A.Mahmud, Hyo Won Chang, Have Yoon Nam, Mi Ra Kim, Jung Je Park,Youngro Byun, Sang Yoon Kim.

12. 5352 Mesenchymal stem cell as delivery carrier for prodrug genetherapy against colorectal cancer cell. Nasrin Salehi, Ching-An Peng.

13. 5353 Efficacy of an innovative, enzyme-activated doxorubicinprodrug in patient-derived dedifferentiated liposarcoma and synovialsarcoma xenograft models. Jasmien Cornillie, Agnieszka Wozniak, LiseVreys, Haifu Li, Thomas Van Looy, Jasmien Wellens, Ulla Vanleeuw, AndréTrouet, Peter Pokreisz, Daphne Hompes, Maria Debiec-Rychter, Raf Sciot,Patrick Schöffski.

14. 5354 The guilty bystander model for electrochemotherapy ofcancer: Verification in vitro. W Clark Lambert, Gregory J. Tsongalis,Claude E. Gagna, Muriel W. Lambert.

15. 5355 Oncolytic viral therapy with immune modulation is aneffective novel treatment strategy for non-small cell lung cancer.Jianrui Liu, Jason Spurrel, Zhong Qiao Shi, WenQian Chen, Don G. Morris.

16. 5356 3D tissue-engineered bone marrow niche as novel methodto study pathophysiology and drug resistance in multiple myeloma.Pilar de la Puente, Rebecca Gilson, Barbara Muz, Feda Azab, Justin King,Samuel Achilefu, Ravi Vij, Abdel Kareem Azab.

17. 5357 Inhibition of collagen receptor discoidin domain receptor-1(DDR1) tyrosine kinase enhances cytotoxicity of anti-mesothelinimmunotoxin for cancer therapy. Fatima G. Ali-Rahmani, DavidFitzgerald, Scott Martin, Paresma Patel, Craig Thomas, Ira Pastan.

18. 5358 The hypoxia-activated EGFR-TKI TH-4000 overcomeserlotinib-resistance in preclinical NSCLC models at plasma levelsachieved in a Phase 1 clinical trial. Adam V. Patterson, Shevan Silva,Christopher Guise, Maria Abbattista, Matthew Bull, Huai-Ling Hsu, Charles Hart,Jessica Sun, Angus Grey, Amir Ashoorzadeh, Robert Anderson, Jeff B. Smaill.

19. 5359 Antitumor efficacy of EC1456 in patient derived xenograftmodels of ovarian, endometrial, NSCLC and TNBC. Joseph A. Reddy,Alicia Bloomfield, Christina Taylor, Katherine Hargett, Melissa Nelson,Christopher Leamon.

20. 5360 The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Willem Dokter, Miranda van der Lee, PatrickGroothuis, Ruud Ubink, Monique van der Vleuten, Tanja van Achterberg,Eline Loosveld, Desirée Damming, Myrthe Rouwette, David Egging, Dielsvan den Dobbelsteen, Patrick Beusker, peter goedings, Gijs Verheijden,Jacques Lemmens, Marco Timmers.

21. 5361 In vitro results and electric fields simulations suggest TumorTreating Fields (TTFields) to be an effective treatment againstMesothelioma. Moshe Giladi, Mijal Munster, Roni Blat, Rosa Schneiderman,Yaara Porat, Zeev Bomzon, Noa Urman, Tali Voloshin, Eilon D. Kirson, UriWeinberg, Yoram Palti.

22. 5362 Andrographolide inhibits prostate cancer by modulatingchemokine and cytokines. Hina Mir, Neeraj Kapur, Rajesh Singh, GuruSonpavde, James W. Lillard, Shailesh Singh.

23. 5363 Navitoclax (Nav) and BMN 673 yield cytotoxicity with lowerdoses than used for single agents in high-grade serous ovarian cancer(HGSOC). Takuhei Yokoyama, Nicolas Gordon, Minshu Yu, Elise C. Kohn,Jung-Min Lee.

24. 5364 Delayed progression of lung metastases in a triple-negativebreast cancer model following delivery of cytosine deaminase thatconverts chemotherapeutic prodrug 5-fluorocytosine to 5-fluorouracil.Louis Dore-Savard, Zhihang Chen, Paul T. Winnard, Balaji Krishnamachary,Marie-France Penet, Venu Raman, Margaret E. Black, Zaver Bhujwalla.

25. 5365 Alternating electric fields (TTFields) in combination withpaclitaxel are therapeutically effective against ovarian cancer cells invitro and in vivo. Mijal Munster, Christopher P. Roberts, Eva M. Schmelz,Moshe Giladi, Roni Blat, Rosa S. Schneiderman, Yaara Porat, Zeev Bomzon,Noa Urman, Aviran Itzhaki, Tali Voloshin Sela, Shay Cahal, Eilon D. Kirson,Uri Weinberg, Yoram Palti.

26. 5366 Propentofylline inhibits TROY/TNFRSF19 signaling toenhance therapeutic efficacy in invasive glioblastoma cells. Harshil D.Dhruv, Serdar Tuncali, Alison Roos, Patrick Tomboc, Nathan Jameson,Ashley Chavez, Joseph Loftus, Michael E. Berens, Nhan L. Tran.

27. 5367 Discovery of dihydro-isoxazole derivatives as novelinhibitors of NAMPT for the treatment of multiple myeloma. DineshChikkanna, Anirudha Lakshminarasimhan, Vinayak Khairnar, Sunil panigrahi,Anuradha Ramanathan, Sumalatha Rani, Narasimha Rao, Karthikeyan S,Kishore Narayanan, Sreevalsam Gopinath, Raghuveer Ramachandra,Charamanna K. B., Shekar Chelur, Chetan Pandit, Murali Ramachandra.

28. 5368 Metarrestin effectively disassembles PNCs and inhibitsmetastasis. Chen Wang, Kevin Frankowski, Teper Yaroslav, SamarjitPatnaik, Frank Schoenen, Noel Southall, Wei Sun, Steve Titus, LesleyGriner, Christopher Dextras, Jamey Sultan, Irawati Kandela, MarzenaLewandowska, Yi-Ping Wen, John Norton, Jin Sol Kang, Andrew Mazar,Wei Zhang, Jeffrey Aubé, Marc Ferrer, Udo Rudloff, Juan Jose Marugan,Sui Huang.

29. 5369 Low asparagine synthetase expression and in vitrosensitivity highlights L-asparaginase potential for the treatment ofaggressive lymphomas. Willy Berlier, Karine Aguera, Fanny Gallix, Anne-Marie Chevrier, Alexandra Traverse-Glehen, Yann Godfrin.

30. 5370 The therapeutic strategy using Nek2 siRNA and 5FU forcholangiocarcinoma cell. Toshio Kokuryo, Yukihiro Yokoyama, JunpeiYamaguchi, Masato Nagino.

2828



Poster Experimental and Molecular TherapeuticsHistone Deacetylase Inhibitors, Methyltransferase Inhibitors, and Other Targets(not eligible for CME credit)


1. 5371 PRMT5 inhibitors as novel treatment for cancers.Hendrik Falk, Richard C. Foitzik, Elizabeth Allan, MelaniedeSilva, Hong Yang, Ylva E. Bozikis, Marica Nikac, Scott R.Walker, Michelle A. Camerino, Ben J. Morrow, Alexandra E.Stupple, Rachel Lagiakos, Jo-Anne Pinson, Romina Lessene,Wilhelmus J. Kersten, Danny G. Ganame, Ian P. Holmes, Gill E.Lunniss, Matthew Chung, Stefan J. Hermans, Michael W.Parker, Alison Thistlethwaite, Karen White, Susan A.Charman, Brendon J. Monahan, Patricia Pilling, JulianGrusovin, Thomas S. Peat, Stefan Sonderegger, EmmaToulmin, Stephen M. Jane, David J. Curtis, Paul A. Stupple,Ian P. Street.

2. 5372 Novel and selective inhibitors of histonedeacetylases (HDAC) 1 and 2 significantly enhance theactivity of the DNA methyltransferase inhibitor azacitidinein acute myeloid leukemia (AML). Chengyin Min, Steven N.Quayle, David Tamang, Simon S. Jones, Min Yang.

3. 5373 AK-1, a specific SIRT2 inhibitor, induces cell cyclearrest by downregulating Snail in HCT116 human coloncarcinoma cells. MIN GYEONG CHEON, Ja-Eun Kim.

4. 5374 Development of a method to measure acetylatedhistone H4 in the nuclei of circulating myeloid cells as asurrogate tissue for the pharmacodynamics of HDACinhibitors in the treatment of solid tumors. Jamieson David,Wai Wong, Gareth Veal.

5. 5375 Combined treatment of trichostatin A enhancescytotoxic effects of sunitinib on renal cell carcinoma cells.Hiromi Sato, Tatsuro Kashiba, Miaki Uzu, Takuya Fujiwara,Yukihiro Shibata, Rina Suzuki, Katsunori Yamaura, AkihiroHisaka.

6. 5376 Identification of the first small molecule PRMT6inhibitor tool compound. Allison Drew, Lorna Mitchell,Nathalie Rioux, Kerren Swinger, Scott Ribich, SuzanneJacques-O’hagan, Trupti Lingaraj, Tim Wigle, Tom Riera,Richard Chesworth, Jesse Smith.

7. 5377 The combination of HDAC inhibitors andmetformin as potential therapeutic agent for bladdercancer. Peter J. Van Veldhuizen, Emma Borrego-Diaz Reyes,Boumediene Bouzahzah, Benjamin Powers.

8. 5378 Epigenetic regugulation of osteosarcomametastatic phenotype via histone deacetylace inhibition.Kurt R. Weiss, Xiaodong Mu, Daniel Brynien.

9. 5379 A potent EZH2 inhibitor exhibits long residencetime and anti-tumor activity. Heidi Ott, Glenn van Aller,Jessica Ward, BaoChau Le, Cynthia Rominger, James Foley,Susan Korenchuk, Charles McHugh, Michael Butticello,Charles Blackledge, James Brackley, Joelle Burgess, CelineDuquenne, Neil Johnson, Jiri Kasparec, Louis LaFrance, Mei Li,Kenneth McNulty, Kenneth Newlander, Stuart Romeril,Stanley Schmidt, Mark Schulz, Dai-Shi Su, Dominic Suarez,Xinrong Tian, Christopher Carpenter, Juan Luengo, RyanKruger, Steven Knight, Michael T. McCabe.

10. 5380 Selective HDAC inhibition by ricolinostat (ACY-1215) or ACY-241 synergizes with IMiD®immunomodulatory drugs in Multiple Myeloma (MM) andMantle Cell Lymphoma (MCL) cells. Steven N. Quayle, IngridAlmeciga-Pinto, David Tamang, Min Yang, Simon S. Jones.

11. 5381 Therapeutic potential of HDAC inhibitors in smallcell carcinoma of the ovary, hypercalcemic type (SCCOHT).Yemin Wang, Pilar Ramos, Anthony N. Karnezis, Jeffrey M.Trent, David G. Huntsman.

12. 5382 Epigenetic targeting of survivin enhancespaclitaxel-mediated antitumor activity against non-small-cell lung cancer. Shuiliang Wang, Ling Zhu, Zhiyong Zeng,Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lu,Qinghua Wang, Lingjing Lin, Huiyue Dong, Weizhen Wu, KaiZheng, Jinquan Cai, Shunliang Yang, Yujie Ma, Shixin Ye, WeiLiu, Yinghao Yu, Bolin Liu, Jianming Tan.

13. 5383 DOT1L inhibitor EPZ-5676 synergizes withcytarabine and azacitidine in preclinical models of MLL-rearranged leukemia. Christine R. Klaus, Scott R. Daigle,Vivek Chopra, Jeffrey A. Keats, Carly T. Campbell, DorothyIwanowicz, Edward J. Olhava, Margaret P. Scott, Roy M.Pollock, Robert A. Copeland, Jesse J. Smith, Jorge DiMartino,Stephen J. Blakemore, Alejandra Raimondi.

14. 5384 Prolonged survival of the TH-MYCN murine modelof high-risk neuroblastoma, in response to the histonedeacetylase inhibitor panobinostat, is the result of bothapoptosis and differentiation. Kelly Waldeck, CarleenCullinane, Jake Shortt, Ben Martin, Kerry Ardley, RichardTothill, Grant McArthur, Paul J. Wood.

15. 5385 Anticancer effects of a novel histone deacetylaseinhibitor, SNUCH-1, in glioblastoma. Seung Ah Choi, Phi AeKwak, Young Eun Lee, Ji Hoon Phi, Jung Won Choi, Kyu-Chang Wang, Chul-Kee Park, Seung-Ki Kim.

16. 5386 Calothrixin A, a metabolite from Calothrixcyanobacteria, inhibits class I histone deacetylases leadingto suppression of cell growth and induction of apoptosis inhuman melanoma cells. Tripti Singh, Su Xu, SadanandanVelu, Santosh K. Katiyar.

17. 5387 ONC201/TIC10 is effective as a monoagent andsynergizes with chemotherapy to induce cell death in non-Hodgkin’s lymphoma. Mala K. Talekar, David Dicker, JoshuaAllen, Wafik El-Deiry.

18. 5388 Methionine S-adenosyltransferase 2A (MAT2A)inhibitors for cancer treatment. Wen Zhang, Vitaliy Sviripa,David Watt, Chunming Liu.

2929



Poster Experimental and Molecular TherapeuticsKinase Inhibitors and Other Targets(not eligible for CME credit)


1. 5389 Novel kinase inhibitor for imatinib-resistant chronic myeloidleukemia with T315I mutation. Soon-Sun Hong, Soo Jung Kim, KyungHee Jung, Hong Hua Yan, Zhenghuan Fang, Joo Han Lim, Jeong Seon Ryu.

2. 5390 The TRK inhibitor RXDX-101 enhances the efficacy oftemozolomide and irinotecan in a xenograft model of neuroblastoma.Radhika Iyer, Rebecca L. Golden, Koumudi Naraparaju, Jamie L. Croucher,Peng Guan, Gang Li, Zachary Hornby, Garrett M. Brodeur.

3. 5391 Preclinical evaluation of AMG 337, a highly selective smallmolecule MET inhibitor, in hepatocellular carcinoma. Zhiqiang Du, SeanCaenepeel, Yuqing Shen, Karen Rex, Yanni Zhang, En-Tzu Tang, OuhongWang, Wenge Zhong, Hui Zhou, Jacqueline Huang, Eric Huang, LiaoyuanHu, Angela Coxon, Mingqiang Zhang.

4. 5392 Small molecule antagonists that mimic the dimerizationdomains of the HGF/c-Met and MSP/RON growth factor systems inhibitpancreatic cancer cell behavior and increase sensitivity to gemcitabine.Kevin J. Church, Leen Kawas, Hank Harris, Brett R. Vanderwerff, RachelleR. Riggers, Joseph W. Harding.

5. 5393 Evaluation of compounds developed against the TAM familykinases. Hong Zhang, Zaihui Zhang, Xiaoqing Shi, Erica Lee, Rick Li,Yuxiang Hu, Jun Yan, Jasbinder Sanghera.

6. 5394 First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 forthe treatment of hematological malignancies. Krzysztof Brzózka,Wojciech Czardybon, Aniela Gołas, Renata Windak, Michał Gałezowski,Ewelina Gabor-Worwa, Bozena Winnik, Agnieszka Przybyłowicz, MaciejSzydłowski, Emilia Białopiotrowicz, Tomasz Sewastianik, Elzbieta Madro,Ewa Lech-Maranda, Krzysztof Warzocha, Przemysław Juszczynski.

7. 5395 Anti-tumor activity of BMS-595, a novel CK2 kinaseinhibitor. Brent A. Rupnow, Chiang Yu, Jonathan G. Pabalan, Urvashi V.Roongta, Jonathan S. Lippy, Ashok R. Dongre, Mary T. Obermeier, AberraFura, Paul A. Elzinga, Benjamin J. Henley, Joseph Fargnoli, Francis Y. Lee,William R. Foster, Christine M. Tarby, Brian E. Fink, John S. Tokarski,Ashvinikumar V. Gavai, Tai W. Wong, John T. Hunt, Gregory D. Vite, AshokV. Purandare.

8. 5396 Characterization of small molecule inhibitors of the PIMkinases in in vitro models of hematological malignancies. Christine E.Sastri, Nadia Guerrero, Dongyin Yu, Bethany Mattson, Ken Dellamaggiore,Yajing Yang, Paul Hughes, Hui-Ling Wang, Victor Cee, Brian A. Lanman,Liping Pettus, Anthony B. Reed, Bin Wu, Ryan Wurz, Andrew Tasker, Li-YaHuang, Daniel Branstetter, Karen Rex, Jeffrey Winston, Teresa L. Burgess,Richard Kendall, J Russell Lipford.

9. 5397 Characterization of INCB053914, a novel pan-PIM kinaseinhibitor. Niu Shin, Maryanne Covington, Richard Wynn, Yanlong Li,Alexander Margulis, Qian Wang, Kathy Wang, Cindy Marando, PatriciaFeldman, Lynn Leffet, Karen Gallagher, Xin He, Hong Chang, He Zhang,Hao Feng, Yun-Long Li, Chu-Biao Xue, Wenqing Yao, Timothy Burn, KrisVaddi, Sharon Diamond-Fosbenner, Swamy Yeleswaram, Gregory Hollis,Robert Newton, Reid Huber, Peggy Scherle, Holly Koblish.

10. 5398 In vivo development of pan-Pim kinase small moleculeinhibitors. Bethany Mattson, Christine. E. Sastri, Nadia Guerrero, DeanHickman, Jie Chen, Tian Wu, Hui-Ling Wang, Andrew Taskar, BrianLanman, Anthony B. Reed, Jude Canon, J. Russell Lipford, Karen Rex.

11. 5399 Anti-cancer activity of a new LIM-Kinases inhibitor: ‘LIM-Pyr1’. Chloé Prunier, Julien Vollaire, Véronique Josserand, Anoek Zomer,Amandine Hurbin, Renaud Prudent, Pascale Cohen, Jacco van Rheenen,Jean-Luc Coll, Marc Billaud, Laurence Lafanechère.

12. 5400 A novel combinatorial therapy for hepatocellular carcinoma(HCC). Jyoti Srivastava, Devaraja Rajasekaran, Ayesha Siddiq, RachelGredler, Chadia L. Robertson, Maaged A. Akiel, Xue-Ning Shen, Kareem A.Ebeid, Aliasger K. Salem, Paul B. Fisher, Devanand Sarkar.

13. 5401 TGF-� signaling inhibition as a potential approach to targetsuboptimally debulked ovarian tumors. Wei Wei, Michael J. Birrer.

14. 5402 A new anticancer strategy based on inhibiting mitochondrialproline dehydrogenase (PRODH) and exploiting synthetic lethalinteractions with p53 restoration and/or glutaminase (GLS1) inhibition.Gary K. Scott, Justine Rutter, Katya Frazier, Daniel Rothschild, ChristinaYau, Christopher Benz.

15. 5403 Targeted therapy of non-small cell lung cancer (NSCLC) bynovel 6-pyrrolo[2,3-d]pyrimidine thienoyl antifolates with selectivetransport by the proton-coupled folate transporter (PCFT). Mike R.Wilson, Zhanjun Hou, Lei Wang, Si Wang, Manohar Ratnam, AleemGangjee, Larry Matherly.

16. 5404 PAK4 allosteric modulators (PAMs) repress the Wnt/�-catenin signaling pathway and tumor growth. William T. Senapedis,Scott Donovan, Gali Golan, Dilara McCauley, Joel Ellis, Marsha Crochiere,Trinayan Kashyap, Boris Klebanov, Sharon Shacham, Yosef Landesman,Erkan Baloglu.

17. 5405 Targeting STAT3 as a novel therapy for ovarian clear cellcarcinoma. Kristin L. Bixel, Uksha Saini, Jack Fowler, Sneja Rajendran,Ross Wanner, Noriomi Matsumura, Kalman Hideg, Ikuo Konishi, DavidCohn, Selvendiran Karrupaiyah.

18. 5406 Osteosarcoma cell lines response to approved andinvestigational anticancer agents and statins along with gene andmicroRNA expression. Gurmeet Kaur, Eric Polley, Joel Morris, ThomasSilvers, Michael Selby, Rene Delosh, Julie Laudeman, Chad Ogle, RussellReinhart, Anne Monks, Annamaria Rapisarda, David Evans, Beverly A.Teicher.

19. 5407 T-type Ca2+ channel inhibitors sensitize ovarian cancer tocarboplatin through downregulation of survivin gene expression.Barbara Dziegielewska, Eli V. Casarez, Wesley Z. Yang, JaroslawDziegielewski, Jill K. Slack-Davis.

20. 5408 The novel retinamide VNLG-152, which targets translationby promoting degradation of MAPK-interacting kinases, haspreferential activity in acute myeloid leukemia with FLT3-ITD. SheetalKarne, Karthika Natarajan, Senthilmurugan Ramalingam, Lalji K. Gediya,Vincent C. Njar, Maria R. Baer.

21. 5409 MEI-344, a novel isoflavone with activity as a mitochondrialoxygenase inhibitor. Yefim Manevich, Miguel Quintela-Fandino, PalomaNavarro, Carolyn Britten, Kenneth D. Tew, Danyelle M. Townsend.

22. 5410 Aspirin attenuates tumor initiating cell growth and inducesreprogramming factors of mesenchymal to epithelial transition inbreast cancer cell. Gargi Maity, Archana De, Snigdha Banerjee, Amlan Das,Sandipto Sarkar, Sushanta K. Banerjee.

23. 5411 Repositioning HIV-based small molecule inhibitors of thestress survival oncoprotein LEDGF/p75 to overcome taxane resistancein prostate cancer. Leslimar Rios Colon, Catherine Elix, Ivana Alicea,Anamika Basu, Christina Du Ross, Tino Sanchez, Nouri Neamati, CarlosCasiano.

24. 5412 Lysosome disruption rapidly and effectively induces necrosisin aggressive thyroid carcinomas. Devora Champa, Antonio DiCristofano.

25. 5413 Intracellular ATP reduction by an artificial protein as a novelapproach to cancer therapy. Dennis Datuin, Matt Hamada, BernardoChavira, Andrew Fontes, Nagaraj Vinay Janthakahalli, Shaleen Korch.

26. 5414 Activity of the pan-PIM kinase inhibitor INCB053914 inmodels of multiple myeloma. Holly Koblish, Niu Shin, Leslie Hall,Xiaoming Wen, Sybil O’Connor, Valerie Dostalik, Qian Wang, Kathy Wang,Maryanne Covington, Cindy Marando, Kevin Bowman, Jason Boer, KristaBurke, Ke Zhang, Hao Feng, Chu-Biao Xue, Yun-Long Li, Wenqing Yao,Reid Huber, Kris Vaddi, Peggy Scherle.

27. 5415 Therapeutic effects of TOPK inhibitor on triple-negativebreast cancer. Jae-Hyun Park, Takashi Miyamoto, Yo Matsuo, YusukeNakamura.

28. 5416 Activity of the pan-PIM kinase inhibitor INCB053914 inmodels of acute myelogenous leukemia. Holly Koblish, Niu Shin, LeslieHall, Sybil O’Connor, Qian Wang, Kathy Wang, Lynn Leffet, MaryanneCovington, Krista Burke, Jason Boer, Kevin Bowman, Ke Zhang, Hao Feng,Chu-Biao Xue, Yun-Long Li, Wenqing Yao, Reid Huber, Kris Vaddi, PeggyScherle.

29. 5417 The identification of BMS-595, an orally active imidazo[1,2-b]pyridazine CK2 inhibitor with in vivo anti-tumor activity. Christine M.Tarby, Liqi He, Brian E. Fink, Andrew Nation, Yufen Zhao, Soong-HoonKim, Libing Chen, John S. Tokarski, Chiang Yu, Jonathan G. Pabalan,Urvashi V. Roongta, Jonathan Lippy, Mary Obermeier, Paul A. Elzinga,Aberra Fura, Benjamin Henley, Joseph J. Fargnoli, William R. Foster,Ashvinikumar V. Gavai, Tai W. Wong, John T. Hunt, Gregory D. Vite, AshokV. Purandare, Brent A. Rupnow.

30. 5418 Lipid modification of c-MYC promoter targetedoligonucleotide stabilizes G-quadruplex formation and enhances itsgrowth inhibitory activity in leukemia cells. Francine Francine, Shelia D.Thomas, Gilles Tapolsky, Donald M. Miller.

3030



Poster Experimental and Molecular TherapeuticsNew Targets 2 / Novel Assay Technologies(not eligible for CME credit)


1. 5419 Structure elucidation of G-quadruplex within the mid-regionof the kRAS promoter and identification of stabilizing small moleculesas promising transcriptional silencers. Rhianna K. Morgan, Tracy A.Brooks, Khondaker M. Rahman.

2. 5420 Ribosomal protein-p53-MDM2 signaling by nucleolar stressresponse and drug discovery. Kohichi Kawahara, Takuto Kawahata,Fumito Horikuchi, Yohei Kamijo, Masatatsu Yamamoto, Yoshinari Shinsato,Kentaro Minami, Kazunari Arima, Toshiyuki Hamada, Tatsuhiko Furukawa.

3. 5421 HER3 inhibition has little efficacy on hepatocellularcarcinoma cell lines. Yong-Shi Li, Yu-Yun Shao, Han-Yu Wang, Ann-LiiCheng, Chih-Hung Hsu.

4. 5422 Inhibition of oxidosqualene cyclase blocks proliferation andsurvival of prostate cancer cells. Yayun Liang, Benford Mafuvadze,Xiaoqin Zou, Cynthia Besch-Williford, Salman M. Hyder.

5. 5423 Identification of immunotargets in Hedgehogmedulloblastoma for immunotherapy. Grace S. Tan, Tom Curran.

6. 5424 Therapeutic targeting of KRAS mutation-driven tumorprogression in colorectal cancer. Christina Wu, Peng-Chan Lin, Po-ChenChu, Hsiao-Ching Chuang, Samuel Kulp, Tanios Bekaii-Saab, Ching-ShihChen.

7. 5425 An anti-Ephrin-A4 calicheamicin conjugate effectivelytargets triple-negative breast and ovarian tumor-initiating cells toresult in sustained tumor regression. Marc Damelin, Alex Bankovich,Albert Park, Jorge Aguilar, Wade Anderson, Marianne Santaguida, SarahFong, Monette Aujay, Kiran Khandke, Virginia Pulito, Elana Ernstoff, PaulEscarpe, Jeff Bernstein, Marybeth A. Pysz, Wenyan Zhong, Erik Upeslacis,Judy Lucas, Justin Lucas, Timothy Nichols, Kathryn Loving, Orit Foord,Johannes Hampl, Robert Stull, Frank Barletta, Hadi Falahatpisheh, PujaSapra, Hans Peter Gerber, Scott J. Dylla.

8. 5426 Tumor cell surface-associated vacuolar-ATPase ‘a2’ isoformpromotes invasion by regulating matrix metalloproteinase activity inovarian cancer. Arpita Kulshrestha, Gajendra K. Katara, Sahithi Pamarthy,Safaa A. Ibrahim, Alice G. Sachs, Kenneth D. Beaman.

9. 5427 Small molecule inhibitors of Musashi family of RNA-bindingproteins. Lan Lan, Carl Appelman, Amber Smith, Jia Yu, Sarah Larsen,Rebecca Marquez, Xiaoqing Wu, Hao Liu, Anuradha Roy, AsokanAnbanandam, Ragul Gowthaman, John Karanicolas, Steven Rogers,Jeffrey Aubé, Roberto De Guzman, Kristi Neufeld, Liang Xu.

10. 5428 Sigma-2 receptor-induced cell death: a novel approach totriple-negative breast cancer treatment. Zongyi Liu, Hilary E. Nicholson,Wayne D. Bowen.

11. 5429 Inhibition of SMARCA2: a novel target for SMARCA4-deficient lung adenocarcinoma. Phil Chapman, Nikki March, GraemeThomson, Emma Fairweather, Samantha Fritzl, James Hitchin, NicolaHamilton, Allan Jordan, Ian Waddell, Donald Ogilvie.

12. 5430 eEF1A2 is a new target for anticancer therapy. AlejandroLosada, Maria José Muñoz, Carolina Garcia, Juan F. Martínez-Leal, FedericoGago, Carmen Cuevas, Luis F. Garcia-Fernández, Juan M. Dominguez, PilarLillo, Carlos M. Galmarini.

13. 5431 Polysialyltransferase ST8SiaII: A novel target for thetreatment of neuroblastoma. Sara M. Elkashef, Virginie Viprey, Rida F.Saeed, Bradley R. Springett, Mark Sutherland, Paul M. Loadman, LaurenceH. Patterson, Steven D. Shnyder, Robert A. Falconer.

14. 5432 Discovery and characterization of USP22 inhibitors as novelanti-cancer agents. Feng Wang, Timothy R. Stanek, Leelabati Biswas,Matthew Kodrasov, James LaRocque, Jian Wu, David Sterner, JosephWeinstock, Michael Mattern, Steven B. McMahon, Suresh Kumar.

15. 5433 Discovery and development of novel USP2 inhibitors forcancer therapy. Suresh Kumar, James P. LaRocque, Jeffrey G.Marblestone, Jian Wu, Joseph Weinstock, David E. Sterner, Michael R.Mattern.

16. 5434 A high through-put bioluminescent assay to monitor thedeamidation of asparagine and isomerization of aspartate residues intherapeutic proteins and antibodies. Said A. Goueli, Kevin Hsiao,Rushikesh Patel, Vishal Nashine.

17. 5435 A bioluminescent assay for measuring glucose uptake.Michael P. Valley, Mary Sobol, Jolanta Vidugiriene, James J. Cali.

18. 5436 Targeting oncoproteins via disruption of proteostasis:Identification of oncoprotein destabilizing agents using luciferasetagged oncoproteins. Richard E. Middleton, Greg Olsen, RussellMcSweeney, Gang Lu, Wenhua Gao, Justin Roberts, Michael R. McKeown,Mark A. Bittinger, Kwok-Kin Wong, James E. Bradner, William G. Kaelin.

19. 5437 A novel method to quantify gamma H2AX foci in circulatingtumor cells in patients receiving chemotherapy for colorectal cancer.Matilde Saggese, Leah Ensell, Clare Vesely, Victoria Spanswick, ElenaPeruzzi, Diana Cunati, Giulio Signorini, John Hartley, Hendrik TobiasArkenau, Tim Meyer.

20. 5438 Multiplexed ICE COLD-PCR coupled to NGS and ddPCRenables enhanced detection of low-level DNA mutations in tissues andliquid biopsies. Katherine A. Richardson, Sarah Statt, Grant Wu, KarissaScott, Erin Montagne, Sheena Jensen, Courtney Cubrich, Phil Krzycki,Jason Stoddard, Amy Kruempel, Emily McCutchen, Stephanie Veys, KyleeBaughman, Sarah Cherubin, Vicki Rosendale, Jaclyn Pope, Paula Bartlett,Phil Eastlake, Stephanie Peterson, Benjamin Legendre.

21. 5439 Development of a robust reporter-based T-cell activationassay for bispecific therapeutic antibodies in immunotherapy. PeteStecha, Jamison Grailer, Zhi-jie Jey Cheng, Jim Hartnett, Frank Fan, MeiCong.

22. 5440 Novel PD-1 blockade bioassay to assess therapeuticantibodies in PD-1 and PD-L1 immunotherapy programs. Zhi-JieJ. Cheng, Natasha Karassina, Jamison Grailer, Jim Hartnett, Frank Fan, MeiCong.

23. 5441 Quantification of PIK3CA mutations in breast cancer patientsusing peripheral blood. Atocha Romero, Fernando Moreno, GloriaSerrano, Eduardo Diaz-Rubio, Trinidad Caldes, Jose Angel Garcia-Saenz.

24. 5442 Microscale methods for preparation and screening ofantibody-drug conjugates. Nicholas C. Yoder, Kalli C. Catcott, Molly A.McShea, Carl Uli Bialucha, Parmita Saxena, Chen Bai, Kathy L. Miller,Thomas G. Gesner, Mikias Woldegiorgis, Stuart W. Hicks, Megan E. Lewis,Michael S. Fleming, Hans K. Erickson, Seth E. Ettenberg, Thomas A.Keating.

25. 5443 Predictive simulation-driven personalization methodologyfor refractory multiple myeloma. Nicole A. Doudican, AmitabhaMazumder, Shireen Vali, Kabya Basu, Ansu Kumar, Neeraj Kumar Singh,Zeba Sultana, Taher Abbasi.

26. 5444 Development of a noninvasive assay to determine drugconcentration in tumor during hsp90 inhibitor therapy. Tony Taldone,Nagavarakishore Pillarsetty, Mark P. Dunphy, John F. Gerecitano, EloisiCaldas-Lopes, Brad Beattie, Radu I. Peter, Yanlong Kang, Anna Rodina,Pengrong Yan, Erica M. DaGama Gomes, Alexander Bolaender, ChristinaPressl, Blesida Punzalan, Anson Ku, Thomas Ku, Smit Shah, MohammadUddin, Mei H. Chen, Elmer Santos, Jacek Koziorowski, Adriana Corben,Shanu Modi, Komal Jhaveri, Oscar Lin, Efsevia Vakiani, Yelena Janjigian,Pat Zanzonico, Clifford Hudis, Steven M. Larson, Jason S. Lewis, GabrielaChiosis.

27. 5445 Dual-color immunohistochemistry assays for measuringAiolos and Ikaros proteins in multiple myeloma patient samples. YanRen, Maria Wang, Suzana Couto, Donna Hansel, Anita K. Gandhi, PatrickHagner, Anjan Thakurta, Rajesh Chopra, Mike Breider.

28. 5446 Continuous real-time measurement of live and dead cells inculture over multiple days. Terry Riss, Jolanta Vidugiriene, SarahDuellman, Wenhui Zhou, Gediminas Vidugiris, Mike Valley, Jean Osterman,Ruslan Arbit, Laurent Bernad, Poncho Meisenheimer, James J. Cali.

29. 5447 Association of the hedgehog signal pathway to Gefitinibsensitivity in a 3D cancer cell lines screening. Gonzalo Castillo, XiuyunJiang.

30. 5448 In vitro drug response (IVDR), biomarkers (BM) and clinicaloutcome (CO) in malignant glioma (GM) patients. Ricardo J. Parker,Michael Myers, Patric Schiltz.

3131



Poster Experimental and Molecular TherapeuticsNovel Mechanisms of Drug Response, Sensitivity, or Resistance 2(not eligible for CME credit)


1. 5449 Transfection of connexin 43 enhances sunitinib-inducedapoptosis in malignant mesothelioma cells possibly via its interactionwith Bax. Miaki Uzu, Hiromi Sato, Tatsuro Kashiba, Takuya Fujiwara,Yukihiro Shibata, Katsunori Yamaura, Akihiro Hisaka.

2. 5450 Naturally occurring mutations in the MPS1 gene predisposecells to kinase inhibitor drug-resistance. Mark D. Gurden, IsaacWestwood, Amir Faisal, Sébastien Naud, Jack Cheung, Craig McAndrew,Amy Wood, Jessica Schmitt, Kathy Boxall, Grace Mak, Paul Workman,Rosemary Burke, Swen Hoelder, Julian Blagg, Rob Van Montfort, SpirosLinardopoulos.

3. 5451 Over-expression of NPM-ALK drives resistance to TKIs inALK+ ALCL but is toxic upon drug withdrawal, permitting prolongedtumour control through discontinuous dosing. Soumya Sundara Rajan,Amit Dipak Amin, Matthew Groysman, Praechompoo Pongtornpipat,Jonathan Schatz.

4. 5452 Inhibition of sodium-independent and sodium-dependentnucleobase transport activities by tyrosine kinase inhibitors. Vijaya L.Damaraju, Michelle Kuzma, Carol E. Cass, Michael B. Sawyer.

5. 5453 Different mechanism of Oxaliplatin resistance in humancolorectal cancer cell lines. Tomoki Yamano, Shuji Kubo, Aya Yano,Naohiro Tomita.

6. 5454 Wogonin overcomes cisplatin resistance of head and neckcancer by targeting antioxidant defense mechanisms. Ji Won Kim, EunHye Kim, Jin Young Park, Minsu Kwon, Jong-Lyel Roh.

7. 5455 Surface accumulation of receptor tyrosine kinases upontreatment with tyrosine kinase inhibitors and resulting enhancement ofactivity upon treatment cessation. Anne-Mette Bjerregaard, Michael V.Grandal, Camilla Frohlich, Trine Lindsted, Christina Egebjerg, Ivan D.Horac, Michael Kragh, Mikkel W. Pedersen.

8. 5456 FGF9 gene amplification can induce resistance to anti-EGFRtherapy in colorectal cancer. Takuro Mizukami, Yosuke Togashi, EriBanno, Masato Terashima, Marco A de velasco, Kazuko Sakai, YoshihikoFujita, Shuta Tomida, Takako Eguchi Nakajima, Narikazu Boku, KazutoNishio.

9. 5457 MAD2�, a new MAD2 isoform, is ubiquitously expressed indistinct cell lines, reduces mitotic arrest, and associates with resistanceto cisplatin-based chemotherapy in testicular germ cell tumors.Alejandro Lopez-Saavedra, Rodrigo Caceres, Fernando Luna, IrwinHernandez, Luis A. Herrera.

10. 5458 Elevated level of Fibrillarin induces chemoresistance byinterfering p53 pathway in cancers. Teng Xu, Suthakar Ganapathy,Meijun Long, Chul Ha, Zhi-Min Yuan, Hang Su.

11. 5459 Overcoming resistance to HER2-targeting drugs using CDK8inhibitors. Martina McDermott, Laura Ivers, Norma O’Donovan, JohnCrown, Igor Roninson, Eugenia V. Broude.

12. 5460 Prevention of peritonitis carcinomatosa after adjuvantchemotherapy by the inhibition of RNA polymerase in drug-tolerantsubpopulations. Satoshi S. Nishizuka, Kohei Kume, Kei Sato, TakeshiIwaya, Go Wakabayashi.

13. 5461 Triapine-mediated ABCB1 induction via PKC induceswidespread therapy unresponsiveness but is not underlying acquiredtriapine resistance. Walter Miklos, Karla Pelivan, Christian Kowol, RitaDornetshuber-Fleiss, Melanie Spitzwieser, Margit Cichna-Markl, GundaKöllensperger, Bernhard Keppler, Walter Berger, Petra Heffeter.

14. 5462 Extracellular ATP promotes cancer cell drug resistance totyrosine kinase inhibitors by competing for the ATP-binding site oftyrosine kinase. Xuan Wang, Yanrong Qian, Yunsheng Li, Xiaozhuo Chen.

15. 5463 Role of the endothelin axis in astrocyte and endothelial cellmediated chemoprotection of cancer cells. Mark S. Kim, Hyun Jin Choi,Ho-Jeong Lee, Junqin He, Qiuyu We, Robert R. Langley, Sin-Jin Kim, IsaiahJ. Fidler.

16. 5464 Host variation in OATP1B1 is associated with treatmentoutcome in pediatric AML. Christina D. Drenberg, Stanley Pounds, Lei Shi,Shelley Orwick, Lie Li, Shuiying Hu, Alice Gibson, Raul Ribeiro, JeffreyRubnitz, Alex Sparreboom, Sharyn D. Baker.

17. 5465 Systematic interrogation of druggable pathways inpancreatic adenocarcinomas using pooled gene-knockdown lentivirallibraries. Edgar Ferrer-Lorenzo, Daniel P. Nussbaum, Peter Winter, KrisWood.

18. 5466 Integrative TCGA analyses identify Basonuclin1 (BNC1) as akey mediator for platinum resistance. Sherry Y. Wu, Justyna Filant,Michael McGuire, Rajesha Rupaimoole, Sunila Pradeep, Anna Unruh,Herbrich Shelley, Cristina Ivan, Ruder Dennis, Cristian Rodriguez-Aguayo,Vasudha Sehgal, Takahito Miyake, Archana Nagaraja, Kshipra Gharpure,Guillermo Armaiz, Rebecca Previs, Gabriel Lopez-Berestein, Prahlad Ram,Keith Baggerly, Anil Sood.

19. 5467 BRCA1 N-terminal-deficient proteins provide PARP inhibitorand platinum resistance. Yifan Wang, Andrea Bernhardy, EmmanuelleNicolas, Ryan Winters, Kathy Cai, Kelly Duncan, James Duncan, MariaHarrell, Elizabeth Swisher, Neil Johnson.

20. 5468 Tirapazamine as a strategy to prevent cell dissemination andovercome drug resistance. Barbara Muz, Pilar de la Puente, Feda Azab,Micah Luderer, Abdel Kareem Azab.

21. 5469 Dexamethasone interrupts paclitaxel-induced apoptosis insolid tumor cells. Marianna Zavodovskaya, Carrie Brachmann, JorgeDiMartino, Daniel Pierce.

22. 5470 Blocking wound-induced tumor repopulation betweenchemotherapy cycles as a novel approach to abrogatechemoresistance. Antonina V. Kurtova, Jing Xiao, Qianxing Mo, SenthilPazhanisamy, Ross Krasnow, Seth P. Lerner, Fengju Chen, Terrence Roh,Erica Lay, Philip L. Ho, Keith S. Chan.

23. 5471 Identification of OAT1/OAT3 as contributors to cisplatinnephrotoxicity. Shuiying Hu, Navjotsingh Pabla, Laura J. Janke, Lie Li,Aksana Vasilyeva, Jason A. Sprowl, Alex Sparreboom.

24. 5472 Selinexor, a selective inhibitor of nuclear export (SINE), actsthrough NF-�B deactivation and combines with proteasome inhibitorsto synergistically induce tumor cell death. Yosef Landesman, TrinayanKashyap, Marsha Crochiere, Boris Klebanov, Sharon Friedlander, WilliamSenapedis, Robert Carlson, Michael Kauffman, Sharon Shacham.

25. 5473 Human cancer cells acquire chemoresistance to gemcitabinemainly through loss-of-function mutations in the DCK gene. Akira Horii,Yuriko Saiki, Tomohiro Nakano, Chiharu Kudo, Makoto Sunamura.

26. 5474 PD-L1 regulates cisplatin chemoresistance in head and necksquamous cell carcinoma. Randall S. Ruffner, Andrew Ramsey, Bert W.O’Malley, Daqing Li.

27. 5475 Cancer exosome promotes cisplatin resistance In bladdercancer and inhibition of exosome sensitizes bladder cancer cells tocisplatin chemotherapy. Chiahao Wu, Chris Silvers, Elizabeths Guancial,Jong-Wei Hsu, Edward Messing, Yi-Fen Lee.

28. 5476 A novel PARP inhibitor resistance mechanism mediated bythe RNA-binding protein HuR. Saswati N. Chand, Akshay R. Kamath,Nicole Meisner-Kober, Charles J. Yeo, Jordan M. Winter, Jonathan R.Brody.

29. 5477 MERIT40 is an Akt substrate that promotes resolution of DNAdamage induced by chemotherapy. Kristin K. Brown, Laleh Montaser-Kouhsari, Andrew H. Beck, Alex Toker.

30. 5478 Curcumin mediates reversion to oxaliplatin-acquiredresistance in colorectal cancer cell lines through modulation of nuclearfactor �B (NF�B) and cyclin-dependent kinase 5 (CDK5). Vicenç Ruizde Porras, Sara Bystrup, Anna Martinez-Cardus, Alba Ginés, Laura Layos,José Luis Manzano, Cristina Bugés, Albert Abad, Eva Martinez-Balibrea.

3232



Poster Experimental and Molecular TherapeuticsPharmacogenomics(not eligible for CME credit)


1. 5479 PGx of gemcitabine in pancreatic ADK: Where didwe go wrong. Cindy SERDJEBI, Florence GATTACCECA,Martina SCHNEIDER, Carole MONTERYMARD, Jaic CARIO,Karine LE MALICOT, Madani RACHID, Bruno LACARELLE,Jean-François SEITZ, Joseph CICCOLINI, Laetitia DAHAN.

2. 5480 Effects of UGT1A1 genotype on pharmacokineticsand toxicities of belinostat administered by continuousinfusion in two clinical trials. Andrew K. Goey, Tristan M.Sissung, Cody J. Peer, Sheryl Ehrlich, Christina Bryla, ArleneW. Berman, Sanjeeve Balasubramaniam, Arun Rajan,Giuseppe Giaccone, Susan E. Bates, William D. Figg.

3. 5481 Effect of genetic polymorphisms on erlotinibpharmacokinetics and toxicity in Japanese patients withnon-small-cell lung cancer. Chihiro Endo-Tsukude, Ji-ichiroSasaki, Sho Saeki, Norihiro Iwamoto, Megumi Inaba, SunaoUshijima, Hiroto Kishi, Shinji Fujii, Hiroshi Semba, KosukeKashiwabara, Yukari Tsubata, Yuki Kai, Hideyuki Saito,Takeshi Isobe, Hirotsugu Kohrogi, Akinobu Hamada.

4. 5482 CYP2D6 genotype and response to neoadjuvanttamoxifen therapy: a prospective study in Japan. HitoshiZembutsu, Seigo Nakamura, Sadako Akashi, TakashiKuwayama, Chie Watanabe, Hiroyuki Takei, Takashi Ishikawa,Yoshie Hasegawa, Soo Chin Lee, Tan Ern Yu, AyamiMatsukata, Hiroshi Matsumoto, Goro Kutomi, YusukeNakamura.

5. 5483 CYP19A1 genetic variation is a potential predictorof outcome in ER-positive postmenopausal early breastcancer patients treated with tamoxifen. Wing-Yee Lo,Werner Schroth, Reiner Hoppe, Marjanka Schmidt,Montserrat Garcia-Closas, Paul Pharaoh, Per Hall, DouglasEaston, Peter Fasching, Hiltrud Brauch, in collaboration withthe Breast Cancer Association Consortium.

6. 5484 FGFR2 amplification is predictive of sensitivity toregorafenib in gastric and colorectal cancers. Yongjun Cha,Hwang-Phill Kim, Sae-won Han, Jiyeon Yun, Sang-HyunSong, Tae-You Kim.

7. 5485 Coactivator PPARGC1B Ala203Pro polymorphismis linked with estrogen-related receptor function andbreast cancer outcome. Pilar H. Saladores, Reiner Hoppe,Wing-Yee Lo, Sibylle Cocciardi, Ute Hofmann, Ute Hamann,Peter Fasching, Marcus Schmidt, Hiltrud Brauch, WernerSchroth.

8. 5486 Identification of novel candidate genesassociated with sorafenib cytotoxicity. Daniel J. Crona,Oscar Suzuki, O. Joseph Trask, Bethany Parks, Amber Frick,Timothy Wiltshire, Federico Innocenti.

9. 5487 Functional analysis of rare dihydropyrimidinedehydrogenase variants relevant to 5-fluorouracil toxicity.Shikshya Shrestha, Steve Offer, Robert B. Diasio.

10. 5488 Utilizing a pathway based analysis of genomewide association data to identify biomarkers of toxicity inbreast cancer patients. Behzad Bidadi, Krishna R. Kalari,Matthias Rubner, Alexander Hein, Matthias W. Beckmann,Peter A. Fasching, Brigitte Rack, Wolfgang Janni, RichardWeinshilboum, Liewei Wang.

11. 5489 A genome-wide association study identifies novelloci associated with taxane-related sensory neuropathy inbreast cancer patients enrolled in a cooperative groupclinical trial (SWOG S0221). Lara Sucheston-Campbell,Alyssa Clay, William E. Barlow, G. T. Budd, Dan Stram, ChrisHaiman, Li Yan, Gary Zirpoli, Song Yao, Dawn Hershman,Kathy S. Albain, Daniel F. Hayes, Halle Moore, Timothy J.Hobday, James A. Stewart, Claudine Isaacs, MuhammadSalim, Julie R. Gralow, Gabriel N. Hortobagyi, Robert B.Livingston, Xin Sheng, Deanna L. Kroetz, Christine B.Ambrosone.

12. 5490 Implementation of genetic sequencing in breastand ovarian cancer patients: a cost analysis. Marissa A.Olson, Seth Tutera, Casey Williams.

13. 5491 Sequential use of first and second generation TKIsare effective on prolonged overall survival in elderlypopulation affected by Ph+ acute lymphoblastic leukemia:the GIMEMA experience. Chiara Sartor, CristinaPapayannidis, Alfonso Piciocchi, Antonella Vitale, IlariaIacobucci, Simona Soverini, Pier Luigi Lollini, Francesco DiRaimondo, Stefania Paolini, Massimiliano Bonifacio, AngeloMichele Carella, Mario Cazzola, Antonio Cuneo, Pietro Leoni,Mario Luppi, Enrica Morra, Giorgina Specchia, Loredana Elia,Robin Foà, Michele Baccarani, Giovanni Martinelli.

14. 5492 Functional characterization of human toll-likereceptor 5 (TLR5) genetic variants. Andrzej J. Wierzbicki,Araba A. Adjei, Nuttapong Ngamphaiboon, ThanyananReungwetwattana, Andrei V. Gudkov, Alex A. Adjei.

15. 5493 Genome-wide study of carboplatin and paclitaxeldisposition in ovarian cancer patients. Bo Gao, Yi Lu,Annemieke J. Nieuweboer, Hongmei Xu, Jonathan Beesley,Ingrid Boere, Anne-Joy M. de Graan, Peter de Bruijn, HowardGurney, Catherine Kennedy, Yoke-Eng Chiew, Sharon E.Johnatty, Philip Beale, Michelle Harrison, Craig Luccarini,Alison M. Dunning, Ron H. Mathijssen, Paul Harnett,Rosemary L. Balleine, Georgia Chenevix-Trench, StuartMacGregor, Anna deFazio.

16. 5494 Cost analysis of genomic-directed therapy inpatients with metastatic lung and colorectal cancers. SethTutera, Marissa Olson, Casey Williams, Brian Leyland-Jones,Mark Huber, Heidi McKean, Addison Tolentino.

17. 5495 Identification of markers predictive ofphosphoramide mustard (PM) cellular sensitivity inlymphoblast cell lines. Lata Chauhan, Brooke L. Fridley, AliceWang, Jatinder K. Lamba.

3333



Poster Experimental and Molecular TherapeuticsRole of the Microenvironment and Tumor Metabolism in Therapeutic Response(not eligible for CME credit)


1. 5496 Effect of BTK inhibitors on differentiation ofhuman monocyte-derived dendritic cells. Zhijian Sun,Dongping Zhou, Lusong Luo.

2. 5497 Cabozantinib eradicates de novo castrate-resistant PTEN/p53 deficient murine prostate cancer viaactivation of neutrophil-mediated anti-tumor innateimmunity. Akash Patnaik, Kenneth Swanson, Katja Helenius,Thornley Thomas, Athalia Pyzer, Vilmosne Csizmadia, SabinaSignoretti, Todd Morgan, Yugang Wang, Olivier Elemento,Lily Wang, Elena Levantini, John Clohessy, John Asara, DavidSmith, Jacalyn Rosenblatt, David Avigan, Steven Balk, LewisCantley.

3. 5498 Multiple mechanisms of action may contribute tothe lymphoma cell-killing activity of SH7139. Monique C.Balhorn, Saphon Hok, Rod Balhorn.

4. 5499 Necuparanib affects tumor progression andinvasion in a 3D co-culture system of pancreatic cancercells and stellate cells. Silva Krause, Amanda Weyers, KatieLoveluck, Birgit Schultes.

5. 5500 A 3D tumor tissue microphysiological system forrealistic tumor microenvironment mimicry and therapeuticmodeling. Agua Sobrino, Dúc Phan, Steven C. George,Christopher C.W. Hughes.

6. 5501 Antagonism of sorafenib and regorafenib actionsby epidermal growth factor in hepatoma cells. Brian I. Carr,Rosalba D’Alessandro, Maria Grazia Refolo, Catia Lippolis,Caterina Messa, Aldo Cavallini.

7. 5502 IAP inhibitor CUDC-427 induces tumor regressionor stasis in preclinical models of B cell lymphoma. Ze Tian,Kaiming Sun, Troy Patterson, Ruzanna Atoyan, Mylissa Borek,Maria Samson, Brianne Hantzis, Anna W. Ma, StevenDellarocca, Brian Zifcak, Guangxin Xu, Jing Wang.

8. 5503 Panaxynol, a potential treatment for colitis,selectively targets pro-inflammatory macrophages forDNA damage and apoptosis. Anusha Chaparala, DeepakPoudyal, Xiangli Cui, Bin Li, Erin E. Witalison, Taixing Cui,Lorne J. Hofseth.

9. 5504 Penfluridol suppresses triple negative breastcancer metastasis to brain by inhibiting �6�4 integrins.Alok Ranjan, Parul Gupta, Sanjay Srivastava.

10. 5505 MyD88-dependent signaling decreases the anti-tumor efficacy of epidermal growth factor receptorinhibition in head and neck cancer cells. Andrean L.Simons-Burnett, Adam T. Koch, Laurie Love-Homan, AdityaStanam.

11. 5506 Anti-angiogenic effects of zoledronic acid onosteotropic breast cancer cells. Cynthia Jackson, WilliamWhalen, Shana Morshedian, Jason A. Bush.

12. 5507 Characterization of ADC bystander killing inadmixed tumor model. Fu Li, Kim K. Emmerton, MechthildJonas, Xinqun Zhang, Che-Leung Law.

13. 5508 Fucoidan from Turbinaria conoides attenuatespancreatic cancer progession by regulating p53 - NF�Bcrosstalk. Caroline R. Delma, Guru Prasad Srinivasan, NuneRaviprakash, Sunil K. Manna, Somasundaram T.Somasundaram, Natarajan Aravindan.

14. 5509 A drug-screening model to identify compoundsactive in cells under metabolic stress. Paola Pellegrini,Martin Haraldsson, Annika Jenmalm Jensen, ThomasLundbäck, Angelo De Milito.

15. 5510 Tamoxifen induces estrogen receptor-independent bioenergetic stress: A synthetic lethalityapproach to target tumor metabolism. Natalie A. Daurio,Stephen Tuttle, Constantinos Koumenis.

16. 5511 Endoxifen inhibits polyamine biosyntheticenzyme activity and up-regulates metabolizing enzymes,spermine oxidase (SMO) and acetyl spermine oxidase(APAO)in breast cancer. T. J. Thomas, Hui-Chen Hsu, MerviHyvonen, Tuomo Keinanen.

17. 5512 Preclinical evaluation of the recombinant humanarginase PEG-BCT-100 leading to arginine deprivation insarcomas. Chi Tung Choy, Hio Teng Cheong, Kin Pong U, ChiHang Wong, Herbert Ho Fung Loong.

3434



Poster ChemistryDrug Delivery(not eligible for CME credit)


1. 5513 Employing a unique panel of breast cancercellular lipids extracts in the development of a novelnanoliposome drug platform. Hanan M. Alharbi, Robert B.Campbell.

2. 5514 Pharmacokinetics of BIND-014 (docetaxelnanoparticles for injectable suspension) in preclinicalspecies and patients with advanced solid tumors. JasonSumma, Daniel Von Hoff, Jasgit Sachdev, Monica Mita,Patricia LoRusso, Peter Eisenberg, Howard Burris, LowellHart, Hagop Youssoufian, Donald Parsons, Susan Low.

3. 5515 Neoadjuvant chemoradiotherapy for rectal cancerwith CRLX101, an investigational nanoparticle-drugconjugate with a camptothecin payload. XI TIAN, MinhNguyen, Henry Foote, Kyle T. Wagner, Hanna K. Sanoff,Autumn J. McRee, Bert H. O’Neil, Benjamin F. Calvo, WilliamA. Blackstock, Joel E. Tepper, Edward Garmey, Scott Eliasof,Andrew Z. Wang.

4. 5516 Biodistribution of liposomal docetaxel prodrugMNK-010 in mice bearing A549 human NSCLC xenografts.Richard M. Fitch, James H. Wible, James A. Blackledge,William D. McGhee.

5. 5517 Polymeric nanogel-based treatment regimen forenhanced efficacy and sequential administration ofsynergistic drug combination in pancreatic cancer. Kruti S.Soni, Michael A. Hollingsworth, Prakash Radhakrishnan,Tatiana K. Bronich.

6. 5518 Development of bio-affinity nanoparticles:Applications for cancer imaging and therapeutics. IditDotan, Philip J. Roche, Elliot Mitmaker, Mark A. Trifiro,Miltiadis Paliouras.

7. 5519 Engineered protein nanocage for targeteddelivery of siRNA to cancer cells. Eun Jung Lee, YoosooYang, In-san Kim, Kwangmeyung Kim, Jeewon Lee.

8. 5520 HER2-targeted gold nanoparticles producepotent antitumor effects on human gastric cancer cells.Tetsushi Kubota, Shinji Kuroda, Katsuyuki Aoyama, HiroshiTazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara.

9. 5521 Interleukin-4 receptor-targeted liposomaldoxorubicin for enhanced targeted drug delivery andantitumor effect in colorectal cancer. Chih-Yung Yang, Chi-Hong Lin, Jeng-Kai Jiang.

10. 5522 Combination of a supramolecularnanotherapeutic targeting MEK and immune checkpointinhibitor exerts a synergistic antitumor outcome. Ashish A.Kulkarni, Venkata Sabbisetti, Prithvi R. Pandey, ShiladityaSengupta.

11. 5523 A novel aptamer targeting agent for prostatecancer. Bethany Powell Gray, Linsley Kelly, Matthew Levy,Bruce A. Sullenger.

12. 5524 Comparison of c-Myc inhibitor effectiveness invarious cancer cell lines. Marija Kuna, Drazen Raucher.

13. 5525 Antibody/drug-conjugated micelle as a versatileplatform technology for targeted tumor delivery. MitsunoriHarada.

14. 5526 Deciphering the basis of CendR-mediatedpenetration into tumors. Hongbo Pang, Gary B. Braun,Tomas Friman, Erkki Ruoslahti.

15. 5527 Oral administration of a nano-enabled form ofMet-Enkephalin peptide controls pancreatic cancergrowth. Preethi Marimuthu, Ijeoma F. Uchegbu, Andreas G.Schätzlein.

16. 5528 Development and evaluation of cell membranelipid-extracted nanoliposomes (CLENs) for the treatmentof cancer using cellular models of human pancreaticcancer. Taha Y. Alqahtani, Robert Campbell.

17. 5529 The advanced strategy for novel EGCG derivativemodified liposome with high targeting ability to tumor.Ikumi Sugiyama, Kunihiro Kaihatsu, Nobuo Kato, YasuyukiSadzuka.

18. 5530 Chitosan amphiphile nanoparticles reduced themyelosuppressive effects of lomustine. Funmilola A. Fisusi,Omotunde Okubanjo, Kar Wai Chooi, Andreas G. Schatzlein,Ijeoma F. Uchegbu.

19. 5531 Combination drug delivery using PBMnanoparticle to improve prostate cancer therapy. RajeshSingh, Shailesh Singh, Guru P. Sonpavde, James W. Lillard.

20. 5532 Polymeric albumin-free paclitaxel intraperitonealtherapy demonstrates superior efficacy over nab-paclitaxel intravenous therapy in a mouse model ofmetastatic ovarian cancer. Kouros Motamed, Neveen Said.

21. 5533 A local chemotherapy with hyaluronan-cisplatinconjugate significantly attenuates growth of lungadenocarcinoma xenografts in mouse model. SusumuIshiguro, Deepthi Uppalapati, Shuang Cai, Katie Turner, JacobHodge, Laird Forest, Masaaki Tamura.

22. 5534 Novel pluronic F127-coated paclitaxelnanoparticles formulation for pancreatic cancer. Murali M.Yallapu, Neeraj Chauhan, Sheema Khan, Meena Jaggi, AdityaGanju, Diane M. Maher, Mara C. Ebeling, Subhash C. Chauhan.

23. 5535 Non-invasive cellular nano-permeabilization toenhance drug delivery and improve therapeutic outcomein solid tumors: Mitigating the path to destruction. MeenaAugustus, Rajah V. Kumar.

24. 5536 KB-164, a novel and highly potent Src familykinase inhibitor, reduces cancer cell invasion andabrogates downstream oncogenic pathways in triplenegative breast cancer. Rabia A. Gilani, Kristoffer R.Brandvold, Li Wei Bao, Sameer Phadke, Michael E. Steffey,Matthew B. Soellner, Sofia D. Merajver.

25. 5537 Nanoparticle delivery of an SN38 conjugate ismore effective than Irinotecan in a mouse model ofNeuroblastoma. Radhika Iyer, Jamie L. Croucher, MichaelChorny, Jennifer L. Mangino, Ivan S. Alferiev, Robert J. Levy,Venkatadri Kolla, Garrett M. Brodeur.

26. 5538 A pH-responsive doxorubicin-lipid conjugateloaded nanomedicine for breast cancer treatment. Feng Li,Marilyn Saulsbury, Simone Heyliger, Mikhail Bondarev,Chengan Du, Corinne C. Ramaley, KiTani P. Lemieux.

27. 5538A Cell size-specific intracellular delivery. May TunSaung, Armon Sharei, Viktor Adalsteinsson, Andrew Liss,Nahyun Cho, Tushar Kamath, Camilo Ruiz, Jesse Kirkpatrick,Robert Langer, Christopher Love, Klavs Jensen.

3636



Poster ChemistryNatural Products(not eligible for CME credit)


1. 5539 Antiproliferative and apoptotic effects of someAfrican natural products in solid and hematopoieticmalignant cell lines. Olufemi E. Akanni, Martin R. Berger.

2. 5540 Antitumor efficacy of synthetic formulations ofactive components in Arum palaestinum extracts in headand neck squamous cell carcinoma. Vikalp Vishwakarma,Kyle Crooker, Vusala Snyder, Jeffrey Straub, Caitlin Cole,Annie Lee, Lisa S. Bittel, Sufi Thomas.

3. 5541 Natural products as possible anti-cancer agentsfor digestive malignancies. Koh Miura, Masayuki Satoh,Makoto Kinouchi, Kuniharu Yamamoto, Yasuhiro Hasegawa,Yoichiro Kakugawa, Masaaki Kawai, Kiyoshi Uchimi, HirokiAizawa, Hiroto Sakurai, Tsuneaki Fujiya.

4. 5542 Flaxseed and its lignan component protect fromasbestos-induced inflammation in mice. Steven M. Albelda,Ralph A. Pietrofesa, Craig W. Menges, Joseph R. Testa, MelpoChristofidou-Solomidou.

5. 5543 Elucidating the cytotoxic effects oftaxol,camptothecin and Lobostemon fruticosus extractson non-small cell lung cancer. Lesetja R. Motadi, LungileNdlovu.

6. 5544 Attempts to synthesize 5,7-dihydroxy-3H-1,2-dithiolo[4,3-d]- pyrimidine, M-47, a potential newtreatment for drug- resistant breast cancer. Canio J.Marasco, Joseph A. Dunn, Paula J. Pera, Alexander E.Macubbin.

7. 5545 Deguelin selectively inhibits proliferation ofluminal androgen receptor (LAR) triple-negative breastcancer cells. Andrew J. Robles, Shengxin Cai, Robert H.Cichewicz, Susan L. Mooberry.

8. 5546 A natural alkaloid, berberine, as a noveltranscriptional repressor of RET proto-oncogene inmedullary thyroid carcinoma. Daekyu Sun, VishnuKumarasamy.

9. 5547 Anti-proliferative activity of hydnocarpin, anatural lignan, is associated with the inhibition of Wnt/�-catenin signaling pathway via axin turnover in coloncancer cells. Won Kyung KIM, Min Ai LEE, Hyen Joo PARK,Ji-Young HONG, Sam Sik KANG, Sang Kook LEE.

10. 5548 Reishi reduces the phosphorylation of STAT-3 ininflammatory breast cancer in vitro and in vivo models.Michelle M. Martínez-Montemayor, Luis A. Cubano, YalizLoperena.

11. 5549 Anti-proliferative effect of Oman’s medicinalplants derived active principles on breast cancer cells(MDA MB 231). Lukmanul Hakkim.

12. 5550 Corilagin, an anti-tumor herb medicine, sensitizespaclitaxel and carboplatin by primarily inhibitingglycolysis pathways in epithelial ovarian cancer. Luoqi Jia,Hongyan Jin, Minzhi Lv, Naiqing Zhao, Shaosong Liu,Zhizhong Zheng, Yiling Lu, Yanling Ming, Yinhua Yu.

14. 5552 Medicinal plants show anticancer splicing activityof apoptotic genes. Zodwa Dlamini, David Bates.

15. 5553 In vivo and in vitro effect of Withania somniferaextract on the proliferation of side population (CD44HIGH/CD24LOW ) cells sorted from MDA-MB-231 breast cancercells. Kamel F. Khazal.

16. 5554 Cisplatin in combination with a potentialantiestrogen wedelolactone applied to differentgynaecological tumor models. Sadia Sarwar, Jun Q. Yu,Fazlul Huq.

17. 5555 Combined effect of modified citrus pectin andionizing radiation on survival and metastatic activity ofprostate cancer cells. Isaac G. Eliaz, Sefora Conti, AkivaVexler, Ben Koren, Nir Honig, Natan Shtraus, Yaron Meir,Shahar Lev-Ari, Ilan Ron.

18. 5556 Enhancing response of Ganoderma lucidum(Reishi) and lapatinib in HER2+ inflammatory breastcancer cells. Yismeilin Feliz-Mosquea, Ivette Suarez-Arroyo,Yaliz Loperena, Luis A. Cubano, Michelle M. Martinez-Montemayor.

19. 5557 Chemotherapeutic and chemomodulatory effectsof naturally occurring O-naphthoquinone and relatedcoumarins against solid tumor cells in-vitro. Mohammed A.Baghdadi, Fahad A. Al-Abbasi, Ali M. El-Halawany, Ahmed M.Al-Abd.

20. 5558 Growth inhibitory effect of perganum, sage, andolive leaves plant extracts on breast and lung cancer celllines. Carla Gibbs, Ola Almusallam, Trent E. Malone, Elbert L.Myles.

21. 5559 Novel synthetic pyridyl analogues of CDDO-Imwith improved stability and their potential use in cancerprevention. Martine Cao, Evans Onyango, Charlotte Williams,Darlene Royce, Gordon Gribble, Michael Sporn, Karen Liby.

22. 5560 Quercetin overcomes chemotherapy resistance intriple negative breast cancer. Asha Srinivasan,Chellappagounder Thangavel, Yi Liu, Sunday Shoyele, RobertB. Den, Ponniah Selvakumar, AshakumaryLakshmikuttyamma.

23. 5561 Violacein inhibits matrix metalloproteinasemediated CXCR4 expression: Potential anti-tumor effect incancer invasion and metastasis. Venkataswarup Tiriveedhi.

24. 5562 BreastDefend enhances the effects of tamoxifenin estrogen receptor-positive human breast cancer in vitroand animal models in vivo. Shujie Cheng, Mark Alvarado,Jagadish Loganathan, Victor Castillo, Georg Sandusky, IsaacEliaz, Daniel Sliva.

25. 5563 Tripterygium induces apoptosis in NSCLC viamitochondria dysfunction. Xing-Xing Fan, Na Li, Jin-Lin Wu,Yan-Ling Zhou, Liang Liu, Jian-Xing He, Elaine L. Leung.

26. 5564 Total synthesis of 6-deoxypladienolide D andassessment of splicing inhibitory activity in a mutantSF3B1 cancer cell line. Kenzo Arai, Silvia Buonamici, BettyChan, Laura Corson, Atsushi Endo, Baudouin Gerard, Ming-Hong Hao, Craig Karr, Kazunobu Kira, Linda Lee, Xiang Liu,Jason T. Lowe, Tuoping Luo, Lisa A. Marcaurelle, YoshiharuMizui, Marta Nevalainen, Morgan Welzel O’Shea, Eun SunPark, Samantha A. Perino, Sudeep Prajapati, Mingde Shan,Peter G. Smith, Parcharee Tivitmahaisoon, John Yuan Wang,Markus Warmuth, Kuo-Ming Wu, Lihua Yu, Huiming Zhang,Guo Zhu Zheng, Gregg F. Keaney.

27. 5565 Antitumor activities of psammaplin A analoguesin human lung cancer cells. Yoonho Shin, Suckchang Hong,Jongheon Shin, Hyeung-geun Park, Sang Kook Lee.

28. 5566 Carnosic acid induces apoptosis throughinhibition of STAT3 signaling and production of ROS inhuman colon cancer HCT116 cells. In Gyeong Chae, Mi-HeeYu, Ki-Woong Park, Kyung-Soo Chun.

29. 5567 Anti-angiogenic activity of Thio-Cl-IB-MECA, anovel A3 adenosine receptor agonist, by regulating ofPI3K/AKT/mTOR and ERK signaling pathways inendothelial cells. Jedo Oh, Gi Dae Kim, Lak Shin Jeong,Sang Kook Lee.

30. 5568 Inhibitory Effect of Partial Electron DecouplingAgents as an Alternate Therapy for Cancer. Omar Bagasra,Kareem Heslop, Krystal Livingston, Keneisha Corbett,Amarachi O. Ejiawoko, Leanna Sealey.

3737



Poster EpidemiologyCancer Risk/Mortality: Exposures, Biomarkers, and Genetics 2(not eligible for CME credit)


1. 5569 p73 dinucleotide polymorphism genotyping ofhuman cancer cell lines. L. Michael Carastro, Kaia K.Hampton, Ricardo A. Cordova Estupinan, Hyun Y. Park,Dongwha Kim, Jong Y. Park.

2. 5570 Heterogeneity of luminal breast cancercharacterized by immunohistochemical expression ofbasal markers. Hyuna Sung, Jenny Chang-Claude, JonineFigueroa, Heli Nevanlinna, Graham G. Giles, Angelia Cox,Simon S. Cross, Melissa C. Southey, Catriona McLean, ManjeetK. Bolla, Mitul Shah, Alison M. Dunning, Joe Dennis, QinWang, Kyriaki Michailidou, Douglas F. Easton, Paul D.Pharoah, Mark E. Sherman, Montserrat Garcia-Closas,Xiaohong R. Yang.

3. 5571 Technologies for molecular epidemiology incancer. Rao L. Divi, Mukesh Verma, Anthony Dickherber.

4. 5572 Tracking the functional analysis of cancer riskvariants. Sharna Tingle, Danielle Carrick, Sheri Schully, MindyClyne, Stefanie A. Nelson.

5. 5573 Effects of endocrine disruptors on rat mammarytranscriptome at critical developmental windows. KalpanaGopalakrishnan, Qian Li, Yula Ma, Luca Lambertini, Jia Chen,Susan Teitelbaum, Fabiana Manservisi, Laura Falcioni,Luciano Bua, Fiorella Belpoggi.

6. 5574 High prevalence of germline TP53 mutations inyoung osteosarcoma cases. Lisa J. Mirabello, MeredithYeager, Phuong L. Mai, Julie Gastier-Foster, Richard Gorlick,Chand Khanna, Ana Patiño-Garcia, Luis Sierrasesúmaga,Fernando Lecanda, Irene L. Andrulis, Jay S. Wunder, NalanGokgoz, Donald A. Barkauskas, Xijun Zhang, Aurelie Vogt,Kristine Jones, Joseph F. Boland, Stephen J. Chanock, SharonA. Savage.

7. 5575 Obesity and genomic changes in patients withmyelodysplastic syndromes. Aziz Nazha, David Seastone,Hideki Makishima, Matt Kalaycio, Hetty E. Carraway, Anjali S.Advani, Ahamd Zarzour, Jennifer Carew, Aaron T. Gerds, SudiptoMukherjee, Jaroslaw P. Maciejewski, Mikkael A. Sekeres.

8. 5576 MnSOD polymorphism is associated withototoxicity in pediatric medulloblastoma patients. AustinL. Brown, Philip J. Lupo, Mehmet F. Okcu, Ching C. Lau, SuryaP. Rednam, Michael E. Scheurer.

9. 5577 Text-mining methods applied to clinical recordssupport an association between androgen deprivationtherapy and subsequent cardiometabolic disease. Kevin T.Nead, Gregory L. Gaskin, Cariad Chester, Nigam H. Shah,Nicholas J. Leeper.

11. 5579 Medication exposures and subsequentdevelopment of Ewing sarcoma: a review of FDA adverseevent reports. Judith U. Cope, Gregory H. Reaman, JosephM. Tonning.

12. 5580 Characterization of HPV integration sites in thehuman genome. Clara Bodelon, Micahel Untereiner, SvetlanaVinokurova, Mitchell J. Machiela, Nicolas Wentzensen.

13. 5581 A model incorporating spirometry to predictabsolute risk of lung cancer: The UK Biobank prospectivecohort study. David C. Muller, Mattias Johansson, PaulBrennan.

14. 5582 Survey of oral cancer screening participantsreveals widespread misconceptions about oral cancer riskfactors, independent of educational background. CariadChester, Jean Sabile, Grace Cho, Annie Hu, Ryoko Hamaguchi,Lauren Ellis, Jonathan S. Erdman, David Praharaj, AbhinavGolla, John Sunwoo.

16. 5584 Exhaled breath as diagnostic tool for malignantpleural mesothelioma. Kevin Lamote, Filip Lardon, Joris VanCleemput, Kristiaan Nackaerts, Olivier Thas, Jan P. vanMeerbeeck.

17. 5585 Analysis of saliva samples from healthy adults innorth central Florida for human papillomavirus infection.Michelle M. Hwang, Hyun-Ji Choi, Taimour Y. Langaee,Henrietta L. Logan, Kevin P. Raisch.

18. 5586 Breast cancer risk prediction: An update to theRosner-Colditz breast cancer incidence model. Megan Rice,Shelley Tworoger, Susan Hankinson, Rulla Tamimi, A HeatherEliassen, Graham Colditz, Bernard Rosner.

19. 5587 Personalized risk prediction tool for esophagealadenocarcinoma in Caucasian population. Xia Pu, Jaffer A.Ajani, Jian Gu, Xiangjun Gu, Yuanqing Ye, Xifeng Wu.

20. 5588 Nevus count and dermoscopic pattern associatedwith MC1R RHC-variant alleles in a case-control study ofmelanoma. Phil McClenahan, Kasturee Jagirdar, Katie Lee,Elizabeth McEniery, Sam Beh, Brian Burke, David L. Duffy, H.Peter Soyer, Richard A. Sturm.

21. 5589 Age-stratified risk of unexpected uterine sarcomafollowing surgery for presumed benign leiomyoma.Andrew S. Brohl, Li Li, Vaagn Andikyan, Angela Cioffi, Joel T.Dudley, Andrew Kasarskis, Robert G. Maki.

22. 5590 Reliability of medical records in diagnosinginflammatory breast cancer in Egypt. Lynne Le, CatherineSchairer, Ahmed Hablas, Mohamed Ramadan, Sofia Merajver,Ibrahim Seifeldein, Amr Soliman.

23. 5591 Factors associated with HPV vaccine initiationamong males aged 11-26 years attending outpatientclinics in the Baltimore Metro Area during 2012 - 2013.Megan Clarke, Darcy F. Phelan-Emrick, Francesca Coutinho,Betty Chou, Corinne E. Joshu.

25. 5593 Cigarette smoke and therapeutic response tochemotherapy and radiotherapy in cancer cells. Graham W.Warren, Michelle Romano, Samantha Sobus, SundaravadivelBalasubramanian.

26. 5594 Progression of paraproteinemia in HIV-positiveversus HIV-negative patients. Erin Jou, Oleg Gligich, AlvitaC. Chan, Diwakar Mohan, Uriel R. Felsen, Sabarish Ayyappan,Henny H. Billett, Edwin P. Hui, Anthony T. Chan, RadhaRaghupathy.

3838




LATE-BREAKING POSTER SESSIONSWednesday, 8:00 a.m.-12:00 p.m.

Halls B-E, Pennsylvania Convention Center

Abstracts will be available online and in the Proceedings Part 2.

Section 40 Late-Breaking Research: Prevention ResearchSection 41 Late-Breaking Research: Molecular and Cellular Biology 4



NCI/NIH-SPONSORED SESSION (not eligible for CME credit)

Wednesday, 10:00 a.m.-11:30 a.m.

Room 105, Pennsylvania Convention CenterResources for Achieving Truly Transdisciplinary Science: Current Models from NCI-Funded Initiatives

Moderator: Krista A. Zanetti, National Cancer Institute, Rockville, MD

Transdisciplinary research is defined as research efforts conducted by investigators from differentdisciplines working jointly to create new conceptual, theoretical, methodological, and translationalinnovations that integrate and move beyond discipline-specific approaches to address a commonproblem. When compared with traditional unidisciplinary research, transdisciplinary research hasconsiderable potential to accelerate scientific discovery and its translation to practice. Current NIHtransdisciplinary research initiatives include the National Institutes of Health Centers for PopulationHealth and Health Disparities (CPHHD) and National Cancer Institute Transdisciplinary Research onEnergetics and Cancer Initiative (TREC).

The CPHHD program responds to a strategic priority at the NIH to address disparities and inequities inthe prevalence and outcomes of several diseases, particularly cancer and heart disease. This programrequires transdisciplinary research involving social, behavioral, biological, and genetic research toimprove knowledge of the causes of health disparities and devise effective methods of preventing,diagnosing, and treating disease and promoting health. The program began in 2003 and has funded19 Centers since its inception, with 10 of the Centers being supported by the NCI.

The TREC initiative is a scientific research effort aimed at reducing cancer linked with obesity, poordiet, and low levels of physical activity. The NCI established the TREC initiative in 2005 in response togrowing public health concern with overweight and obesity in the United States and mountingevidence that obesity plays a role in the development of many types of cancer. The Centers includedscientists from multiple disciplines and encompassed projects spanning the basic biology and geneticsof behavioral, socio-cultural, and environmental influences on nutrition, physical activity, weight,energy balance, energetics, and cancer risk. The current TREC initiative expands into other researchareas including cancer survivorship, childhood obesity, genomics, and environmental aspects ofobesity that include use of tools such as geospatial analysis.

This session will include a brief introduction and presentations by researchers who have been fundedand/or are currently funded through the CPHHD program and TREC initiative. The session will highlightand discuss the necessary resources and strategies to address the scientific and logistic complexity oflarge transdisciplinary initiatives, including a discussion of leadership and management challenges andcommunications and decision-making procedures. Specifically, the presentations in this session willhighlight best practices for performing transdisciplinary research as modeled though the CPHHD andTREC initiatives and will include perspectives from basic, social, clinical, and behavioral sciencesresearchers. This session will provide a venue to explore the opportunities and challenges to achievetruly transdisciplinary research from these varying scientific perspectives. The goal of this session willbe to provide a forum at which investigators with extensive experience in performing transdisciplinaryresearch within large initiatives can stimulate discussion and ideas for improving collaborations toprevent, diagnose, and treat cancer and promote health. Moreover, attendees will benefit from a deeperunderstanding of how large transdisciplinary collaborations are developed and managed effectively toaddress critical research questions.

Speakers:

Sarah Gehlert, Washington University, St. Louis, MO

Marian L. Neuhouser, Fred Hutchinson Cancer Research Center, Seattle, WA

Nathan A. Berger, Case Western Reserve University, Cleveland, OH

Kathryn H. Schmitz, University of Pennsylvania, Philadelphia, PA



MAJOR SYMPOSIAWednesday, 10:00 a.m.-12:00 p.m.

Room 204, Pennsylvania Convention CenterThe Bayard D. Clarkson Symposium: Stem Cells and Cancer Cell of OriginChairperson: Connie J. Eaves, BC Cancer Agency,Vancouver, BC, Canada

Tumors arise as rare events from cells present in establishedtissues, typically through a multistep process that may spanmany years and likely multiple cell generations. Most tumorswith the attributes of invasive malignant cells are alsocapable of continuous growth in vivo through thegeneration of a self-sustaining progeny line; hence theconcept of tumor stem cells. As in normal tissues,heterogeneity of biological as well as phenotypic features isalso a cardinal feature of the individual cells produced bymalignant populations. However, tumors are not onlygenetically perturbed populations, they are also constantlyevolving genetically – characteristics that add furthercauses of diversification in their make-up. These issuesunderscore the importance of clonal tracking methods toanalyze the process of tumor initiation, establishment andmaintenance. This Symposium will highlight new andunexpected insights obtained using clonal approaches todelineating the process of tumor propagation and evolutionin various different tissues in vivo.

10:00 a.m. Introduction

10:10 a.m. Defining the origin of tumor heterogeneityin epithelial cancers [SY45-01]*Cedric Blanpain, Université Libre deBruxelles, Bruxelles, Belgium

10:30 a.m. Discussion

10:35 a.m. Tumor-propagating cells in non-small cell lung cancerCarla F. Kim, Children’s Hospital Boston,Boston, MA


11:00 a.m. Clonal dynamics in gastrointestinal cancersHanno Glimm, National Center for TumorDiseases, Heidelberg, Germany


11:25 a.m. Barcoding reveals new outputs of normaland malignant mammary cellsConnie J. Eaves, BC Cancer Agency,Vancouver, BC, Canada


11:50 a.m. General Discussion

Room 113, Pennsylvania Convention CenterEnhancing Efficacy of CancerImmunotherapy by Use of Ablative TherapyChairperson: Bo Lu, Thomas Jefferson University Hospital,Philadelphia, PA

Combining immune checkpoint inhibitors such as PD1 orPDL1 inhibitors and ablative radiotherapy has thetheoretical advantage of inducing synergistic immuneresponse against cancer cells that have developedmetastases. Potential therapeutic gain from suchcombination in stage IV cancer patients will beunprecedented and of high clinical impact. The speakers inthis session will provide preclinical results and clinical datato demonstrate viability of such strategy as well as theneed for optimization. These investigations will providevaluable guidance for designing relevant clinical trials ofcombing immunotherapy with ablative radiotherapy.


10:10 a.m. Targeting immune checkpoints in cancertherapy: New insights and opportunities James P. Allison, The University of Texas MDAnderson Cancer Center, Houston, TX


10:35 a.m. Tapping the potential of immunogenicmodulation to attack malignant cells that survive therapy James W. Hodge, National Cancer Institute,Bethesda, MD


11:00 a.m. Radiation-mediated DNA sensing pathway forimmunity and tumor regression [SY39-03]*Yang-xin Fu, University of Chicago, Chicago, IL


11:25 a.m. Immune responses to DNA damage andDNA modulation in cancer cells Drew M. Pardoll, Johns Hopkins KimmelComprehensive Cancer Center, Baltimore, MD






Room 120, Pennsylvania Convention CenterEpigenetic Mechanisms in Cancer RiskChairperson: Cheryl Lyn Walker, Texas A&M UniversityHealth Science Center, Houston, TX

Methylation of cytosine (5-mC) bases in DNA, one of thefirst epigenetic mechanisms known to participate in cancerdevelopment, has now come of age, and moved into therealm of personalized medicine with the emergence DNAmethylation biomarkers with predictive potential for cancerrisk and response to therapy. However, the field continuesto discover new epigenetic mechanisms that contribute tocancer etiology. These include the recently discoveredoxidized 5-mC bases, such as 5-hydroxymethylcytosine.This discovery has brought with it a new appreciation thatthe dynamics of DNA methylation/demethylation play animportant role in the etiology of many cancers. It is nowalso becoming clear that epigenetic alterations contributeto the development hereditary cancers. The epigeneticlandscape greatly influences the penetrance of inheritedmutations in genes that predispose to cancer, and in somesettings, constitutional “epimutations” disrupt expressionof these genes via epigenetic rather than mutationalmechanisms to increase cancer risk. Unlike mutations,“epimutations” exhibit non-Mendelian inheritance and canbe reversible between generations. Finally, epigeneticprogrammers are emerging as a unique target forenvironmental exposures early in life, which disrupt the activity of epigenetic “readers, writers, and erasers” toreprogram the epigenome and increase individual risk ofdeveloping cancer in adulthood.


10:10 a.m. Title and speaker to be announced


10:30 a.m. Deciphering the sixth base (5-hydroxymethylcytosine) in the cancer genome Yun (Nancy) Huang, Texas A&M UniversityHealth Science Center, Houston, TX


10:50 a.m. Epigenetic dysregulation as theintermediary from cancer risk-associatedgenetic variant to cancer development Megan P. Hitchins, Stanford University CancerCenter, Palo Alto, CA


11:10 a.m. Immunomodulatory and tumor cell killingeffects of the demethylating agent 5-azacytidine in ovarian cancer **Katherine B. Chiappinelli, Johns HopkinsSchool of Medicine, Baltimore, MD


11:30 a.m. Reprogramming of the epigenome by MLLlinks early life environmental exposures toadult cancer risk Cheryl Lyn Walker, Texas A&M UniversityHealth Science Center, Houston, TX



*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).**NextGen Star, selected to give a talk by the AACR President and Annual Meeting Program Chairperson through a competitive application process designedto bring more visibility to early-career scientists. Abstract can be found in the Invited Abstracts: NextGen Stars section of the Proceedings.



MAJOR SYMPOSIAWednesday, 10:00 a.m.-12:00 p.m.

Grand Ballroom (300 Level), Pennsylvania Convention CenterInnate and Adaptive Immunity In CancerChairperson: Douglas T. Fearon, Cold Spring HarborLaboratory, Cold Spring Harbor, NY, and Weill CornellMedical College, New York, NY

A characteristic of cancers is their association with astromal microenvironment that is replete with cells of theinnate immune system, which has been likened to a“chronic healing wound” and a tissue-protective process.Conversely, cancers also frequently induce adaptiveimmune responses that lead to the accumulation ofcancer-specific CD4+ and CD8+ T cells, which could causetissue injury that, in this instance, would be beneficial forthe host. The speakers in this session will discuss ourunderstanding of the interplay of innate and adaptiveimmunity that leads to the promotion or suppression oftumor growth.


10:10 a.m. Regulatory T cells in cancer Alexander Rudensky, Memorial SloanKettering Cancer Center, New York, NY


10:35 a.m. Discovery of intratumoral, antitumoralpathways through dynamic imaging Matthew Krummel, University of California,San Francisco, CA


11:00 a.m. Tumor-associated macrophages: Frommechanism to therapy Jeffrey W. Pollard, The Queens MedicalResearch Institute, Edinburgh, United Kingdom


11:25 a.m. Immune suppression by T cell exclusion inpancreatic cancer [SY41-04]*Douglas T. Fearon, Cold Spring HarborLaboratory, Cold Spring Harbor, NY, and WeillCornell Medical College, New York, NY



Room 103, Pennsylvania Convention CenterNucleotide Metabolism in Cancer CellGrowth and SurvivalChairperson: Brendan D. Manning, Harvard School ofPublic Health, Boston, MA

In recent years, studies on cancer cell metabolism have ledto the reemergence of interest in the role of nucleotidemetabolism in cancer progression and treatment. It is nowevident that cancer cells exhibit metabolic strategies toincrease their nucleotide pools to meet the demands forRNA and DNA synthesis to fuel cell growth andproliferation. Unlike the normal cells from which they arise,cancer cells are believed to acquire their nucleotidesprimarily through de novo synthesis. Importantly, asexhibited with classic cancer drugs, such as 5-fluorouraciland methotrexate, targeting this nucleotide pool offers apromising therapeutic approach. This session will discussrecent advances in delineating the diverse mechanismsused by cancer cells to synthesize or obtain nucleotidesand potential areas of vulnerability related to nucleotidesynthesis and use.


10:10 a.m. Induction of de novo nucleotide synthesisby oncogenic signaling pathways Brendan D. Manning, Harvard School ofPublic Health, Boston, MA


10:35 a.m. One-carbon flux in cancer cells Joshua D. Rabinowitz, Princeton University,Princeton, NJ


11:00 a.m. One carbon metabolism and cancer[SY42-03]*Karen H. Vousden, Beatson Institute forCancer Research, Glasgow, United Kingdom


11:25 a.m. MTH1 inhibition for depersonalizedanticancer treatment Thomas Helleday, Karolinska Institute,Stockholm, Sweden






Room 201, Pennsylvania Convention CenterOncometabolitesChairperson: Craig B. Thompson, Memorial Sloan KetteringCancer Center, New York, NY

Cancer-inducing mutations have long been shown to alterproteins that participate in signal transduction and/ortranscription. Recently, it has become apparent that cancer-associated mutations in metabolic enzymes can also play apathogenic role. These mutations result in accumulations ofmetabolites which contribute to cellular transformation.Additional evidence suggests that oncometabolites can alsobe produced in trans during wound repair and inflammation,and contribute to early steps in transformation. Examples ofthese concepts will be presented.


10:10 a.m. Stereochemistry matters: L-2HG as a tumorresponse to hypoxia [SY43-01]*Craig B. Thompson, Memorial Sloan KetteringCancer Center, New York, NY


10:35 a.m. Mismatch repair, gut microbiota, and theetiology of colon cancer [SY43-02]*Alberto Martin, University of Toronto,Toronto, ON, Canada


11:00 a.m. Modulating the oncometabolite 2-hydroxyglutarate in cancer Marion Dorsch, Agios Pharmaceuticals,Cambridge, MA


11:25 a.m. Epigenetics and TCA cycle metabolites Navdeep S. Chandel, NorthwesternUniversity, Chicago, IL



Room 121, Pennsylvania Convention CenterProteogenomics and Phosphoproteomics inCancer: Analysis of the TCGA Tumor SamplesCo-Chairpersons: Steven A. Carr, Broad Institute of MITand Harvard, Cambridge, MA; Douglas R. Lowy, NationalCancer Institute, Bethesda, MD

The Cancer Genome Atlas has provided an important

foundation for understanding the scope and relationshipsof genomic alterations in human cancers. The NationalCancer Institute recognized that global proteomiccharacterization of genomically annotated TCGA samples,leveraging recent dramatic improvements in the depth andquantitative capability of mass spectrometry-basedproteomics, could provide complementary as well asunique information about cancer biology and signaling thatcannot be inferred from genomic analyses alone. Thissession will present results of the proteomic andphosphoproteomic analyses of breast, colon, and ovariantumor TCGA samples conducted by the Clinical ProteomicTumor Analysis Consortium. The unique information thatglobal MS-based proteomics provides will be emphasized,together with integrated analysis of the relationshipsbetween genomic and proteomic characteristics. Theincreasing importance of targeted mass spectrometry todevelop and apply highly multiplexed thematic panels ofquantitative assays to study cancer pathways of interestwill also be highlighted.


10:10 a.m. Proteogenomic analysis of human colon andrectal cancer [SY44-01]*Daniel C. Liebler, Vanderbilt University,Nashville, TN


10:35 a.m. Proteogenomic and phosphoproteomicanalysis of breast cancer [SY44-02]*Philipp Mertins, Broad Institute of MIT andHarvard, Cambridge, MA


11:00 a.m. Proteogenomic and phosphoproteomicanalysis of ovarian cancer [SY44-03]*Karin D. Rodland, Pacific Northwest NationalLaboratory, Richland, WA


11:25 a.m. Targeted MRM mass spectrometry enableshighly multiplexed quantification of cellsignaling in response to DNAdamage [SY44-04]*Amanda G. Paulovich, Fred HutchinsonCancer Research Center, Seattle, WA





RECENT ADVANCES IN EPIDEMIOLOGY AND PREVENTION RESEARCHWednesday, 10:00 a.m.-12:00 p.m.

Room 119, Pennsylvania Convention CenterEarly Detection and Overdiagnosis in CancerChairperson: Denise R. Aberle, UCLA David Geffen School of Medicine, Los Angeles, CA

The session will discuss the broader notion of early detection and overdiagnosis of cancer. The sessionwill include a general overview of the goals of screening and overdiagnosis as a harm of screening.The evidence for overdiagnosis across several tumor types and potential approaches to bettercharacterize and communicate the notion of overdiagnosis are discussed. Specific considerations ofearly detection and overdiagnosis are reviewed in the context of breast and lung cancer screening.

10:00 a.m. An overview of overdiagnosisEdward F. Patz, Jr., Duke University Medical Center, Durham, NC


10:30 a.m. Lung cancer screening: Early detection and overdiagnosis Denise R. Aberle, UCLA David Geffen School of Medicine, Los Angeles, CA


11:00 a.m. Breast cancer screening: Early detection and overdiagnosis Otis W. Brawley, American Cancer Society, Atlanta, GA


11:30 a.m. Panel Discussion



Room 108, Pennsylvania Convention CenterBarrett’s Esophagus: Models, Genomics,and GeneticsChairperson: Anil K. Rustgi, University of PennsylvaniaSchool of Medicine, Philadelphia, PA

Barrett’s esophagus (BE) is the leading recognizable riskfactor for esophageal adenocarcinoma (EAC). Dietary andlifestyle variables, such as cigarette smoking, obesity, anderadication of H. pylori infection, play contributing roles inthese conditions. This session will emphasize using mousemodels to understand the cellular origin of BE throughlineage labeling, modeling BE through other platforms(namely 3-D organoid cultures) and presenting currentknowledge on the genomics and genetics of BE and EAC.

10:00 a.m. Introduction Anil K. Rustgi, University of PennsylvaniaSchool of Medicine, Philadelphia, PA

10:05 a.m. Mouse models and cell of origin for Barrett’sesophagus Timothy C. Wang, Columbia UniversityMedical Center, New York, NY

10:25 a.m. Discussion 10:30 a.m. Using 3-D organoid culture systems to

model inflammatory microenvironments inBarrett’s esophagus John P. Lynch, University of Pennsylvania,Philadelphia, PA

10:50 a.m. Discussion 10:55 a.m. Functional genomics of Barrett’s esophagus

and esophageal adenocarcinomaAdam J. Bass, Dana-Farber Cancer Institute,Boston, MA

11:15 a.m. Discussion 11:20 a.m. Insights from the genetics of familial

Barrett’s esophagusAmitabh Chak, Case Western ReserveUniversity, Cleveland, OH

11:40 a.m. Discussion 11:45 a.m. Panel Discussion

Room 114, Pennsylvania Convention CenterColorectal Cancer Subtypes: How Many,How Meaningful?Chairperson: Alberto Bardelli, IRCC, University of TurinMedical School, Candiolo, Italy

Colorectal cancers (CRC) are presently classified based onclinical and histopathological features. Recently, severalgroups used unsupervised clustering of large geneexpression datasets to delineate previously uncharted CRCsubtypes. Depending on the classification, CRCtranscriptional subtypes variably overlap with othermolecular traits including microsatellite instability,methylation, and the mutational status of the RASsignaling pathway. This session will provide the mostrecent updates on this subject, as well as major advanceson the biological and clinical significance of molecularclassification of colorectal tumors.

10:00 a.m. Colorectal cancer subtypes with differentcharacteristics and cellular phenotypes Anguraj Sadanandam, The Institute of CancerResearch, Sutton, United Kingdom

10:20 a.m. Discussion 10:25 a.m. Consensus on CRC subclassification,

biological interpretation, and clinicalapplications Sabine Tejpar, Catholic University of Leuven,Leuven, Belgium

10:45 a.m. Discussion 10:50 a.m. Colorectal cancer subtyping: From human

tumors to preclinical models and back Enzo Medico, IRCC, University of Torino,Candiolo, Italy

11:10 a.m. Discussion 11:15 a.m. Molecular subtypes of colon cancer and

immune reaction Pierre Laurent-Puig, University of Paris VRené Descartes, Paris, France


RECENT ADVANCES IN ORGAN SITE RESEARCHWednesday, 10:00 a.m.-12:00 p.m.



RECENT ADVANCES IN ORGAN SITE RESEARCHWednesday, 10:00 a.m.-12:00 p.m.

Room 115, Pennsylvania Convention CenterHeterogeneity and Microenvironment:Drivers of Breast Cancer EvolutionChairperson: Jeffrey M. Rosen, Baylor College of Medicine,Houston, TX

This session will focus on our current understanding of therole of intratumoral heterogeneity and themicroenvironment on breast tumor evolution. Questions tobe addressed will be: 1) How does our understanding ofparacrine signaling pathways in normal developmentprovide new insights into functional pathways involved inintratumoral heterogeneity? 2) What is the impact ofgenetic heterogeneity on the progression from in situ toinvasive breast cancer and from primary breast cancer tometastatic disease in treatment naive patients? 3) How canintratumoral heterogeneity in clinical breast cancer bemeasured and what type of heterogeneity is important? 4)How can we identify the “real” drivers of breasttumorigenesis? 5) What type of stromal heterogeneityexists in triple-negative breast cancer and how is thisassociated with patient outcome?

10:00 a.m. Developmental insights into tumorheterogeneity Jeffrey M. Rosen, Baylor College of Medicine,Houston, TX

10:20 a.m. Discussion 10:25 a.m. Making sense of intratumor genetic

heterogeneity and breast cancer Jorge S. Reis-Filho, Memorial Sloan KetteringCancer Center, New York, NY

10:45 a.m. Discussion 10:50 a.m. Clinical and functional relevance of

intratumor heterogeneity in breast cancer Kornelia Polyak, Dana-Farber CancerInstitute, Boston, MA

11:10 a.m. Discussion 11:15 a.m. Stromal heterogeneity in triple-negative

breast cancer Morag Park, Canadian Institutes of HealthResearch, Montréal, QC, Canada


Room 118, Pennsylvania Convention CenterPancreatic Cancer in 2015: An IntegratedView of a Complex DiseaseChairperson: Christine A. Iacobuzio-Donahue, MemorialSloan Kettering Cancer Center, New York, NY

Accumulating evidence indicates the multifactorial natureof PDA neogenesis, behavior, and progression. Theseinclude both cell-autonomous and non-cell autonomousfactors such as somatic genetic alterations, epigeneticmodifications, immunologic suppression, metabolicdysregulation and stromal remodeling, among others.Indeed, this multitude of factors likely influence oneanother over the natural history of the neoplasmculminating in the lethal phenotype encountered atdiagnosis. The extent to which these factors play a rolethroughout carcinogenesis and progression, at distincttime points or within specific contexts remains to beclarified. The goal of this session is to therefore provideparticipants an integrated overview of the most currentunderstanding of pancreatic cancer through distinctexamples of cutting edge research in the field related topancreatic cancer risk, early genetic events, whole genomesequencing, and metastasis.

10:00 a.m. Branched chain amino acid metabolism inpancreatic cancer riskBrian M. Wolpin, Dana-Farber CancerInstitute, Boston, MA

10:15 a.m. Discussion 10:20 a.m. Transcriptional mechanisms for autophagy

regulation and metabolic reprogramming inpancreatic cancer**Rushika M. Perera, Massachusetts GeneralHospital Cancer Center, Harvard MedicalSchool, Boston, MA

10:35 a.m. Discussion 10:40 a.m. KRAS and immunity

Dafna Bar-Sagi, New York UniversityLangone Medical Center, New York, NY

10:55 a.m. Discussion 11:00 a.m. Genetic subtypes of pancreatic cancer

Andrew V. Biankin, University of Glasgow,Glasgow, United Kingdom

11:15 a.m. Discussion 11:20 a.m. Genetic and phenotypic heterogeneity in

pancreatic cancer progression Christine A. Iacobuzio-Donahue, MemorialSloan Kettering Cancer Center, New York, NY


*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).**NextGen Star, selected to give a talk by the AACR President and Annual Meeting Program Chairperson through a competitive application process designedto bring more visibility to early-career scientists. Abstract can be found in the Invited Abstracts: NextGen Stars section of the Proceedings.



Terrace Ballroom I-IV (400 Level), Pennsylvania Convention CenterAACR Annual Meeting 2015 Highlights: Vision for the FutureChairperson: Nancy E. Davidson, University of Pittsburgh Cancer Institute, Pittsburgh, PA

12:00 p.m. Introductory remarks Nancy E. Davidson, University of Pittsburgh Cancer Institute, Pittsburgh, PA

12:05 p.m. Basic researchLewis C. Cantley, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College,New York, NY

12:25 p.m. Clinical and translational researchCarlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

12:45 p.m. Early detection and prevention researchWilliam G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

1:05 p.m. Wrap up and vision for the future José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY

PLENARY SESSIONWednesday, 12:00 p.m.-1:30 p.m.


wednesday, april 22 at-a-glance

Documents